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Abstract 
 
A new method for the production of peptides through biological expression was 
developed, utilising lactonisation-prone chlorinated amino acids for latent peptide bond 
digestion. Incorporation of halogenated amino acids into proteins is possible due to the 
inherent inability of the biological synthetic machinery to discriminate against 
compounds structurally similar to the natural substrates. As isoleucine, leucine and 
valine are primarily recognised by size exclusion, all isosteres with a methyl group 
replaced by similarly-sized chlorine are mistaken as substrates, and the ability of 
halogens to mimic the bonding interactions of sulfur enabled the design of a chlorinated 
and a brominated analogue of methionine. 
Amino acids with chlorine at the 4-position, incorporated into proteins in place of 
isoleucine, leucine or methionine during cell-free protein expression, were found to 
trigger cleavage of the proximal peptide bond on the C-terminal side at elevated 
temperatures. The reaction mechanism is similar to that of cyanogen bromide induced 
cleavage, driven by the formation of a highly favourable 5-membered ring. This 
presents the first case of heat induced proteolysis, resulting in almost instantaneous 
peptide bond cleavage through exposure to 100°C in water, and avoids the need for 
toxic, expensive or sensitive external agents. When encoded in a fusion protein, the 
chlorinated residues can be used for rapid separation of the fusion partners. 
The utility of the method was demonstrated through the preparation of small peptides 
human gastrin releasing peptide prohormone, cholecystokinin prohormone and 
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oxytocin, lacking isoleucine, leucine and methionine, respectively, expressed as fusion 
proteins. Through simultaneous replacement of two amino acids, deuterated and 
fluorinated analogues of the peptides were also prepared. The method was then 
expanded to prepare more complicated targets. Homologous substitution of leucine with 
isoleucine, and vice versa, enabled the preparation of a small protein aprotinin. A crystal 
structure of the mutated aprotinin demonstrated that the protein structure was not 
affected by the substitution, thus establishing that interchange of similar amino acids 
can be used to overcome sequence limitations. 
In stark contrast, amino acids with chlorine at the 3-position are resistant to high 
temperature. Through the ability to substitute valine or isoleucine during protein 
expression, the chlorides were incorporated into aprotinin, thus establishing a method 
for the preparation of proteins of essentially unlimited size containing 3-chloro amino 
acids. Crystal structures of the chlorinated aprotinin showed that the amino acid 
analogues are not inherently detrimental to protein structure and can lead to stable 
proteins, while the preparation through the expression of heat-labile fusion proteins 
juxtaposed the differences in reactivity between amino acids halogenated at the 3- and 
4-positions. 
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Chapter 1. Introduction 
 
 
eptides are critical in biological systems[1] and are becoming increasingly 
important in medicinal applications.[2-4] Due to greater potency and specificity as 
compared to small molecule agents as well as non-toxic metabolic break-down products 
(amino acids), synthetically produced peptides and proteins are being approved for 
therapeutic use with increasing rate, with around a hundred peptide drugs currently in 
use and more than five hundred in various stages of clinical trials,[5] steadily replacing 
small molecule chemotherapeutics, antivirals, cardiovascular medication and 
antimicrobial drugs as well being increasingly used as vaccines and diagnostic tools 
instead of attenuated pathogens. In addition, over the last two decades the peptides 
developed for pharmaceutical use have been increasing in size, and the trend is likely to 
continue.[4] The precisely defined sequence[6] and the highly specific interactions make 
peptides valuable tools in nanotechnology[7] as well. As the demand for peptides 
continues to grow, new methods for peptide production are continuously developed. 
 
1.1. Production of proteins 
Short amino acid sequences are referred to as peptides, while longer chains are known 
as proteins, but the boundary between the two is artificial and not well defined. The size 
of the target generally determines the production method. For large proteins 
P
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over-expression in biological systems is the only currently feasible option.[8] Ever since 
organisms were demonstrated to translate foreign genetic material into proteins in the 
1970s,[9] the easy-to-handle bacterium Escherichia coli became a routine host for 
protein expression.[10,11] The procedures have been perfected over the years,[8,11-13] with 
the development of modified cell strains, optimised growth media, customised 
expression vectors and highly refined protocols. Despite all the advances, however, 
recombinant protein production is not always trivial,[11] as protein yields vary 
significantly and unpredictably, and even when satisfactory amounts of protein are 
obtained, protein may lack activity. 
While many strategies to overcome the difficulties of recombinant protein expression in 
cells have been devised,[13] many of the problems can be overcome by the use of cell-
free systems. The earliest cell-free protein expression systems were explored in the 
1950s,[14] and the first practical application of the system was achieved in 1961 with the 
deciphering of the genetic code.[15] Since then these systems have become significantly 
more sophisticated and their use for protein production has become routine.[14,16,17] 
Cell-free systems hold an advantage over whole-cell systems in that cellular extracts (or 
reconstituted mixtures) can be stored and handled as chemicals and can be directed to 
produce a single protein, as native genetic material is absent; multiple proteins can be 
co-expressed simultaneously without the need to consider plasmid complementarity[18] 
(an issue affecting the use of related vectors in living cells). Expressed protein can then 
be extracted without further treatment of the mixture. As all (or most) metabolic activity 
is uncoupled from protein production, the background processes do not interfere with 
protein production and most proteases are neutralised beforehand. On the other hand, 
due to the uncoupling of protein expression from the catabolic machinery, energy for 
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protein synthesis could no longer be generated from cheap and stable nutrients like 
sugars or protein hydrolysates. Energy in the form of ATP (or immediate sources of 
activated phosphate) has to be supplied and constantly replenished throughout the 
reaction. This led to the development of continuous-flow (CFCF) and continuous-
exchange cell-free (CECF) systems where the sensitive nutrients were constantly 
resupplied and reaction by-products removed, allowing the system to function for 
longer (Figure 1.1). Regardless, scale-up using cell-free systems has remained to date 
problematic. 
 
 
Figure 1.1. The principles of continuous-flow (A) and continuous-exchange (B) cell-free 
protein expression systems. Reproduced with permission from Springer.
[14]
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Another problem associated with heterologous protein production is protein instability. 
The lack of native machinery required to process and facilitate correct protein folding 
may lead to non-functional or completely insoluble protein. On occasion, homologous 
chaperone proteins are co-expressed in efforts to stabilise the target protein.[19] A more 
routine approach, however, is to express the target protein as a part of a larger fusion 
protein.[11,20] In 1977, the first target to be produced from synthetically generated DNA, 
14-residue long hormone somatostatin, was attached to the C-terminus of 
β-galactosidase,[21] which has become a common strategy with small peptides.[22,23] 
Since then, other proteins like SUMO (small ubiquitin-like modifier), MBP (maltose 
binding protein) and GST (glutathione S-transferase) were demonstrated to stabilise 
sensitive proteins and have become routine fusion partners. Attached protein tags, like 
His6-tag, c-Myc or FLAG-tag, also facilitate protein purification. Some fusion partners, 
like MBP or GST, serve both as stabilisers and purification tags. 
The ability to artificially increase the target size enables biological production of 
smaller peptides.[24] More routinely, however, chemical synthesis is employed for short 
targets.[25-27] This severs the reliance on biological machinery and the need for handling 
DNA. The difficulty, though, lies in the size and the linear nature of proteins and 
peptides, requiring sequential addition of monomers. As the polymer is extended, 
incomplete coupling and side reactions result in product heterogeneity and introduce 
purification challenges.[28] Introduction of solid phase peptide syntesis in 1963[29] and 
the subsequent developments[25,30] in automation, racemisation suppressants and the 
protection group chemistry made the sequential build-up of peptide more efficient and 
less time-consuming. Still, yields and purity drop off with increasing chain length, and 
the success of the synthesis is somewhat sequence dependent, with some nascent chains 
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failing to extend due to aggregation. Long peptides (up to 100 amino acids) have been 
prepared by using harsh denaturing conditions[31] or conformationally restricted amino 
acid derivatives[32] to disrupt chain aggregation, but more routinely assembly of smaller 
fragments, some obtained through biological means, is required.[26,33,34] These 
modifications, however, significantly extend the preparation time and costs, making the 
biological approaches more favourable. Additionally, biological methods are 
significantly easier to scale up and are more amenable to continuous as opposed to batch 
synthesis. As a result, several hundreds of therapeutic proteins are still produced 
through recombinant expression,[3] and the treatment costs of tens of thousands of 
dollars per patient annually associated with the use the celebrated 36 residue long 
synthetic HIV fusion inhibitor enfuvirtide[35] prompted the development of biological 
routes of production.[23] 
A continuous exchange cell-free (CECF) protein expression system derived from E. coli 
BL21 Star (DE3) strain[16] was used to conduct the research described in this Thesis. 
 
1.2. Proteolytic methods 
As mentioned above, proteins are routinely expressed as larger constructs to facilitate 
proper folding or purification. When the tag is considered a potential hindrance in the 
following experiments, the added sequence is removed. Proteases are routinely used for 
protein digestion,[36] as enzymes function under conditions that do not adversely affect 
other proteins. Many proteases with specific target sequences, like enterokinase, 
factor Xa and tobacco etch virus (TEV) protease, have been characterised and adapted 
in routine laboratory work. The enzymes, however, are generally introduced in catalytic 
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amounts and take up to 24 hours to complete the reaction. In this prolonged reaction, 
most enzymes are prone to cleave additional non-specific sequences. Additionally, 
enzymes require specific buffers, pH and temperature to function properly, as well as 
soluble substrate and exposed proteolytic sites. Thus, the use of enzymes can be 
problematic. 
Chemical reagents can perform under significantly more diverse conditions than 
enzymes and the small molecule nature of these agents makes them easy to remove after 
the reaction is complete. Therefore, chemical proteolysis methods that can cleave 
peptides in a sequence dependent manner (also known as limited proteolysis) are an 
attractive alternative to enzymatic cleavage. 
While proteases are divided into classes based on the mechanism of action[37] (serine 
proteases like enterokinase or trypsin and cysteine proteases like papain use an internal 
nucleophile, whereas aspartate proteases like pepsin and HIV protease position a water 
molecule for direct bond hydrolysis), they all split the substrate at the peptide bond 
(Scheme 1.1). Chemical agents exhibit a far more diverse array of cleavage mechanisms 
and tend to irreversibly modify the targeted amino acids introducing chemistry required 
to facilitate the chain cleavage. 
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Scheme 1.1. Enzymatic hydrolysis of peptide bonds. 
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Metal based cleavage reagents do hydrolyse amide bonds as metals have Lewis acid 
characteristics and peptide break-down proceeds via enzyme-like transition states. Early 
examples[38] of metal-catalysed proteolysis were more position than sequence dependent 
(i.e. N-terminal or C-terminal amino acids were cleaved). However, metal ions do have 
different affinities for different amino acids and can hydrolyse peptide bonds in the 
vicinity of their recognised sequences.[39,40] They are proposed to catalyse the bond 
cleavage by forming a multivalent complex with the protein, although the exact 
mechanistic details remain to be confirmed (Figure 1.2). 
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Figure 1.2. Proposed hydrolytic protein – metal complexes.
[39]
 The scissile bond is highlighted. 
 
One of the earliest and the most wide-spread chemical proteolysis reagent is cyanogen 
bromide, giving some of the highest yields and generating the least amount of side 
reactions. Cyanogen bromide was used for the cleavage of the aforementioned 
β-galactosidase-somatostatin fusion protein.[21] 
Cyanogen bromide was found to selectively cyanylate the residue of methionine on the 
sulfur atom, thus predisposing the side chain of methionine for a nucleophilic 
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substitution.[41,42] In a peptide chain the closest available nucleophile is the amide bond 
at the C-terminal side of the modified residue that can displace the cyanosulfonium 
group with concomitant formation of a 5-membered ring; aqueous hydrolysis of a newly 
formed imine bond leads to cleavage of the peptide bond (Scheme 1.2). The reaction 
takes place at room temperature and, reportedly, leads to near quantitative breakage of 
susceptible bonds. 
Cyanogen bromide was identified as a peptide cleavage reagent as a part of a larger 
screen of related alkylating compounds, like methyl iodide and iodoacetamide, all of 
which were capable of promoting protein fragmentation.[43] While any alkylation of the 
side-chain of methionine can promote the reaction, cyanogen bromide gave the highest 
yields at the mildest conditions. 
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Scheme 1.2. Original proposed mechanism of peptide cleavage with cyanogen bromide.
[41,42]
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The viability of the method was first demonstrated on a small dipeptide ethyl 
N-benzoyl-DL-methionylglycinate that enabled unambiguous establishment of the 
reaction mechanism by characterisation of the products,[41] followed by more thorough 
mechanistic analysis in subsequent years.[44] It was then tested on ribonuclease,[42] a 
protein routinely used for protein folding experiments. On the very first set of 
experiments cyanogen bromide fragmentation allowed for a correction of previously 
mis-identified sequence of ribonuclease. 
Subsequent work uncovered several alternative pathways cyanylation of methionine can 
follow. In cases where methionine is followed by a serine or threonine, the close 
hydroxyl group can participate in a second intramolecular ring formation (with opening 
of the first ring) and thus ‘rescue’ the peptide chain (Scheme 1.3, right).[45] Over the past 
few decades the procedure has been optimised to reduce the likelihood of this pathway 
and up to 80% of alkylated methionine-serine/threonine bonds result in cleavage.[46] The 
reaction is routinely conducted in 70% aqueous formic acid to minimise participation of 
the hydroxyl groups as well as to limit the oxidation[47] of methionine that renders it 
immune to cyanylation. 
Another alternative is the participation of the peptidic bond at the N-terminal side of 
methionine (Scheme 1.3, left).[48] In this case a 6-membered ring is formed and does not 
immediately result in spontaneous chain cleavage. The amide bond is instead replaced 
by a new ester bond that can be selectively hydrolysed under mild alkaline conditions. 
This pathway has not been observed in long peptide chains, possibly because, all things 
being equal, 5-membered rings form more favourably. Studies on small molecules and 
N-terminal acetylated peptides, however, revealed the pathway is possible. 
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Scheme 1.3. The possible outcomes of cyanylation of methionine. The classical pathway 
resulting in peptide cleavage (middle)
[41,42,44]
 can be precluded if methionine is followed by a 
serine or threonine (right).
[45,46]
 Alternatively, the N-terminal peptide bond can be replaced by an 
ester bond (left).
[48]
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Scheme 1.4. Cleavage of peptide bond resulting from oxidation of tryptophan.
[49,50]
 
 
Oxidation of aromatic amino acids results in peptide bond hydrolysis following an 
analogous mechanism. After initial attempts with harsh oxidants like 
N-bromosuccinimide (NBS),[38] that can substantially damage the protein in untargeted 
regions, more sensitive and select reagents have been developed. BNPS-scatole 1[49] and 
iodosobenzoic acid 2,[50] when prepared with great purity, can oxidise tryptophan with 
little or no damage to tyrosine, the other highly susceptible amino acid (Scheme 1.4). 
Conversely, electrolysis has been used to oxidise tyrosine (Scheme 1.5).[51] Prolonged 
exposure to the oxidants leads to oxidation of histidine, which, again, leads to bond 
cleavage at the modified residue.[38] After Birch reduction of the protein, even peptide 
bond cleavage near phenylalanine becomes mechanistically possible.[38] 
1 
2 
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Scheme 1.5. Mechanism of peptide bond cleavage as a result of oxidation (by electrolysis or 
otherwise) of tyrosine.
[51]
 
 
In a similar fashion, iodolactonisation of allylglycine that was incorporated into proteins 
through the use of chemically acylated tRNA (vide infra) led to peptide bond cleavage 
(Scheme 1.6).
[52,53]
 
 
 
Scheme 1.6. The mechanism of iodine-mediated peptide bond cleavage next to allylglycine. 
Reproduced with permission from ACS.
[53]
 
 
The chemical treatments described above lead to the formation of 5-membered rings by 
promoting a nucleophilic attack by the oxygen of the proximal amide bond at the 
C-terminal side of the reacted residue; the peptide bond breaks as a result of the ring 
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formation. The amide can act as an electrophile when the side-chain of aspartate or 
glutamate is reduced to a nucleophilic OH. The highly favourable lactone replaces the 
otherwise more thermodynamically stable amide (Scheme 1.7).[38] 
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Scheme 1.7. Protein fragmentation caused by reduced aspartyl residue.
[38]
 
 
Yet another example of peptide bond cleavage on the C-terminal side of the residue 
involves hydroxylamine treatment of threonine or serine after oxidation with DCC 
(Scheme 1.8).[38] Due to side reactions the newly oxidised residues can undergo, 
however, this method is not applicable to large proteins. 
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Scheme 1.8. Bond cleavage induced by treatment of oxidised threonyl residue with 
hydroxylamine.
[38]
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All of the bond cleavage reactions described above are driven by the formation of a 
5-membered ring (with the exception of reduced glutamyl residue) at the C-terminal 
side of the modified residue. If, however, a shorter residue is modified or the side chain 
is trimmed by the treatment, the favourable ring forms in the opposite direction, 
resulting in bond cleavage on the N-terminal side of the residue. 
Reaction of cysteine residues with chloroformates or chlorothioformates is a 
prototypical method of peptide bond cleavage, with yields of cleavage up to 70% 
(Scheme 1.9).[38] Similar results are obtainable by reaction of serine and threonine with 
phosgene, although higher temperatures are required for the reaction to proceed.[38] 
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Scheme 1.9. Fragmentation of X-cysteinyl peptide bond due to treatment with chloroformates 
or chlorothioformates.
[38]
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Scheme 1.10. The mechanisms of peptide cleavage by cyanylation of cysteine by NTCB 3 
(left)
[54]
 and oxidation of asparagine by diacetoxyiodobenzene 4 (right).
[55]
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More sensitive cysteine modifying reagents 2-nitro-5-thiobenzoic acid (NTCB) 3[54] and 
Cyssor-I[56] were later introduced to make the reaction cleaner. The modified residue is 
able to form a ring with the participation of the amide bond on the N-terminal side, 
forming an imide-like intermediate that facilitates peptide bond cleavage. Cyanylation 
of cysteine is also achieved by reacting disulfide bonds directly with inorganic 
cyanide.[38] Years later oxidation of asparagine with diacetoxyiodobenzene 4 was found 
to lead to a Hofmann rearrangement and peptide bond cleavage, by a virtually isosteric 
mechanism (Scheme 1.10).[55] 
When the electrophilic site is set up closer to the α-centre, the N-terminal peptide bond 
can react through the oxygen, as was the case with N-acetylmethionine (Scheme 1.3, 
left). Tosylated (or otherwise sulfonylated) serine presents a good leaving group for a 
substitution reaction by the neighbouring carbonyl group.[38] The transformation 
resolves in an oxazolinium ring that leads to cleavage of the peptide chain 
(Scheme 1.11). 
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Scheme 1.11. Peptide bond cleavage as a consequence of tosylation of serine.
[38]
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More conventional laboratory chemicals were also used to achieve partial protein 
hydrolysis. Hydroxylamine was found to preferentially hydrolyse asparagine-glycine 
bonds (Scheme 1.12), proceeding once again through a cyclic intermediate.[57] 
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Scheme 1.12. Hydroxylamine-induced break-down of asparaginylglycine bond.
[57]
 
 
Peptide chain can also fragment a result of an introduced α-β unsaturated amino acid, 
generally prepared from serine or cysteine by β-elimination. The enamine hydrolysis 
has been achieved under mild conditions (Scheme 1.13),[58] once the dehydroalanine has 
been produced. 
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Scheme 1.13. Hydrolysis of the dehydroalanine enamine.
[58]
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A more elaborate mechanism has been proposed for a recently introduced copper 
reagent that hydrolyses the peptide bond at the N-terminal side of serine.[59] While the 
reaction intermediates have not be detected and the reaction mechanism has not been 
verified, this aerobic method completely strips off the side-chain of serine converting 
the amide bond into a more labile imide (Scheme 1.14). 
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Scheme 1.14. Mechanism proposed for the peptide cleavage at serine.
[59]
 
 
A labile nitrogen-oxygen bond of (aminooxy)acetic acid, another analogue incorporated 
into proteins through chemical acylation of mutated tRNA (vide infra), is cleaved under 
mild reducing conditions (Scheme 1.15).[60] 
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Scheme 1.15. Reductive cleavage of (aminooxy)acetic acid.
[60]
 
 
A self-digesting protein purification system has also been developed. Named 
‘IMPACT’ (intein mediated purification with an affinity chitin binding tag), the 
procedure involves the expression of the target protein as a fusion with a chitin affinity 
tag, joined via a mutated intein.[61] The mutant of yeast intein VMA is unable to 
complete the excision sequence, resulting in the formation of a thioether and 
subsequently the release of the target protein (Scheme 1.16). The reaction is triggered 
by thiol reagents, like DTT 5, 2-thioethanol or cysteine, and proceeds cleanly at low 
temperatures, but progresses slowly. The reaction can be carried out while on the chitin 
column, allowing for elution of clean cleaved protein and leaving the tag still bound to 
the column. 
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Scheme 1.16. The mechanism of intein-mediated protein cleavage.
[61]
 
 
Cysteine also displays a capacity to spontaneously undergo an N→S acyl shift (or 
N→Se shift in case of selenocysteine),[62] particularly when positioned at the C-terminal 
side of glycine, histidine or another cysteine.[63] The reaction is catalysed by aqueous 
acid at elevated temperatures (60°C), leading to the formation and, subsequently, 
hydrolysis of the thioester bond, resulting in protein fragmentation (Scheme 1.17). 
5 
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The cleavage reaction can be carried out under milder conditions (neutral pH and lower 
temperatures) when catalysed by small thiol reagents like thioacetic acid 6 or 
3-thiopropionic acid.[63] The thiol group can intercept the rearranged peptides, but due to 
the participation of the neighbouring carboxylate the peptide thioester spontaneously 
hydrolyses in water, leading to the production of a free peptide.  
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Scheme 1.17. The mechanism of thioether-mediated proteolysis.
[63]
 
 
The multitude of methods for partial protein hydrolysis (and the continuing 
development) demonstrates that protein digestion plays an important role in protein 
research. Site-specific protein cleavage is essential for protein preparation, but is also 
important for protein analysis. For all the diversity among the above described methods, 
one commonality is the long reaction times needed to achieve completion. A more rapid 
method to selectively digest proteins would be beneficial. 
6 
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1.3. Unnatural amino acids in proteins 
Proteins are made up primarily from 20 L-α-amino acids, known as canonical or 
proteogenic, encoded by the 64 codons of the genetic code. The sequence of amino 
acids in a protein is determined by the gene sequences during protein translation as the 
ribosome moves along messenger RNA (mRNA), transcribed from DNA.[64] Transfer 
RNAs (tRNAs) with anticodons complementary to the mRNA codons deliver their 
respective amino acids to the ribosome as the nascent peptide chain grows.  
The fidelity of protein translation relies on correct codon-anticodon match between the 
mRNA and tRNA in the ribosome as well as the tRNA being charged with the correct 
amino acid. Every proteogenic amino acid has its respective amino acyl-tRNA 
synthetase (AARS) that has evolved to discriminate the native, or cognate amino acid 
and the corresponding tRNAs.[65, 66] The charging of a tRNA is a two stage process, 
involving first the activation of an amino acid by reacting it with ATP, followed by the 
reaction with the 3’ stem of the tRNA (Scheme 1.18); throughout the whole process the 
amino acid remains bound to the enzyme.[67] 
The macromolecular interaction between the AARSs and the corresponding tRNAs 
enables correct substrate recognition.[65] Discrimination of small amino acids, on the 
other hand, is significantly more difficult.[67-69] Half of the synthetases are able to 
distinguish their substrate with complete selectivity by virtue of a specific 
interactions.[69] Tyrosyl-tRNA synthetase (YRS) ensures proper recognition of the 
substrate by forming highly specific hydrogen bonds with the phenolic hydroxy 
group,[70] while chemical properties of thiol groups enable cysteinyl-tRNA synthetase 
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(CRS) to selectively bind and activate cysteine even in the presence of isosteric 
serine.[71] 
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Scheme 1.18. The charging of an amino acid. 
 
The other half of AARSs requires stringent proof-reading ability to discard incorrectly 
recognised amino acids. Many possess two active sites, one for activation of potential 
substrates and one for proof-reading.[67-69] This is referred to as the ‘double sieve’ 
mechanism:[72] due to the difference of a single carbon unit, both isoleucine 7 and valine 
8a are activated by the activating domain of isoleucyl-tRNA synthetase (IRS), as valine 
8a is small enough to fit the active site, yet big enough to bind with sufficient 
affinity.[73,74] The active site in the editing domain, the ‘second sieve’, however, is small 
enough to only accommodate and hydrolyse valine 8a. (Later studies have also found 
proof-reading ability in the activating domain.) As a result of the rigorous screening 
valine 8a replaces isoleucine 7 in proteins only 3 times out of 10000,[75] contrary to the 
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early estimations by Linus Pauling in 1957.[76] Similarly, the editing domain of valyl-
tRNA synthetase (VRS) only accepts polar threonine that is activated along with the 
isosteric valine 8a by the activating domain.[77] 
When a structurally related amino acid that the system had no exposure to throughout 
evolution is introduced, however, selection mechanisms may fail and the analogue 
becomes a potential substrate for the enzyme, albeit with lesser affinity. Dozens of 
non-canonical amino acids that are erroneously translationally incorporated into 
proteins due to structural similarity have been identified and utilised for research 
applications.[78-81] (S)-Canavanine 9 (Figure 1.3), discovered in the 1960s, is an 
analogue of arginine 10 that leguminous plants produce to fend off insects; upon 
ingestion of plant material containing cavananine, the insects start producing non-
functional protein with lethal consequences.[82] Furanomycin 11 is an antibacterial agent 
isolated from a species of Streptomyces.[83] While at first glance it bears little 
resemblance to any of the canonical amino acids, in 3D it is conformationally very 
similar to isoleucine 7 and was shown as a substitute in E. coli systems during protein 
synthesis.[84] Azetidine-2-carboxylic acid 12 is an analogue of proline 13 found in sugar 
beets that was shown to be toxic to a wide range of species.[85] 
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Figure 1.3. Some of the naturally occurring non-canonical amino acids (above) that are 
translationally incorporated into proteins and their proteogenic isosteres (below). 
 
This promiscuity has been taken advantage of in research and the scope of 
mis-recognised unnatural amino acids has been further widened. (S)-Canavanine 9, due 
to the non-discriminate disruption of protein function, was one of the most widely used 
analogues in protein function studies.[78] Other amino acids were applied in more 
specific circumstances. Azetidine-2-carboxylic acid 12 was useful in collagen 
studies,[78] the threonine analogue β-hydroxynorvaline 14 was found to interfere with 
protein glycosylation,[78] 2-amino-3-chlorobutyric acid 15a was used in protein 
degradation experiments in the 1960s through the 80s,[86] and aza-tryptophan 16, when 
substituted for tryptophan, produces fluorescent proteins that can be tracked without 
9 
10 
11 
7 13 
12 
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further labelling[87] (Figure 1.4). Even without detailed knowledge about the active site 
of the enzyme some predictions can be made about possible allowed modifications of 
the substrate, and with screening and improving knowledge of the AARSs the number 
of potential amino acid analogues has increased tremendously.[79,80] Carefully selected 
analogues have been shown to produce functional proteins without apparent aberrations. 
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Figure 1.4. Some of the non-canonical amino acids used in protein studies. 
 
Even though foreign amino acids are recognised by native AARSs, the cognate amino 
acids still bind with higher affinity and out-compete the analogues.[69] Incorporartion of 
toxic amino acids like canavanine 9[82] or furanomycin 11[84] that produce aberrant 
proteins does not have to be extensive for the toxin to be effective as small amounts of 
non-functional protein can disrupt cellular function, although a surplus of the cognate 
amino acid can alleviate the toxic effects. For practical applications, however, high 
degree of substitution is required; therefore, the natural amino acid must be excluded 
from the system. In vivo studies benefit from the innate inability of many tissues to 
synthesise essential amino acids that are often the targets for replacement. When the 
14 15a 16 
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work is carried out in competent organisms, however, this auxotrophy has to be 
introduced by a deliberate deletion of a gene involved in the biosynthesis of the 
substituted amino acid.[88] Auxotrophic bacterial strains were successfully used to 
prepare proteins with high degree substitution with unnatural amino acids analogues, 
but a separate strain is required for each tested amino acid.[80,89-91] Cell-free protein 
expression systems are more favourable than whole-cell approaches when unnatural 
amino acids are involved as the natural counterparts can be completely excluded during 
the system reconstitution.[14,16,17] Therefore, cell-free systems tend to give higher degree 
of amino acid substitution due to lower background levels. Recent advances enabled 
incorporation of multiple (as many as five) unnatural amino acids in a single protein,[81] 
whereas multiply auxotrophic cells are difficult to generate. Additionally, cell-free 
systems are not poisoned by toxic amino acids (regardless of mechanism of toxicity). 
More recently, the scope of possible analogues was further widened by genetic 
manipulation of the AARSs. In 1991 phenylalanyl-tRNA synthetase (FRS) was mutated 
to relax the size restriction of the substrate.[92] While the wild type synthetase could 
mis-incorporate p-fluorophenylalanine 17a in place of phenylalanine 17, the mutant 
with the relaxed active site was able to recognise p-chlorophenylalanine 17b and 
p-bromophenylalanine 17c as well. Directed evolution coupled with structural 
knowledge of AARSs allowed for the incorporation of nearly a hundred unnatural 
amino acids with novel functionalities that facilitated protein chemical labelling, 
crosslinking or spectroscopic monitoring capabilities.[93,94] Through genetic 
modification of the tRNAs to recognise one of the ‘stop’ codons or an extended 4-base 
codon, the foreign amino acid recognised by the engineered AARS becomes the 21st 
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amino acid, incorporated site-specifically into an engineered protein; this is generally 
referred to as the ‘expanded genetic code’. 
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Figure 1.5. Para-halogenated analogues of (S)-phenylalanine 17. 
 
Chemical protein synthesis allows even greater diversification of the protein structure, 
alleviating restriction of the polymer assembly to (2S)-α-amino acids,[25,27] and native 
chemical ligation strategies enable the fusion of such modified peptides with longer 
proteins.[34] The chemical synthesis approach allows almost unlimited product design, 
but more elaborate functionality requires customised synthetic procedures, limiting the 
use of automation and thus making the procedures prohibitively long and complicated. 
Hence, unnatural compounds most commonly introduced into peptides through 
chemical peptide synthesis are still highly reminiscent of the natural counterparts,[3] 
with inverted stereocentres (D-amino acids), N-methylation (e.g. sarcosine), modified 
chain length, expanded aromatic systems, hydrogen-to-fluorine substitutions, β-amino 
acids and des-amino appendages at the N-termini. 
A hybrid method between chemistry and biology for the incorporation of modified 
amino acids was also developed, whereby the tRNA is chemically charged with an 
amino acid that is then incorporated into a growing protein chain via ribosomal 
17 
17a, X = F 
17b, X = Cl 
17c, X = Br 
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translation.[52,53,60,95] A dinucleotide from the end of tRNA is acylated with an 
N-protected amino acid and subsequently enzymatically ligated onto a truncated tRNA 
molecule; the photo-labile N-6-nitroverastryloxycarbonyl (NVOC) or the iodine-labile 
N-4-pentenoyl protecting group is then removed (Scheme 1.19). The charged tRNA is 
isolated and supplied to the expression mixture. 
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Scheme 1.19. Chemical acylation of tRNA. 
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The benefits of the expanded range of amino acids incorporated into proteins are 
undeniable. However, considerable efforts have to be invested into the engineering of 
artificial systems that reliably produce modified proteins. The natural promiscuity of 
amino acyl-tRNA synthetases, on the other hand, can be easily exploited for the 
incorporation of unnatural amino acids and still holds a lot of unexplored potential. The 
innate promiscuity of the protein synthetic machinery was utilised in the work described 
in this Thesis. 
 
1.4. Analogues of the branched-chain amino acids 
The three amino acids that comprise the branched-chain amino acid (BCAA) family, 
(S)-valine 8a, (S)-leucine 18 and (2S,3S)-isoleucine 7, all have simple and relatively 
similar branched hydrocarbon chains as side-chain. Thus, to distinguish between the 
them, the corresponding synthetases all possess editing sites, making discrimination 
based on hydrophobic size and shape possible.[69,74,77,96] Structurally related compounds, 
however, are able to compete with the canonical substrates and evade proof-reading, as 
exemplified by the analogues 19-21 (Figure 1.6).[78] 
 
NH
2
O
O
OH
NH
2
S
O
OH
NH
2
O
OH
OH
 
Figure 1.6. Analogues of (S)-leucine 18 and (2S,3S)-isoleucine 7 used to study protein 
processing. 
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Fluorine is a typical isostere for hydrogen.[97,98] The recognition of fluorinated BCAA 
isosteres by the protein synthetic machinery was tested through a number of studies and 
in most cases the hydrogen-to-fluorine substitution did not preclude the incorporation of 
the tested analogues (Table 1.1). For some analogues the synthetase had to be over-
expressed to make the incorporation noticeable, but the active site was not altered. 
 
Table 1.1. Tested fluorinated analogues of the branched chain amino acids. 
Natural substrate Unnatural analogues 
     
NH
2
O
OH
 
NH
2
CF
3
O
OH
 
NH
2
F
3
C
O
OH
 
  
8a 22a[99]  22b*[99]   
NH
2
O
OH
 
NH
2
O
OH
F
3
C
 
NH
2
O
OH
CF
3  
NH
2
O
OH
CF
3
F
3
C
 
 
18 23a[100] 23b[100] 23c*[101]  
NH
2
O
OH
 
NH
2
CF
3
O
OH
 
NH
2
O
OH
CF
3  
NH
2
CF
3
O
OH
 
NH
2
F
3
C
O
OH
 
7 24a[91]  24b[91]  22a[99]  22b*[99] 
-amino acid was incorporated into protein 
*-the synthetase was over-expressed 
-amino acid was tested for incorporation, but no incorporation detected 
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Hydrogen and fluorine are similar in size, but, when grouped together, the 
trifluoromethyl group becomes substantially bigger than a methyl group.[98] One 
diastereomer of trifluorinated valine 22a and one regiomer of modified isoleucine 24a 
were rejected by the corresponding synthetases; no enzyme activity was detected in the 
presence of the two analogues, suggesting they are rejected by the activating domain 
(the ‘first sieve’),[91,99] while the analogue of valine 22b was recognised by IRS.[99] 
A recent study re-evaluated the ability of chlorinated isosteres to emulate BCAAs 
(Table 1.2).[102] The analogue 15a was shown to be so potent that it could even 
effectively compete with (S)-valine 8a, the natural substrate of VRS; the diastereomer 
15b was less efficient. Leucyl-tRNA synthetase (LRS) was also unable to discriminate 
against the chloride 25, although IRS appeared to reject the chlorinated analogue 26a, 
an isostere of (2S,3S)-isoleucine 7 (the regiomer 27 was not tested in the study). ATP 
turn-over by IRS in the presence of 26a indicated proof-reading activity. In light of 
these data it was proposed that the difference in size between the van der Waals radii of 
a chloro and a methyl groups (1.75 Å vs 2.0 Å) is more apparent on a primary chloride 
and IRS is able to register the difference. 
Based on these studies IRS appeared to have the capacity to register very tiny changes 
in the size of potential substrates. The seemingly opposite substitution pattern of the 
rejected isoleucine isosteres 26a and 24a prompted an investigation into the recognition 
mode of IRS, which is described in Chapter 2 of this Thesis. The chemical properties of 
the amino acid 26a uncovered in the study led to the development of a new method for 
the preparation of small peptides; this application is described in Chapter 3. 
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Table 1.2. Chlorinated analogues of the branched chain amino acids with a single methyl 
group-to-chlorine substitution. 
Natural substrate Unnatural analogues 
     
NH
2
O
OH
 
NH
2
Cl
O
OH
 
NH
2
Cl
O
OH
 
  
8a 15a[102]  15b[102]    
NH
2
O
OH
 
NH
2
O
OH
Cl  
   
18 25[102]     
NH
2
O
OH
 
NH
2
O
OH
Cl  
NH
2
Cl
O
OH
 
  
7 26a
[102]  27*   
-amino acid was incorporated into protein 
-amino acid was tested for incorporation, but no incorporation detected 
*-not tested 
 
The chloride 15a was known to interfere with protein function and had been utilised in 
studies of cellular protein expression.[86] Antimicrobial effect against select species that 
was mitigated by leucine was also observed for the chloride 25,[103] with the 
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incorporation studies[102] pointing to a potential mode of action. The underlying effects 
on protein, however, had not been explored. 
The effects of (S)-canavanine 9 are well understood: the additional oxygen atom reduces 
the basicity of the guanidino group in turn reducing the ability to form salt bridges and 
other polar interactions that proteins rely on for function.[82] The mode of action of 
many other analogues found in nature is not so clear cut, and while hypotheses have 
been proposed, the true mechanism is not yet certain and warrants further investigation. 
To investigate the potential effects of halogenated amino acids on proteins, bovine 
pancreatic trypsin inhibitor (BPTI), also known as aprotinin, was expressed with valine 
analogues 15a and 15b and crystal structures of the modified protein were obtained. 
This work is described in Chapter 4. 
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1.5. Substitution of methionine 
Methionyl-tRNA synthetase (MRS) is particularly notorious for substrate 
promiscuity.[104] Table 1.3 lists the structural analogues of (S)-methionine 28 that are 
accepted by MRS from E. coli, the largest array of substrate analogues of any AARS, as 
well as structurally related rejected compounds. Some of the amino acids were only 
incorporated into proteins when the enzyme was over-expressed and/or the amino acid 
was supplied in unnaturally high concentrations, but the enzyme was not modified. 
Taking advantage of selenomethionine 29 that revolutionised protein 
crystallography[105] and effective protein tagging with the introduction of 
azidohomoalanine 34[106] and the unsaturated analogues 35-36,[107,108] MRS is the 
becoming the most frequently exploited synthetase. Similar substrate promiscuity is 
observed with orthologues from yeast[109] and multicellular organisms, with even more 
diverse diazo-compounds incorporated in place of (S)-methionine 28.[110] 
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Table 1.3. Conditions required for the incorporation of analogues of methionine into protein. 
Conditions Analogues 
     
Readily 
incorporated 
NH2
O
OH
Se  
NH2
O
OH
Te  
NH2
O
OH
S
 
NH2
O
OH
S
N
O  
NH2
O
OH
S
(S)-Methionine
 
29
[111] 30[111] 31[111,112] 32[113] 
NH2
O
OH
O  
NH2
O
OH
N
N
+
N
-
 
NH2
O
OH
 
NH2
O
OH
 
33
[114] 34[106] 35[107,108] 36[107,108] 
NH2
O
OH
 
NH2
O
OH
S
CHF2
 
NH2
O
OH
S
CF3
 
 
 37[107,108,111,114] 38[115] 39[116]  
MRS overexpressed 
NH2
O
OH
 
NH2
O
OH
 
  
 40[107] 41[107]   
    
28 
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Table 1.3. continued. 
  
MRS overexpressed; 
analogue supplied in 
large concentration 
NH2
O
OH
 
NH2
O
OH
 
NH2
O
OH
 
NH2
O
OH
 
 42[107] 43[107] 44[107] 45[107] 
Not incorporated 
NH2
O
OH
F3C  
NH2
O
OH
O
 
NH2
O
OH
 
NH2
O
OH
N
N
+
N
-
 
 46[107] 47[107] 48[107] 49[106] 
 
 
Methionyl-tRNA synthetase (MRS) only possesses one active site, used for both 
activation and proof-reading.[117] The hydrophobic pocket is created upon substrate 
binding, resulting in extensive rearrangement of the protein, and a bonding interaction is 
established between the thioether of methionine side-chain and ζO of tyrosine Y260 in 
the active site (Figure 1.7) to ensure correct substrate recognition. 
The proof-reading ability of the active site relies on the chemistry of bound substrate. 
The primary competitor for methionine 28, present in cells under physiological 
conditions, is the precursor homocysteine 50.[75] Effective rejection of homocysteine 50 
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by MRS is critical as erroneous production of proteins with the thiol 50 (that can occur 
via a different pathway) has lethal consequences for the organism.
[118]
 As a free thiol, 
homocysteine 50 can undergo thio-lactonisation to form a 5-membered ring 51, whereas 
methionine 28, as a thioether, is unable to follow that pathway. Following 
mis-activation of homocysteine 50, the synthetase then facilitates cyclisation of the 
adenylated amino acid and release of the degraded thiolactone 51 (Scheme 1.20),
[75]
 
whereas methionine 28 and other non-hydrolysable analogues are transferred onto the 
Met
tRNA and incorporated into proteins. 
 
 
Figure 1.7. The active site of methionyl-tRNA synthetase with methionine 28 (purple) bound. 
A bond between the sulfur of methionine 28 and 
ζ
O of Tyr260 is important for substrate 
recognition. Reproduced with permission from Elsevier.
[117]
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Scheme 1.20. The proofreading mechanism of mis-activated homocysteine 50 by MRS. 
 
The highly specialised editing mechanism of MRS directed against a single target 
makes mis-incorporation of a vast array of analogues possible. The promiscuity of MRS 
was exploited in the introduction of peptide chain-cleaving analogues of 
(S)-methionine 28; this work is described in Chapter 5. 
 
  
50 
51 
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Chapter 2. Substrate Selectivity of Isoleucyl-tRNA 
Synthetase 
 
 
s indicated in the Introduction, the chlorinated isoleucine analogue 26a was 
reported to be rejected by IRS during protein expression, standing out from the tested 
chlorinated analogues of the BCAA family (Table 1.2). γ-Chlorovaline 26a was 
produced by direct treatment of (S)-valine 8a with chlorine in trifluoroacetic acid 
(Scheme 2.1). The mixture of the isomers 26a, 52a and 53a and the unreacted starting 
material 8a was used for protein synthesis in the original study as only the acid 26a was 
a potential substitute for isoleucine 7.[102] For more detailed enzyme binding studies, 
however, pure material was required. 
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Scheme 2.1. Preparation of γ-chlorovaline 26a and its derivatives by direct chlorination. 
It was anticipated that the products of chlorination with protected N-termini would be 
easier to fractionate on reverse phase HPLC as reduced polarity of the compounds 
A
8 26 52 53 
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1
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 = H 
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would increase interactions with the stationary phase. Free and N-acetylated amino 
acids lead to similar patterns of side-chain modification during the chlorination 
reaction,
[119]
 hence (S)-N-acetylvaline 8b was used for chlorination (Scheme 2.1; 
R
1
 = H, R
2
 = Ac). The obtained mixture was analysed by reverse phase HPLC and good 
resolution was achieved on an Alltima C18 column (22×250 mm, 5µ) eluting with 20% 
methanol in 0.1% TFA (Figure 2.1). Three peaks (*) matching the mass of the isomers 
26b, 52b and 53b were identified by ESI-MS. 
 
 
Figure 2.1. HPLC chromatogram showing the separation of the isomers 26b, 52b and 53b on 
an Alltima C18 column (22×250 mm, 5µ), eluting with 20% methanol in 0.1% TFA, 
10 mL/min. 
 
Hβ signals in the 2 ppm to 3 ppm region in the proton NMR spectrum are the most 
diagnostic in the identification of the chlorination products of (S)-N-acetylvaline 8b due 
to great separation (Figure 2.2). The Hβ multiplet of the unreacted starting material 8b 
resonates at δ 2.16 ppm and the corresponding protons of the γ-chlorinated products 26b 
and 52b appear at δ 2.28 ppm and δ 2.46 ppm (stereochemistry not assigned in the 
original study).
[119]
 The β-chlorinated product 53b is not visible in the chosen region as 
8b 
* 
* * 
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it lacks Hβ protons and is identified by the signals of the methyl groups at δ 1.73 ppm 
and δ 1.64 ppm. 
Material eluting at 39.6 min had the signals attributable to the β-chloride 53b and was 
thus no longer pursued. Signals at δ 2.46 ppm and δ 2.28 ppm (weak) corresponding to 
the sought diastereomers 26b and 52b were detected in the 33.7 min and 36.0 min 
fractions, respectively, but the same fractions also contained very prominent signals at 
δ 2.61 ppm and δ 2.77 ppm that were very weak or not observed at all in different 
batches of the original mixture of chlorination products. 
 
 
Figure 2.2. The diagnostic region of 
1
H NMR of the chlorination mixture of (S)-N-acetylvaline 
8b and two purified HPLC fractions. 
 
Sample contamination was ruled out after several purification attempts as the 
‘contamination’ pattern was reproducible and unique to individual fractions. It thus 
chlorination 
mixture 
33.7 min peak 
36.0 min peak 
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became apparent the unidentified peaks at δ 2.61 ppm and δ 2.77 ppm were arising due 
to degradation of the chlorinated compounds 26b and 52b. Lactone formation was 
considered as the most likely route to decomposition as 5-membered rings are highly 
favourable thermodynamically. The degradation products were isolated by HPLC and 
analysed by 1H NMR (Figure 2.3). 
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Figure 2.3. 
1
H NMR spectra of the decomposition products of the chlorinated products eluting 
at 33.7 min (above) and 36.0 min (below). 
 
The downfield shift of the Hγ proton signals from δ 3.5 ppm for both diastereomers 26b 
and 52b[119] indicated the chlorides were substituted by the more de-shielding 
carboxylate groups and together with the geminal splitting of the Hγ protons 
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(δ 4.45 ppm and δ 3.89 ppm for the 33.7 min peak and δ 4.46 ppm and δ 4.07 ppm for 
the 36.0 min peak) confirmed the presence of the rings. Thus, the NMR analysis 
confirmed the decomposition products were the 5-membered lactones. 
Stereochemistry of the lactones was then investigated. Configuration at the α-centre was 
known as (2S)-amino acids were used for the synthesis. Conformational analysis was 
employed to determine the relative stereochemistry between the two stereo centres. 
Avogadro modelling software was used to model the geometry of the lactone products. 
For the trans-lactone the dihedral angle between the Hα and Hβ hydrogens was 
calculated to be 164° and the angles between Hβ and each of the Hγ protons were 39° 
and 162°; for the cis-lactone the dihedral angle between the Hα and Hβ was 39° and the 
angles between Hβ and each of the Hγ were 37° and 86° (Figure 2.4). 
For related systems, a dihedral angle of 164° between two protons is expected to result 
in substantially stronger coupling between the two protons than 39°, hence the lactone 
with the coupling constant 3Jαβ = 11.3 Hz at the Hα position and was identified as the 
trans–lactone 54b and the decomposition product with the coupling constant 
3
Jαβ = 7.8 Hz and was identified as the cis-compound 54a. The coupling constants 
3
Jβγ = 10.5 Hz and 8.3 Hz were consistent with the predicted 162° and 39° angles for the 
trans-lactone and 3Jβγ = 5.9 Hz and 2.1 Hz corresponded well with 37° and 86° angles 
for the cis-ring. As the stereocentres of the chlorinated products are not affected during 
lactonisation, the established stereochemistry on the rings 54a and 54b could be 
translated to the starting materials 26b and 52b (Scheme 2.2). 
 
Chlorinated Amino Acids in Peptide Production 
Chapter 2. Substrate Selectivity of Isoleucyl-tRNA Synthetase 
46 
 
O
O
H
NH
H
H
H
O
3.099A
2.374A
3.059A
O
O
H
NH
H
H
H
O
2.509A
2.754A
2.494A
 
Figure 2.4. Top: ball and stick models of the trans (left) and cis (right) lactones. The geometries 
were optimised with Avogadro software. Bottom: distances between the spatially fixed protons 
of the two lactones, measured from the optimised structures. 
 
Chlorinated Amino Acids in Peptide Production 
Chapter 2. Substrate Selectivity of Isoleucyl-tRNA Synthetase 
47 
NAc
O
OH
Cl
H
H
2.28 ppm
2.8 ppm
2.46 ppm
2.6 ppm
O
O
H
NHAc
H
H
H
O
O
H
NHAc
H
H
H
4.81 ppm, J = 7.8 Hz
4.08 ppm, J = 9.0, 2.1 Hz
4.47 ppm, J = 9.0, 5.9 Hz
4.30 ppm, J = 11.3 Hz
3.89 ppm, J = 10.5, 8.8 Hz
4.45 ppm, J = 8.8, 8.3 Hz
NAc
O
OH
Cl
H
H
 
Scheme 2.2. Decomposition of the diastereomers 26b and 52b. 
 
Nuclear Overhauser Effect (NOE) was employed to verify the coupling constant 
analysis. Selective irradiation of a single proton cross-excites the other protons in the 
molecule, and the magnitude of excitation is proportional to proximity through space, 
hence allowing relative distance measurements between the interacting protons. As the 
experiment is repeated with longer mixing times, i.e. the protons are allowed to interact 
for longer, a linear relationship between time and intensities of the signals of the cross-
excited protons is expected, and a larger gradient of the correlation trend indicates the 
protons are closer in space. 
Based on the modelled structures of the lactones 54a and 54b, the spatial distance 
between Hα and Hβ is comparable to the distance between Hβ and the Hγ proton on the 
same side of the ring (Figure 2.4; bottom). Hence, measurement of relative distances 
between the concerned protons could be used to confirm relative stereochemistry. 
26b 
52b 
54a 
54b 
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For the cis-lactone 54a the resonance at δ 2.8 ppm was irradiated (Figure 2.5). As 
expected, the Hα peak at δ 4.81 ppm and the two Hγ protons at δ 4.47 ppm and 
δ 4.08 ppm were cross-excited. A weaker signal at δ 1 ppm for the methyl group was 
also visible, but that was less useful for structural analysis due to the free rotation of the 
C-C bond. 
As the mixing time τ was increased the NOE became stronger (linearly with respect to 
the mixing time initially, then started to plateau at τ > 400 ms), but the relative 
intensities between the signals remained constant. The NOE of the δ 4.47 ppm signal 
was significantly stronger than the δ 4.08 ppm signal, suggesting the δ 4.47 ppm signal 
corresponds to the Hγ on the same face of the ring as the Hβ and the δ 4.08 ppm signal 
corresponds to the Hγ on the opposite face. The δ 4.81 ppm NOE was marginally 
stronger than the δ 4.47 ppm signal, indicating the Hα and the Hβ protons are on the 
same side of the ring, thus confirming the identity of the lactone 54a as cis, consistent 
with the coupling constant analysis. 
A similar analysis was attempted on the lactone 54b, but was not successful as the NOE 
resulted in partially inverted signal. 
Finally, the measurements were compared to previous reports.[120] The cis-lactone 54a 
had been isolated from a marine source. For consistency, all analysis of the compounds 
in the current work was carried out in methanol. When recorded in deuterated 
chloroform, as reported,[120] the spectrum of the lactone 54a was a perfect match to the 
reported values, thus unambiguously confirming the determined stereochemistry. 
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Figure 2.5. Top: NOE measurements of the lactone 54a. The Hβ at δ 2.8 ppm was selectively 
irradiated and cross-excitation was measured after 70-500 ms. Bottom: the plot of relative 
intensities of the cross-excited δ 4.81 ppm (), δ 4.47 ppm () and δ 4.08 ppm () peaks 
against the mixing time. 
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The mixture of the chlorinated compounds 26b and 52b could be stored indefinitely 
without decomposition, likely due to the residual TFA suppressing the nucleophilicity 
of the carboxylate, but under aqueous conditions lactonisation of the labile species made 
purification impossible. As the acetamido group does not contribute to the process of 
lactonisation, similar behaviour would be expected from the free amino acids 26a and 
52a. Interestingly, no decomposition had been previously observed.[102] Decomposition 
of the substrate 26a under physiological conditions, depending on the rate, could 
account for the apparent rejection of the chloride 26a by IRS, thus stability of the free 
amino acids was re-examined. 
The key regions of 1H NMR spectra were nearly identical for the chlorination mixtures 
of (S)-valine 8a and (S)-N-acetylvaline 8b, with the Hβ resonances of the acetylated 
compounds shifted up-field correspondingly (Figure 2.6). Thus, the structural analysis 
conducted on the acetylated compounds 26b and 52b was easily correlated to the free 
amino acids 26a and 52a. Based on this, the Hβ signal of the biologically relevant 
(2R,3S)-3-chlorovaline 26a was at δ 2.40 ppm and the δ 2.62 ppm signal corresponded 
to the (2S,3S)-diastereomer 52a, with the signal of the starting material (S)-valine 8a at 
δ 2.31 ppm. 
To assess the stability of γ-chlorinated amino acids 26a and 52a under physiological 
conditions, the mixture of chlorinated isomers was dissolved in D2O and pD was 
adjusted to ca. 7. 1H NMR spectra were recorded every 10 min for 2 h at 37°C and Hβ 
peak intensities of the amino acids 26a and 52a were measured relative to that of valine 
8a. Even during the first scan (t = 0), the γ-chlorovaline 26a resonance at δ 2.40 ppm 
was significantly smaller than the diastereomer 52a signal at δ 2.62 ppm (Figure 2.7), 
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having partially decomposed during the set-up of the experiment, signifying the 
biologically relevant diastereomer 26a is significantly less stable of the two; they are 
produced in roughly equal amounts during the chlorination reaction. The amino acid 
26a was essentially fully consumed within the first hour of the experiment and could no 
longer be reliably measured against the background, whereas decomposition of the 
diastereomer 52a was tracked throughout the experiment. Logarithmic plot showed 1
st
 
order kinetics and the compound 26a was found to decompose with a half-life of ca. 
15 min, whereas the by-product 52a was substantially more stable with a half-life of just 
under 4 h. Formation of the lactonisation products was also visible during the 
experiment (δ 2.8 ppm), but the compounds could not be used to monitor the 
decomposition of the chlorides as they were themselves unstable. 
 
 
Figure 2.6. Comparison of 
1
H NMR spectra of free (above) and acetylated (below) amino acids 
in methanol. 
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Figure 2.7. Decomposition of the amino acids 26a ( ) and 52a ( ) under physiological 
conditions. Top: intensities of Hβ signals relative to Hβ signal of valine 8a. Bottom: logarithmic 
plots of the intensities; points for the chloride 26a were ignored past 40 min. 
 
 
The findings of the kinetic test are in direct contradiction to the previous report.
[102]
 The 
propensity of the isoleucine analogue 26a to lactonise under physiological conditions 
might lead to the complete consumption of the IRS substrate before the cell-free 
reaction was even set up, thus appearing as though the amino acid 26a was rejected. 
However, the chlorinated analogue of leucine 25 (whose two diastereomers were 
reported to lactonise with half-lives of 2.0 and 2.6 h)
[102]
 was successfully incorporated 
into proteins in the same study. To test whether the instability of the isoleucine analogue 
26a under physiological conditions was precluding protein synthesis, the reaction 
protocol was altered to ensure that the chloride 26a was present in the mixture at the 
start of the reaction. 
When amino acids produced by chlorination are used for protein expression, the sample 
is first neutralised as even drying under high vacuum fails to completely remove TFA. 
(The residual TFA inhibits lactonisation, thus crude samples can be stored on shelf 
indefinitely.) To ensure the desired amino acid was present in the reaction mixture at 
least in the early stages of the experiment, mixtures containing γ-chlorovaline 26a and 
N-acetyl-γ-chlorovaline 26b were neutralised in the final minutes before the assembly 
of the reaction chamber. Under these conditions small amounts of the test protein 
peptidyl-prolyl cis-trans isomerase B (His6PpiB) were produced (Figure 2.8). 
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Amino acids         
Ile 7:  + ‒  + ‒ ‒  
Analogue:  ‒ 26a  ‒ ‒ 26b  
 
   
  
Figure 2.8. SDS-PAGE analysis of His6PpiB produced via cell-free protein expression with 
mixtures containing the chlorides 26a (left) and 26b (right) instead of (2S,3S)-isoleucine 7. 
 
In the case of the free amino acid 26a, discrete peaks of partially substituted His6PpiB 
were observed in the MS spectrum (Figure 2.9). The strongest peaks at 19413.3 Da and 
19433.4 Da correspond to 8/10 and 9/10 isoleucine residues replaced by the chloride 
26a, respectively. Some fully substituted protein (19453.9 Da) was also seen, while the 
species with fewer substitutions (7/10 to 1/10) formed an array of decreasing peaks. 
This indicated that in the initial stages of the experiment the chloride 26a was used for 
protein expression until the concentration rapidly decreased and expression ceased. 
Small, but rising amounts of background valine 8a became available as the reaction 
progressed, leading to some production of all-natural protein (19249.5 Da). 
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Figure 2.9. Deconvoluted ESI-MS spectrum of His6PpiB produced in the presence of unpurified 
chloride 26a. 
 
With the acetylated analogue 26b, MS indicated incorporation of more than 10 chlorine 
atoms into the protein (Figure 2.10). This could be explained by the presence of small 
amounts of over-chlorinated species bearing several chlorine atoms in the crude reaction 
mixture that is also accepted by IRS. However, due to time constraints and the 
complexity of the chlorination mixture the identity of the suggested species was not 
pursued. 
The pattern of incorporation of the chloride 26a is highly indicative that the instability 
of the chlorinated amino acid is responsible for lack of protein production in the 
previous study.[102] However, in order to completely rule out the discrimination of the 
analogue by the synthetase, a way of sustaining a steady concentration of the potential 
substrate 26a in solution was required.  
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Figure 2.10. Deconvoluted ESI-MS spectrum of His6PpiB produced in the presence of 
unpurified chloride 26b. The red line indicates the expected mass of His6PpiB upon full 
substitution of the 10 isoleucine residues with the analogue 26a (19454 Da), the green line 
marks the all-native unsubstituted protein (19250 Da). 
 
As the instability of the chlorinated species 26a and 52a was investigated, parallel work 
in the group had just shown that a range of common protecting groups, like methyl 
esters, were removed from (2S)-amino acids by the S30 (vide infra). Several synthetic 
amino acids were deprotected in situ during protein synthesis, thus reducing the steps of 
chemical synthesis. Hence, it was considered to supply the chlorinated amino acid 26a 
with the carboxylate protected during protein expression: lactonisation would not be 
possible until the protecting group was removed. 
In order to assess the viability of using protected amino acids for cell-free expression, 
the rate of amino acid deprotection was compared to the rate of protein synthesis. 
Protein production was found to be continuous throughout the 6 hour experiment (vide 
infra). The rate of deprotection of two potential protecting groups, methyl ester and 
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tert-butyl ester, that were shown to be fully and partially deprotected in the time frame 
of protein expression, respectively, was measured, by monitoring the deprotection of 
(S)-leucine methyl ester 55a and (S)-leucine tert-butyl ester 55b. 
The protected amino acids 55a and 55b were incubated at 37°C with S30 for 6 h, and 
aliquots of the mixtures were taken throughout the experiment. Consumption of the 
(S)-leucine derivatives 55a and 55b and production of (S)-leucine 18 was monitored 
using the Waters AccQ.Tag method (vide infra). 
The quinolone-based AccQ.Tag derivatisation reagent and most derivatised amines have 
an absorption maximum at 250 nm. Interestingly, the absorption maximum of 
derivatised (S)-leucine methyl ester 55a shifted to 230 nm, making the peak difficult to 
track at 250 nm, thus the reaction was monitored at both frequencies (Figure 2.11, 
Figure 2.12). 
Consumption of leucine methyl ester 55a and the concomitant production of leucine 18 
were mostly linear for the first 2.5-3 h of the experiment, slowing down in the final 
hours of the reaction after the amount of the ester 55a had decreased substantially. 
The deprotection reaction of (S)-leucine tert-butyl ester 55b also progressed linearly, 
albeit significantly slower, with just under half of the material consumed in the 6 h 
window (Figure 2.13). 
A similar zero order reaction profile can be expected for all deprotection reactions 
executed by the enzymes in the S30. The exact rate is likely determined by the amounts 
of the involved enzymes present in the extract as well as the activities of the enzymes 
towards the particular substrates. 
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Figure 2.11. HPLC chromatograms of AccQ.Tag
TM
-derivatised reaction mixture showing the 
consumption of (S)-leucine methyl ester 55a incubated with the S30 extract at 37°C for 6 h, and 
the production of (S)-leucine 18, detected by UV at 250 nm. 
 
The rate of deprotection of leucine methyl ester 55a matched the rate of protein 
expression (vide infra), whereas the tert-butyl ester 55b reacted significantly slower. A 
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methyl ester was therefore considered the best protecting group for the unstable 
isoleucine analogue 26a. 
 
 
 
Figure 2.12. HPLC chromatograms of AccQ.Tag
TM
-derivatised reaction mixture showing the 
consumption of (S)-leucine methyl ester 55a incubated with the S30 extract at 37°C for 6 h, and 
the production of (S)-leucine 18, detected by UV at 230 nm. 
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Figure 2.13. HPLC chromatograms of AccQ.Tag
TM
-derivatised reaction mixture showing the 
consumption of (S)-leucine tert-butyl ester 55b incubated with the S30 extract at 37°C for 6 h, 
and the production of (S)-leucine 18, detected by UV at 250 nm. 
 
As amino acid side-chain reactivity was not perturbed by functionalisation of the amino 
groups, it was anticipated simple derivatisation of the carboxy group would not 
influence the reaction either. Hence, (S)-valine methyl ester 8c was chlorinated (Scheme 
2.1; R
1
 = Me, R
2
 = H). Formation of the predicted products 26c, 52c and 53c was 
confirmed by 
1
H NMR by comparison with the spectra of the free acids; the two classes 
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of compounds had nearly identical spectra (apart for the ester signals). The similarity of 
the spectra also enabled the assignment of stereochemistry to the esters, with the 
δ 2.44 ppm signal attributable to the (2R,3S)-ester 26a and the δ 2.60 ppm signal 
assigned to the (2S,3S)-diastereomer 52a (Figure 2.14). Both esters were stable in 
aqueous solutions at physiological conditions. 
 
 
Figure 2.14. Comparison of 
1
H NMR spectra of the chlorinated amino acids (below) and their 
methyl esters (above). 
 
The mixture containing the diastereomers 26c and 52c was used for the initial protein 
expression test. Successful production of the test protein His6PpiB confirmed the ester 
26c supports protein synthesis (Figure 2.15); ESI-MS analysis of the product showed 
that 10/10 isoleucine residues in the protein were substituted by the chlorinated amino 
acid 26a. This confirmed that the analogue 26a is prone to being mistaken for isoleucine 
52a 26a 
8a 
52c 26c 8c 
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7 by IRS and the reported rejection was an artefact of the misrecognised instability of 
the substrate 26a under physiological conditions. 
 
Amino acids:  
Ile 7:                   +          ‒         ‒ 
26c:                   ‒          ‒         + 
 
 
  
Figure 2.15. SDS-PAGE analysis of His6PpiB produced via cell-free protein expression with 
unpurified analogue 26c instead of isoleucine 7. 
 
As the methyl ester 26c is chemically stable, its isolation from the reaction mixture was 
attempted. Reverse phase HPLC was used, but the free amines were causing severe 
tailing, likely due to strong interactions with the silanols of the stationary phase, making 
the separation more complicated. Figure 2.16 shows a typical trace obtained from a C18 
HPLC column, even though the column was specifically designed for separation of 
highly polar compounds. The starting material 8c was separable from the chlorinated 
species, but the three major chlorinated products 26c, 52c and 53c tended to co-elute. 
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Figure 2.16. HPLC chromatogram of the chlorinated esters 26c, 52c and 53c on an Atlantis 
dC18 column (4.6×250 mm, 5µ), eluting with acetonitrile gradient from 5% to 20% in 
0.1% TFA over 20 min, 1 mL/min. 
 
A variety of reverse phase columns (Atlantis dC18, Fortis C18, Alltima C18), buffers 
and solvent gradients gave similar results. Hydrophilic interaction chromatography 
(HILIC), a version of normal phase chromatography increasingly used for the separation 
of polar compounds,
[121]
 also failed to separate the mixture. More promising results 
were obtained with a mixed mode column (Primesep 100) that separates the analytes 
both by cation exchange and hydrophobic interaction. For the first time some resolution 
of the chlorinated species 26c, 52c and 53c was achieved (Figure 2.17). This suggested 
the cation exchange component is necessary for the separation of the ester 26c, but no 
separation was achieved on ion exchange columns. Ion pairing chromatography was 
then attempted. While TFA is routinely used for HPLC separation of polar molecules, 
the ion pairing capability of trifluoroacetate counterion is limited and the interaction 
with the stationary phase is weak. Sodium dodecylsulfate (SDS) as an amphiphilic 
moiety with the longest commonly available hydrophobic chain was used instead of 
TFA to maximise the effects of ion paring and minimise tailing. After optimisation the 
8c 26c+52c+53c 
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components of the reaction mixture eluted as three well defined peaks, with β-chloride 
53c in a separate fraction from the γ-chlorides 26c and 52c, but the two diastereomers of 
γ-chlorovaline methyl ester 26c and 52c were inseparable by this approach 
(Figure 2.18). 
 
 
Figure 2.17. HPLC chromatogram of the chlorinated esters 26c, 52c and 53c on a Primesep 100 
column (4.6×150 mm, 5µ), eluting with 20% acetonitrile in 0.1%TFA, 1 mL/min. 
 
 
Figure 2.18. HPLC chromatogram of the chlorinated esters 26c, 52c and 53c on an Alltima C18 
column (4.6×250 mm, 5µ), eluting with acetonitrile gradient from 30% to 40% in 20 mM SDS 
over 30 min, 1 mL/min. 
8c 26c+52c+53c 
8c 53c 26c+52c 
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Purification with sodium perchlorate in the mobile phase was attempted as a last resort 
as perchlorates were shown to improve the behaviour of amines on reverse phase.
[122]
 
Initial attempts were promising as separate peaks for all four analytes 8c, 26c, 52c and 
53c were observed for the first time on the Atlantis dC18 (4.6×250 mm, 5µ) column 
(Figure 2.19). Optimisation of solvent gradient failed to improve resolution, so a second 
Atlantis dC18 column (4.6×150 mm, 3µ) was connected in tandem to increase the 
length of stationary phase. Solvent flow rate had to be reduced to 0.8 mL/min to avoid 
overpressure, but the resolution improved to the extent that individual peaks of the 
analytes 26c, 52c and 53c could be collected and analysed by NMR. Furthermore, the 
sample could be injected twice per run (2 min apart), doubling the amount of purified 
material (Figure 2.20). Residual perchlorate was removed by counter-ion exchange 
HPLC on a Primesep 100 (4.6×150 mm, 5µ) column eluting with 0.4% TFA in 20% 
acetonitrile. 
 
 
Figure 2.19. HPLC chromatogram of the chlorinated esters 26c, 52c and 53c on an Atlantis 
dC18 column (4.6×250 mm, 5µ), eluting with 20% acetonitrile in 100 mM NaClO4, 1 mL/min. 
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Figure 2.20. HPLC chromatogram of the chlorinated esters 26c, 52c and 53c on an Atlantis 
dC18 column (4.6×150 mm, 3µ) in tandem with an Atlantis dC18 column (4.6×250 mm, 5µ), 
eluting with 20% acetonitrile in 100 mM NaClO4, 0.8 mL/min. Two injections per run were 
achieved by stopping the run immediately after the first injection and injecting again after 
2 min. 
 
Only 1.3 mg of the target compound 26c was obtained as large scale purification on 
analytical columns is not feasible, but that was sufficient for an incorporation study. The 
test protein His6PpiB was successfully produced with the purified isoleucine analogue 
26c (Figure 2.21), thus validating the assignment of stereochemistry. Incorporation of 
the chlorinated analogue of isoleucine 26a was confirmed by MS. 
  
8c 8c 53c 53c 52c 
52c 
26c 26c 
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Amino acids:  
Ile 7:                +           ‒         ‒ 
26c:                ‒           ‒         + 
 
 
  
Figure 2.21. SDS-PAGE analysis of His6PpiB produced via cell-free protein expression with 
the purified ester 26c instead of (2S,3S)-isoleucine 7. 
 
The successful utilisation of the methyl ester 26c in protein expression confirmed the 
previous attempts of protein production with the free amino acid 26a were unsuccessful 
solely due to the instability of the substrate, and the biological selection mechanism 
employed by IRS does not have the capacity to discriminate between primary chloro 
and methyl groups. This work has been published
[123]
 and copied on the following 
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In Situ Deprotection and Incorporation of Unnatural Amino 
Acids during Cell-Free Protein Synthesis 
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2.1. Alternate approaches to γ-chlorovaline methyl ester 
The methyl ester 26c is stable and can support protein expression and, when produced 
by chlorination of (S)-valine methyl ester 8c without excessive chlorination, is the only 
product in the mixture that can replace (2S,3S)-isoleucine 7 (Scheme 2.1). As such, 
unfractionated mixture was successfully used to establish the incorporation of the 
isoleucine analogue 26a (Figure 2.15). However, due to limited solubility of the esters 
in aqueous solutions, use of the mixture for protein production is problematic as the 
compounds interfere with the synthetic machinery when supplied in larger amounts. As 
the established purification method for the target 26c (vide supra) is not suitable for 
preparative scale, a new synthetic route was sought. 
Total synthesis of enantiomerically pure amino acid 26a was reported[124] and the 
method could be modified to produce the ester 26c; however, the procedure requires 11 
sequential synthetic steps. Direct chlorination of valine 8a can lead to the target in a 
single step, thus development of a new purification method seemed more promising. 
To increase the retention of the target compound on the reverse phase, the mixture of 
chlorination products obtained from chlorination of valine methyl ester 8c was protected 
with the tBoc group (Scheme 2.3). The acid labile tBoc protecting group was chosen as 
the target compound 26c is stable in strong acid. 
Reverse phase HPLC was used for fractionation of the mixture. The γ-chlorinated 
diastereomers 56a and 56b separated from all other components in the mixture, but 
were not separable (Figure 2.22). 
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Scheme 2.3. Preparation of the protected analogues of isoleucine. 
 
The diastereomers 56a,b with flexible chains appeared inseparable, hence separation of 
conformationally restricted lactones 57a and 57b was considered, followed by 
reinstallation of the desired functionality afterwards (Scheme 2.4). 
 
 
Figure 2.22. HPLC chromatogram of the separation of the chlorides 56a,b on an Alltima C18 
column (22×250 mm, 5µ), eluting with 60% methanol, 10 mL/min. 
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Scheme 2.4. The proposed route for the large scale preparation of pure protected analogue 26c. 
 
After chlorination of valine 8a, the mixture was dissolved in water and pH was 
neutralised to promote lactonisation of the chlorinated species 26a and 52a. The amino 
groups were subsequently protected and the mixture was analysed by HPLC. As 
expected, the diastereomeric lactones 57a and 57b eluted as separate fractions (Figure 
2.23). Stereochemistry was established by 1H NMR by comparison with the spectra of 
N-acetylated lactones 54a and 54b used in the previous study (vide supra) as well as the 
published spectra of the lactones 57a and 57b.[125] 
The lactones 57a and 57b are useful compounds for chemical synthesis[125] and could be 
elaborated to the chlorides 26c and 52c on a large scale, as proposed in Scheme 2.4. 
However, this route was deemed too long for the preparation of analogues for protein 
expression and was not attempted. 
 
8a 26a 52a 53a 
57a 57b 26c 52c 
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Figure 2.23. HPLC chromatogram showing the separation of the lactones 57a and 57b on an 
Alltima C18 column (22×250 mm, 5µ), eluting with 40% methanol, 12 mL/min. 
 
Instead, the mixture of the diastereomers 56a,b isolated earlier (Figure 2.22) was 
deprotected with TFA and the resultant mixture of the chlorides 26c and 52c was used 
for all subsequent experiments. The two esters were completely soluble in aqueous 
mixtures at concentrations needed for effective protein expression, and the diastereomer 
52c was not recognised by the protein synthetic machinery. 
 
2.2. Incorporation of 3’,3’,3’ – trifluoroisoleucine 
As mentioned in the Introduction, 3’,3’,3’-trifluoroisoleucine 24a was not a replacement 
for isoleucine 7 during protein expression and ATP consumption assays with purified 
IRS showed no activity, suggesting the analogue 24a was rejected by the activating 
domain of the enzyme.
[91]
 The fluoride 24a was reinvestigated alongside the 
chloride 26a. 
A literature procedure
[126]
 was employed for the preparation of the analogue 24a 
(Scheme 2.5). Methyl isocyanoacetate 58 was coupled with 1,1,1–trifluorobutanone 59 
57b 
57a 
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in the presence of sodium tert-butoxide; the strong base formed the alkene 61 via the 
oxazoline intermediate 60 with 25% yield in a single step. Technical grade methyl 
isocyanoacetate 58 was used for the synthesis, which accounts for the lower than 
expected yield. 
The alkene intermediate 61 was then hydrogenated over Pd/C and deprotected with 
aqueous hydrochloric acid. As exclusively the Z-olefin was formed during the coupling, 
the amino acid 24a was obtained as a single diastereomer. 
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Scheme 2.5. The synthesis of trifluoroisoleucine 24a. 
 
Only background levels of the test protein His6PpiB were produced when the fluoride 
24a was supplied in place of isoleucine 7 during cell-free expression (Figure 2.24). MS 
24a 
58 
59 
61 
60 
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analysis of the produced protein showed trace incorporation of the fluoride 24a, 
resulting in partially fluorinated His6PpiB (Figure 2.25). 
 
Amino acids:  
Ile 7:                     +         ‒         ‒ 
24a:                     ‒         ‒         + 
 
 
  
Figure 2.24. SDS-PAGE analysis of His6PpiB produced via cell-free expression with the 
fluoride 24a instead of (2S,3S)-isoleucine 7. 
 
These findings confirm the analogue 24a is for the most part rejected by IRS. While 
trace amounts of the amino acid were incorporated into protein, the error rates are far 
too low to support protein synthesis. 
These observations are consistent with the proposed size exclusion mechanism. While a 
single hydrogen-to-fluorine substitution is considered inconsequential, the entire methyl 
group is replaced by a trifluoromethyl group in the analogue 24a, increasing the steric 
bulk of the residue. The cumulative effect of the triple substitution on the shorter arm of 
isoleucine is likely registered by the synthetase as discrimination of size on the shorter 
branch of the substrate is critical for the discrimination against (2S,3R)-allo-isoleucine 
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62, a diastereomer of isoleucine that is not found in proteins, but none the less is present 
in the cell (Figure 2.26).[127] 
 
 
 
 
 
 
 
 
 
Figure 2.25. Deconvoluted ESI-MS spectrum of the trace amounts of His6PpiB produced in the 
presence of the analogue 24a. The mass increase of 54 Da between the protein species indicates 
a higher level of substitution with the fluoride 24a. 
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Figure 2.26. The diastereomers of (2S)-isoleucine. 
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2.3. Synthesis of 5,5,5 – trifluoroisoleucine 
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Scheme 2.6. The attempted synthesis of 5,5,5-trifluoroisoleucine 24b. 
 
For direct comparison of the trifluorinated analogues of isoleucine, the regioisomer 
5,5,5-trifluoroisoleicine 24b was also pursued (Scheme 2.6). Following a literature 
procedure,[128,129] cyanoacetic acid 63 and acetone 64 were condensed under Dean-Stark 
conditions. The condensate was then distilled to produce 3-methylbut-3-ennitrile 65. 
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During the distillation, the olefin 65 was prone to isomerise to the more favourable 
3-methylbut-2-ennitrile, and the distillate contained a mixture of the two isomers, but 
was used without further purification. 
The mixture was electrolysed in the presence of trifluoroacetic acid. Eight major triplets 
(3JFH = 11 Hz) were seen in the 
19F NMR spectrum of the electrolysate, indicating the 
presence of (2,2,2-trifluoroethyl)- groups, thus confirming the alkene 65 was 
trifluoromethylated, but also suggesting the intermediate radical species may have 
partially undergone subsequent polymerisation, thus consuming part of the product. 
The electrolysed mixture was distilled under vacuum to remove any polymeric species 
and then hydrogenated over Pd/C. This significantly reduced the complexity of the 
mixture (down to four major triplets in the 19F NMR spectrum). Isolation of 
5,5,5-trifluoro-3-methylpentannitrile 66 was attempted by distillation. Due to the nature 
of the mixture, however, complete purity of the nitrile 66 was unattainable; Figure 2.27 
displays a 1H NMR spectrum of the fluoride 66 obtained after repeated distillation, 
including through a Vigreux column. Nevertheless, analytical purity was not required at 
this stage of the synthesis, and the crude material was carried over to the next step. 
While the intermediate 66 was not isolated as a single species, greater purity was 
obtained than had been in previous attempts,[91] thus enabling unambiguous assignment 
of the signals in the 1H NMR spectrum; previously it had been impossible to even 
confirm the δ 1.19 ppm peak belongs to the compound 66, with the δ 1.02 ppm signal 
potentially assigned. 
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Figure 2.27. 
1
H NMR spectrum of partly purified 5,5,5-trifluoro-3-methylpentannitrile 66. 
 
5,5,5-Trifluoro-3-methylpentannitrile 66 was treated with aqueous hydrochloric acid to 
hydrolyse the cyano group. Upon neutralisation of the hydrolysis solution the product 
5,5,5-trifluoro-3-methylpentanoic acid 67 dissolved in the aqueous solution, whereas 
non-hydrolysable material (likely partly polymerised hydrocarbons) remained in a 
separate layer. After re-acidification of the aqueous layer, 5,5,5-trifluoro-3-
methylpentanoic acid 67 separated into a separate organic layer and after redistillation 
was obtained as a colourless foul-smelling liquid. 
5,5,5-trifluoro-3-methylpentanoic acid 67 was isolated in only 2% yield, based on 
cyanoacetic acid 63. The low yield is primarily attributable to the observed 
polymerisation during the electrolysis, largely facilitated by the lack of proper apparatus 
and electrodes for efficient current control, as well as loss of material during the 
attempted purification of 5,5,5-trifluoro-3-methylpentannitrile 66. A more conventional 
synthesis of the acid 67 was then considered. A Wittig reaction between 
4,4,4-trifluorobutanone 68 and benzyl (triphenylphosphoranylidene)acetate 69 followed 
66 
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by hydrogenation gave 67. However, only 19% yield was achieved. Due to the limited 
availability of the materials scaling up of this reaction was problematic and the low 
yields made it difficult to attain large amounts of the product. 
Hell-Volhard-Zelinsky reaction with the acid 67, followed by treatment with aqueous 
ammonia of the resultant bromide 70 was used for the preparation of 
5,5,5-trifluoroisoleucine 24b. The amino acid was detected in the reaction mixture by 
MS, but the material was lost during purification attempts. Low yields throughout the 
synthesis partly complicated the purification efforts and resulted in loss of material. It 
was therefore decided to develop a new route to the analogue 24b. 
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Scheme 2.7. The attempted synthesis of 5,5,5-trifluoroisoleucine 24b via the Schöllkopf 
oxazoline 72. 
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Based on the synthesis of the fluoride 24a via the Schöllkopf oxazoline 60 (Scheme 
2.5), an analogous route to the fluoride 24b via the alkene 71 was considered (Scheme 
2.7). A one-pot procedure to generate the intermediate 71 from methyl isocyanoacetate 
58 and 4,4,4-trifluorobutanone 68 was attempted (Scheme 2.7, route A), as was done 
with the fluoride 61, but the target was not detected. The intermediate oxazoline 72 was 
then synthesised using gentler conditions[130] (Scheme 2.7, route B). Base treatment, 
however, led to complete decomposition of the substrate 72. 
The difficulty of handling 4,4,4-trifluorobutanone 68 is a consequence of the 
β-trifluoromethyl-carbonyl arrangement of the molecule, making it extremely 
susceptible to enolisation and/or HF-elimination. This susceptibility persists in 
derivatives of the ketone 68, thus explaining the decomposition of the oxazolinone 72 
under basic conditions. As the butanone 68 could participate in a Wittig reaction 
(Scheme 2.6), it was attempted to pre-install the amino acid functionality on the 
phosphonate prior to the coupling reaction. Unfortunately, the Wittig-Horner reaction 
with the phosphonate 73 was not successful (Scheme 2.8). 
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Scheme 2.8. Wittig-Horner reaction with 4,4,4-trifluorobutanone 68. 
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Finally, the synthesis of 5,5,5-trifluoroisoleucine 24b was attempted through 
microwave-assisted alkylation of diethyl acetamidomalonate 74 with 3-chloro-1,1,1-
trifluorobutane 75 (Scheme 2.9).[131] Unfortunately, only starting material 74 was 
recovered; the chloride 75 was likely consumed by elimination. Elimination is known to 
compete with substitution when saturated alkyl halides are used for alkylation, but at 
least small amounts of the alkylation product are generally achieved.[131] The 
trifluoromethyl group, however, appears to overwhelmingly promote elimination by 
increasing the acidity of the neighbouring methylene group, resulting in rapid 
consumption of the substrate 75. 
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Scheme 2.9. Attempted alkylation of diethyl acetamidomalonate 74. 
 
After the unsuccessful attempts to synthesise the isoleucine analogue 24b it was 
apparent that the pathway via the acid 67 was the most viable. At this stage, however, 
the discrepancy regarding the incorporation of unnatural analogues was resolved; hence 
the synthesis of fluoride 24b was abandoned. 
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2.4. Incorporation of amino acids for ‘click’ chemistry 
The permissiveness of AARSs can be utilised for incorporation of amino acids for 
residue-specific modification. In particular, the alkyne-bearing analogue of isoleucine 
77a could enable rapid labelling of protein via azide-alkyne cycloaddition. Protein with 
the alkyne 77a had been prepared in the past, but live cell protein expression was used 
and the amino acid was supplied to the medium as a racemic mixture.[89] In the current 
study the diastereomer precursors 81a and 81b were separated and enzymatic 
deacylation was used to obtain the target amino acid 77a as a single enantiomer 
(Scheme 2.10). 
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Scheme 2.10. The synthesis of 2-amino-3-methylpent-4-ynoic acids 77a and 77b. 
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But-3-yn-2-ol 78 was brominated by triphenylphosphite dibromide generated from 
triphenylphosphite and bromine.[132] The alcohol 78 in ether was added to the solid 
triphenylphosphite dibromide and the heterogeneous reaction was allowed to proceed 
for 3 h. Afterwards the reaction mixture was vacuum distilled and 3-bromobut-1-yne 79 
was collected as a colourless fruity-smelling liquid in 66% yield. 
During alkylation of diethyl acetamidomalonate 74,[133] 3-bromobutyne 79 underwent 
both direct SN2 substitution to give the desired product 80, and SN2’ substitution to 
produce some undesired by-product. Regardless, both of the products were 
decarboxylated, and the mixture was then purified by reverse phase HPLC. 
Upon decarboxylation of the malonate 80 the desired (2S,3S)-(±)-enantiomeric pair 81a 
formed preferentially. After deprotection with acylase the isoleucine analogue 77a was 
used in the production of His6PpiB (Figure 2.28). 
 
Amino acids:  
Ile 7:         +            ‒            ‒                   +        ‒ 
77a:         ‒            ‒            +                   ‒        + 
 
 
  
Figure 2.28. SDS-PAGE analysis of His6PpiB produced via cell-free expression with the alkene 
77a instead of (2S,3S)-isoleucine 7. 
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As expected, large amounts of protein were produced when (2S,3S)-isoleucine 7 was 
replaced with the alkyne 77a, confirming the analogue is a suitable replacement for 
isoleucine.[89] Surprisingly, though, nickel affinity purification of substituted His6PpiB 
failed, as most of the protein did not bind the metal resin and was collected in the flow-
through. Such failure of hexahistidine-tagged protein to bind Ni(II)-NTA resin has not 
been reported. It was hypothesised that the alkyne, due to the affinity to transition 
metals, could in some way interfere with nickel-histidine interaction. In the previous 
expression[89] of dihydroxyfolate reductase (DHFR) with the analogue 77a the product 
was successfully isolated by affinity to immobilised nickel, although only ca. 70% 
substitution of isoleucine was achieved. Nevertheless, the mechanism for reduction of 
binding affinity is difficult to propose, and addition of butynol 78 to wash buffers did 
not obstruct the purification of unsubstituted His6PpiB. 
As a means to counter the poor binding, the hexahistidine-tag on the protein was 
extended to a dodecamer. The stronger binding of the His12PpiB enabled the use of 
more stringent conditions during purification, resulting in cleaner product. Even with 
this modification, however, the alkyne 77a-bearing protein had poor affinity to the resin 
(Figure 2.29) and required several cycles of purification to isolate all of the product for 
analysis. 
The incorporation levels of the analogue 77a into His12PpiB were analysed by 
2D NMR. 13C-HSQC spectra were recorded in 6 M urea-D6 in D2O to ensure the protein 
is unfolded (Figure 2.30). Signals corresponding to the methyl groups of isoleucine 7 
residue had reduced to background levels in the sample containing modified His12PpiB 
and strong peaks due to the analogue 77a were observed. 
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Figure 2.29. SDS-PAGE analysis showing the poor binding of His12PpiB produced with the 
alkyne 77a to Ni(II)-NTA resin during protein purification. 
 
Quantification of the substitution of isoleucine 7 based on the NMR signal strength was 
attempted. Peak intensities in 2D NMR spectra depend heavily on the nature of the 
species, making quantification unreliable, but signals corresponding to chemically 
similar groups are expected to have similar intensities.[134] For that reason signals 
corresponding to the methyl groups of leucine 18, isoleucine 7 and valine 8a were 
integrated and divided by the number of protons they represent (based on protein 
sequence). Similar intensities per proton were obtained for valine 8a and leucine 18, 
whereas signals for isoleucine 7 were smaller by about 20%, thus signifying a large 
error margin associated with the employed method (Figure 2.31). Relative to leucine 18, 
the signals for isoleucine in protein expressed with the alkyne 77a were reduced by 
more than 98%, indicating that only background levels of isoleucine 7 were 
incorporated into the modified protein. However, the intensity of the signal attributed to 
the methyl group of the analogue 77a was weaker than the signals of the excluded 
isoleucine. Thus, while the NMR analysis showed the alkene 77a was very effectively 
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incorporated into protein in place of isoleucine 7, due to the error associated with the 
method exact level of substitution cannot be established. 
 
 
Figure 2.30. Detection of 77a in His12PpiB by 
13
C-HSQC. The spectrum of modified protein 
(orange and light blue) is off-set from the control (red and blue). Signals attributable to 77a are 
clearly visible in the modified protein (solid arrows), whereas those of isoleucine 7 are 
significantly weaker (hollow arrows). The signals of the methyl groups of BCAA are assigned. 
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Figure 2.31. Normalised 
13
C-HSQC signal strength (per proton) of the methyl groups of BCAA 
in spectra of natural His12PpiB (■) and modified with 77a (■). The signals of isoleucine 7 are 
reduced by >95% in the spectrum of the modified protein. 
 
2.5. Conclusions 
In the present study the chlorinated analogue of leucine 26a was shown to be unstable 
under physiological conditions and the instability was demonstrated to be the 
underlying reason for failure to support protein synthesis. The methyl ester 26c that is 
deprotected in situ at a rate that matches the rate of protein expression enables the 
incorporation of the unstable chloride 26a, thus confirming that a chlorine atom is a 
suitable replacement for a methyl group. A practical route for the preparation of the 
ester 26c was established. 
In contrast, the rejection of trifluorinated analogue 3’,3’,3’-trifluoroisoleucine 24a 
during protein synthesis was confirmed. The miniscule levels of incorporation of the 
analogue are consistent with the proposed size exclusion mechanism, with the 
trifluoromethyl group being on the boundary of what is accepted into the active site of 
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IRS. It is theorised that the increase in size due to the triple hydrogen-to-fluorine 
replacement is the reason for rejection. 
An alkyne analogue of isoleucine 77a was prepared as a single enantiomer and was 
incorporated into protein. The incorporation was confirmed by 2D 13C-HSQC. 
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s described in the previous chapter, the isostere of isoleucine γ-chlorovaline 
26a was prone to rapid decomposition to a 5-membered lactone under physiological 
conditions, making direct incorporation into proteins through cell-free expression 
impossible. The problem was circumvented with the use of the methyl ester 26c that 
was deprotected in situ, thus providing a constant supply of the analogue 26a and 
allowing the production of modified protein. Subsequently, it was observed that the 
propensity of the chloride 26a to lactonise was retained after incorporation into protein, 
leading to the cleavage of the proximal peptide bond, following a mechanism 
reminiscent of cyanogen bromide-mediated methionine-specific proteolysis, but 
required elevated temperatures to proceed; chlorinated protein was stable at or below 
physiological temperature, but began to fragment at 60°C and decomposed within 
minutes at 100°C. Both diastereomers of the analogue of leucine 4-chloronorvaline 25 
were found to impart the same properties onto modified proteins, signifying heat-
induced mediation of peptide bond cleavage is a common property of γ-chlorinated 
amino acids, driven by the formation of highly favourable 5-membered rings. The 
mechanism of fragmentation was confirmed by ESI-MS analysis of peptide fragments 
generated after heat treatment of chlorinated test protein His6PpiB. In contrast, 
β-chlorinated analogues of valine 15a and 15b and the previously uninvestigated 
A
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isostere of isoleucine (2R,3S)-(±)-3-chloronorvaline 27 led to proteins that were not 
fragmented in response to heat, consistently with the properties of free amino acids. 
The latent leucine- and isoleucine-specific heat-controlled peptide bond cleavage was 
developed as an alternative method to the more traditional biological or chemical 
proteolysis for the production of small peptides, expressed as parts of larger fusion 
proteins. The validity of the method was demonstrated through the preparation of 
gastrin releasing peptide prohormone (GRPG), utilising the isostere of isoleucine 26c to 
exact the bond cleavage, and cholecystokinin prohormone (CCKG), using the analogue 
of leucine 25 for the release of the peptide, as well as modified analogues of the two 
peptides bearing perdeuterated or fluorinated residues. Preparation of prolactin releasing 
peptide prohormone (PRPG) via this route was not successful, however, due to the 
N-terminal serine of PRPG interfering with the bond hydrolysis reaction. 
Concurrently, dehydro isosteres of leucine and isoleucine were shown to induce peptide 
bond cleavage upon exposure to iodine at 0°C following an analogous mechanism, as 
demonstrated with allylglycine[52,53] (Scheme 1.6). The utility of the iodination-sensitive 
amino acids was demonstrated through the preparation of GRPG and PRPG, following 
an analogous approach. 
The two new methods of bond cleavage for peptide production were contrasted with 
traditional enzymatic protein digestion, exemplified by preparation of calcitonin 
prohormone CTG and six modified analogues through digestion of the corresponding 
fusion proteins with enterokinase. The latent chemical cleavage methods had distinct 
advantages over the enzymatic approach, like shorter reaction times, the ability to digest 
insoluble material and the lack of need for expensive reagents. 
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In the work described, an application of functionalised ‘activated’ amino acids 
introduced into proteins in place of aliphatic amino acids with non-functionalised 
side-chains was demonstrated. All possible singly-chlorinated isosteres of the BCAA 
family were incorporated into proteins through cell-free protein expression. The 
γ-chlorides were shown to be latent peptide bond cleavage triggers, and the resulting 
protein fragmentation was utilised in the production of small peptides, whereas the 
β-chlorides led to stable proteins, potentially enabling orthogonal chemistry to be 
carried out on the two classes of the chlorinated amino acids. This work has been 
published in ChemBioChem and the following pages contain the published manuscript. 
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he discernment of the propensity of γ-chlorinated amino acids for lactonisation 
has led to the development of a heat-responsive proteolysis trigger that has been 
successfully employed for the preparation of peptides, as described in the previous 
chapter. A potential limitation of the method is that the target peptide must lack one of 
the amino acids that can be substituted by a latent proteolysis-inducing analogue, 
isoleucine or leucine, thus seemingly limiting the method to the production of 
specifically selected targets. As a potential solution, interchange of the structurally 
similar amino acids from the BCAA family was considered. To test the feasibility of 
this approach, a small inhibitor of proteases aprotinin containing both two isoleucines 
and two leucines in the sequence was chosen as a target. 
Aliphatic halogenated amino acids have been successfully employed in the past for 
diverse protein modifications, including protein labelling,[135] formation of cyclic 
peptides,[136] protein cross-linking[137] and protein chemical ligation.[138] In contrast, 
amino acids with functionalised side chains for bioorthogonal reactions on proteins can 
only react with specially tailored chemical agents.[94,139] The resistance of the 
β-chlorinated amino acids to heat treatment, as demonstrated in the previous chapter, 
suggested the reactive functionalities would be retained in the produced peptides and 
T 
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could be used for subsequent elaboration. However, the reported loss of protein function 
after expression with 2-amino-3-chlorobutyric acid,[78,86] posed another serious 
limitation to the potential use of the chlorinated amino acids in protein engineering. 
 
4.1. Expression of aprotinin 
Aprotinin, also known as bovine pancreatic trypsin inhibitor, or BPTI, was identified as 
the most suitable target for the investigation. The 58 amino acid protein with 
extensively studied structure[140] contained both two isoleucine and two leucine 
residues, making it a representative protein in terms of amino acid composition. Due to 
the smaller size, aprotinin could not be expressed individually in a cell-free protein 
expression system, thus requiring the use of a carrier protein. Additionally, the protein 
contains a single valine in the sequence that can be substituted by the chlorinated 
analogues 15a and 15b, meaning any restructuring would originate from a single point 
in the protein, allowing for a clearer evaluation of the effects of the chlorides.[141] 
Finally, as an inhibitor of serine proteases, aprotinin readily crystallises as a complex 
with trypsin,[140] thus allowing for the direct observation of protein activity by X-ray 
crystallography. 
As described in the previous chapter, aprotinin was fused to the gene of the carrier 
protein peptidyl-prolyl cis-trans isomerase B (PpiB), with leucine encoded between the 
two proteins for heat controlled separation through the use of the chloride 25. To 
prevent the heat labile analogue from incorporation into aprotinin, the leucine residues 
in aprotinin were mutated to isoleucine (L6I,L29I), and the hexahistidine tag was 
attached directly to the mutated aprotinin, at the C-terminus, to enable purification of 
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aprotinin through metal affinity chromatography (Figure 4.1). The cell-free reaction to 
express the fusion protein was carried out in 10 mL of inner reaction mixture with the 
4-chloronorleucine 25 in place of leucine (Figure 4.2). Due to the selectivity afforded by 
the biological machinery, the chloride 25 could be used as a mixture with its precursor 
(S)-norvaline (and other by-products); only the two diastereomers of the chloride 25 
(both of which have similar reactivity) were recognised and incorporated into expressed 
protein. This substantially simplified the preparation of materials, particularly on a 
larger scale. To further reduce the number of steps, the heat-labile fusion protein was 
not purified after expression, but instead the entire reaction mixture was subjected to 
100°C for 5 min. After the heat shock, 6 M guanidinium chloride was added to 
solubilise the precipitated proteins and the tagged aprotinin was extracted through 
Ni(II)-affinity chromatography under denaturing conditions. Refolding of aprotinin was 
not impeded by either the histidine-tag or the homologous substitutions, and active 
inhibitor was obtained after overnight incubation of the purified peptide in Tris buffer. 
Activity was confirmed through a trypsin inhibition assay. 
 
MVTFHTNHGD IVIKTFDDKA PETVKNFLDY CREGFYNNTI FHRVINGFMI 
QGGGFEPGMK QKATKEPIKN EANNGLKNTR GTLAMARTQA PHSATAQFFI 
NVVDNDFLNF SGESLQGWGY CVFAEVVDGM DVVDKIKGVA TGRSGMHQDV 
PKEDVIIESV TVSENGGGAL RPDFCIEPPY TGPCKARIIR YFYNAKAGIC 
QTFVYGGCRA KRNNFKSAED CMRTCGGAHH HHHH 
Figure 4.1. The sequence of PpiB_BPTI_His6 fusion protein. The BPTI segment is in bold, the 
mutated L6I and L29I residues are italicised, and the cleavage point is underlined. 
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Amino acids:  
Val 8a:  + ‒ ‒  + ‒ ‒  
Analogue:  ‒ 15b 15a  ‒ 15b 15a  
 
 
  
Figure 4.2. Production of modified aprotinin. Left: crude reaction mixtures containing PpiB-
aprotinin fusion proteins; right: aprotinin obtained after Ni(II)-affinity purification of heat 
treated (100°C for 5 min) reaction mixtures. 
 
 
The fusion protein was then expressed with a double substitution. Next to the analogue 
of leucine 25, as described above, (2R,3S) and (2R,3R)-2-amino-3-chlorobutyric acids 
15b and 15a were separately added to the expression mixtures in place of valine 8a. 
Expression levels of the doubly-substituted fusion proteins were similar with the singly-
substituted material (Figure 4.2). After heat treatment to induce bond cleavage, the 
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chlorinated analogues of aprotinin were purified and refolded like the peptide composed 
solely from the proteogenic amino acids. Over 1 mg of aprotinin was obtained in all 
three cases, despite the carrier protein PpiB accounting for three quarters of expressed 
material. The scalability of cell-free protein expression makes large-scale production of 
proteins feasible. 
The production process of aprotinin highlights the stark differences in the chemical 
properties of β- and γ-functionalised amino acids. Similar reactivity towards external 
reagents had been observed with both classes of halogenated amino acids,[136] but the 
γ-functionalised amino acids show high propensity for cyclisation, driven by the 
formation of 5-membered rings, with elevated temperatures needed to compensate for 
the reduced nucleophilicity of the carboxy-group in a peptide chain, whereas the halide 
at the β-position is unaffected by raised temperatures. 
 
4.2. Crystallisation and crystal analysis 
The produced proteins were complexed with trypsin. Due to the propensity of trypsin to 
self-digest, pure active trypsin is unattainable, with partially digested protein present 
even in highest grade material. To ensure these fragments do not interfere with the 
crystallisation process, the complexes were re-purified through Ni(II)-affinity 
chromatography, this time under native conditions. As the C-terminus of aprotinin is on 
the face opposite to the trypsin binding region, the hexahistidine-tag was not 
sequestered by the complexation and thus free to bind to immobilised metal ions. The 
complexes were crystallised by hanging drop method using conditions previously used 
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for the aprotinin-trypsin complex.[140] Hexagonal crystals suitable for X-ray diffraction 
were obtained within a week (Figure 4.3). 
 
 
Figure 4.3. Crystals of aprotinin-trypsin complexes. 
 
The complex composed of natural amino acids was solved to 1.7 Å resolution (C1). The 
same resolution was achieved for the complex containing (2R,3R)-2-amino-3-
chlorobutyric acid 15a (C3), whereas an even greater resolution of 1.6 Å was attained 
for the complex with the (2R,3S)-diastereomer 15b (C2, Table 4.1). The positions of the 
electron-rich chlorine atoms were clearly visible in the electron density maps during 
refinement. The structures were refined using the published model (PDB id: 3OTJ) as a 
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starting structure. In all three solved structures the electron density for the C-terminal 
his-tag on aprotinin was not visible, suggesting the tag did not adopt an ordered 
structure. The first two N-terminal residues Arg1 and Pro2 were also not observed, as is 
often the case with the flexible termini protruding from globular structures. 
In the structure containing (2R,3S)-2-amino-3-chlorobutyric acid 15b, the modelled 
chlorinated side-chain contained a surplus of electron density around the chlorine atom 
than was observed from the diffraction pattern, indicating the position was partly 
occupied by valine 8a that was in competition with the chloride 15b during protein 
expression. A good fit with the detected electron density was observed after the 
occupancy of the chlorine atom was reduced to 80%; accounting for the contribution of 
valine residue, about 70% incorporation of the chloride was achieved. In contrast, the 
modelled side-chain of (2R,3R)-2-amino-3-chlorobutyric acid 15a fit the experimental 
electron density, indicating good (>90%) replacement of valine. 
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Table 4.1. Crystallographic data and refinement statistics. 
Structure C1 C2 C3 
Data collection
[a]
    
Unit cell parameters    
a / Å 74.6 74.6 74.9 
b / Å 80.6 81.0 80.7 
c / Å 124.4 124.1 124.2 
α / ° 90.0 90.0 90.0 
β / ° 90.0 90.0 90.0 
γ / ° 90.0 90.0 90.0 
Space group I222 I222 I222 
Resolution / Å 37.28-1.70 (1.73-1.70) 32.69-1.60 (1.62-1.60) 37.42-1.70 (1.73-1.70) 
Observed reflections 282892 (12434) 351682 (16263) 202246 (8828) 
Unique reflections 39898 (1973) 50182 (2455) 41146 (1986) 
Completeness / % 96.6 (91.4) 100.0 (100.0) 99.1 (88.6) 
Multiplicity 7.1 (6.3) 7.0 (6.6) 4.9 (4.4) 
Rmerge
[b] 0.084 (0.359) 0.060 (0.316) 0.090 (0.733) 
< I/σ(I) > 12.8 (4.2) 17.3 (4.7) 8.1 (1.6) 
    
Structure refinement
[a]
    
Resolution / Å 1.70 (1.75-1.70) 1.60 (1.64-1.60) 1.70 (1.75-1.70) 
Rwork
[c]
 0.154 (0.208) 0.163 (0.223) 0.163 (0.300) 
Rfree
[c] 0.190 (0.251) 0.193 (0.291) 0.201 (0.326) 
No. reflections 37893 (2618) 47649 (3435) 39065 (2644) 
No. free R reflections 1997 (142) 2520 (195) 2071 (148) 
No. non-hydrogen atoms 2430 2427 2449 
No. protein atoms 2084 2085 2084 
No. water molecules 320 316 339 
Average B factor / Å2 20.9 18.3 24.2 
R.m.s.d. bonds / Å 0.023 0.026 0.020 
R.m.s.d. angles / ° 2.170 2.393 1.913 
Ramachandran plot / %    
favoured regions 98.9 98.2 98.9 
allowed regions 1.1 1.8 1.1 
disallowed regions 0 0 0 
[a] The number in parentheses in the value in the highest resolution shell. [b] Rmerge = ∑hkl∑i|Ihkli-<Ihkl>| / 
∑hkl∑i<Ihkli>, where Ihkli is the intensity of the ith observation of reflection hkl and <Ihkl> is the average 
intensity. [c] Rwork = ∑||Fobs|-|Fcalc|| / ∑|Fobs|; Rfree was calculated using 5% of randomly selected reflections 
for cross-validation. 
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The observed extent of incorporation of the chlorinated amino acids is in good 
agreement with earlier reports of valyl-tRNA synthetase displaying twenty-fold[142] 
greater affinity for the (2R,3R) diastereomer 15a, that is even able to compete with the 
natural substrate (S)-valine 8a,[102] than the (2R,3S) chloride 15b that is highly 
suppressed by the natural substrate. The enzyme appears to tolerate replacement of the 
methyl groups of (S)-valine 8a with more polar groups differently, with modification of 
the pro-S position significantly more acceptable.[142] This is reflected by the recognition 
of (2S,3R)-threonine as a substrate by the synthetase, requiring subsequent editing to 
prevent misincorporation of the hydroxylated amino acid into proteins,[69,77] whereas no 
activity is detectable with (2S,3S)-allo-threonine.[142] 
The substitution of the two endogenous leucine residues Leu6 and Leu29 with isoleucine 
did not cause any restructuring in the conformation of protein structure, as compared to 
the structure of wild-type protein (Figure 4.4). Both of the residues are positioned on the 
surface of aprotinin, facing away from trypsin in the protein complex. In the crystal 
lattice, the side-chain of residue6 is protruding into a solvent channel, whereas residue29 
is close to a crystallographic two-fold screw axis that occurs as a result of the presence 
of both a crystallographic dyad and body centring in the I222 space group; the residue is 
positioned ca. 4 Å from Ile19 and Val34 of symmetry-related aprotinin unit and likely 
forms a stabilising hydrophobic interaction during crystallisation. No rearrangement of 
protein backbone or neighbouring residues is evident as a result of amino acid 
replacement, which can likely be explained by the aliphatic amino acids exhibiting 
similar properties, at least with respect to the maintenance of protein folding. 
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Figure 4.4. An overlay of the crystal structures of (L6I,L29I)-aprotinin/trypsin complex (green) 
and wild-type aprotinin/trypsin complex (PDB id: 4Y0Y; blue). Residue
29
 is in close proximity 
to a hydrophobic patch created by Val
34
 and Ile
19
 of a symmetry partner (grey) and occupies the 
space of the replaced residue, whereas residue
6
 is exposed to a solvent channel. Neither the 
overall structure of the protein (a) nor the local environments of the substituted residues (b,c) 
are affected by the mutation. 
  
c) 
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Similarly, the protein structure was not influenced by the inclusion of the chlorinated 
analogues of valine (Figure 4.5). The sole valine residue in aprotinin Val34 is located on 
the surface of the protein and comes in close contact with trypsin in the inhibitory 
complex, with the methyl groups of Val34 less than 4 Å from Oζ of Tyr154 in the trypsin 
chain, but is otherwise included in a hydrophobic pocked created by the hydrocarbon 
chain of Arg17 in aprotinin and the hydrophobic patch formed with the symmetry-
related unit, as described above. Both of the chlorinated amino acids adopted the exact 
same position and conformation as valine in the original structure, with the chlorine 
atoms assuming the respective positions occupied by the corresponding methyl groups 
of valine. 
The complete overlap of the chlorinated side-chains and the background (S)-valine in 
the crystal structures further reiterates the capacity of the chlorides to functionally 
replace the proteogenic isostere. After adjustment of the occupancies, the B-factors of 
the halogenated side-chains matched the average B-factors of the respective overall 
structures, as was the case with the native structure, indicating the positions of the 
modified side-chains were well defined. 
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Figure 4.5. The conformation of aprotinin chain residue
34
 in the aprotinin-trypsin complex 
containing a) valine, b) (2R,3S)-2-amino-3-chlorobutyric acid 15b and c) (2R,3R)-2-amino-3-
chlorobutyric acid 15a. Carbon is orange, nitrogen - blue, oxygen - red and chlorine is green. 
The three structures are presented from the same perspective. Electron density maps are 
contoured at 1.5 σ. 
 
4.3. HPLC purification of aprotinin 
To demonstrate the wider feasibility of the approach, free un-tagged aprotinin was also 
sought. Mutants of aprotinin devoid of isoleucine (I18L,I19L) and leucine (L6I,L29I) 
were attached to PpiB via the corresponding residues and the hexahistidine-tags were 
attached at the N-termini of the fusions (Figure 4.6). The constructs were expressed 
c) 
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with the chlorides 26c and 25, respectively, and purified by Ni(II)-ion affinity 
chromatography. After exposure to 100°C, the samples were analysed by reverse phase 
HPLC. To ensure that the produced aprotinin was not attached to other peptide 
fragments through disulfide bridges after the exposure to high temperatures (aprotinin 
contains six cysteines, forming three disulfide bridges when folded), the samples were 
reduced with tris(2-carboxyethyl)phosphine (TCEP) prior to analysis. This resulted in 
greater retention of the peptides on the reverse phase resin, but isolation of aprotinin 
was nevertheless successful (Figure 4.7). While the purification through immobilised 
metal ion affinity was clearly advantageous for larger proteins, the isolation of mutants 
of aprotinin through HPLC served as a clear proof of concept that peptide production 
through heat treatment is not limited to short peptides. 
 
MHHHHHHMVT FHTNHGDIVI KTFDDKAPET VKNFLDYCRE GFYNNTIFHR 
VINGFMIQGG GFEPGMKQKA TKEPIKNEAN NGLKNTRGTL AMARTQAPHS 
ATAQFFINVV DNDFLNFSGE SLQGWGYCVF AEVVDGMDVV DKIKGVATGR 
SGMHQDVPKE DVIIESVTVS ENGGGAIRPD FCLEPPYTGP CKARLLRYFY 
NAKAGLCQTF VYGGCRAKRN NFKSAEDCMR TCGGA 
 
MHHHHHHMVT FHTNHGDIVI KTFDDKAPET VKNFLDYCRE GFYNNTIFHR 
VINGFMIQGG GFEPGMKQKA TKEPIKNEAN NGLKNTRGTL AMARTQAPHS 
ATAQFFINVV DNDFLNFSGE SLQGWGYCVF AEVVDGMDVV DKIKGVATGR 
SGMHQDVPKE DVIIESVTVS ENGGGALRPD FCIEPPYTGP CKARIIRYFY 
NAKAGICQTF VYGGCRAKRN NFKSAEDCMR TCGGA 
Figure 4.6. The sequences of His6PpiB_I_BPTI(I18L,I19L) and His6PpiB_L_BPTI(L6I,L29I) 
fusion proteins. The BPTI segments are in bold, the mutated residues are italicised, and the 
cleavage points are underlined. 
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Figure 4.7. Top: isolation of aprotinin-I18L,I19L produced after heat treatment of 
His6PpiB_I_BPTI fusion protein expressed with the chloride 26a by HPLC; bottom: aprotinin 
standard. 
 
4.4. Use of trypsin column 
Finally, to contrast the newly described route with earlier methods, aprotinin was 
produced following an earlier established procedure.[143] A trypsin cleavage site (lysine) 
was introduced at the boundary between aprotinin and the carrier protein PpiB (Figure 
4.8). As described above, aprotinin is not digested by trypsin, but instead forms an 
inhibitory 1:1 complex with trypsin. Thus, when the fusion protein was exposed to 
trypsin in solution, the carrier protein was digested and free aprotinin was observed by 
SDS-PAGE (Figure 4.9). Following established protocols,[143] trypsin in HEPES buffer 
(pH 7.5) was incubated on a shaker with N-hydroxysuccinamide-activated agarose 
beads for 4 h at 4°C for immobilisation. The beads were then blocked with 1 M 
ethanolamine for 1 h at 4°C and packed in a column. The fusion protein was then 
loaded, and the column was incubated on a shaker for 16 h at 4°C, allowing the carrier 
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protein to be separated and completely destroyed, along with other contaminants, while 
aprotinin was bound to the resin and subsequently eluted with an acidic buffer (Figure 
4.9, right). While aprotinin was obtained in the end, the lengthy procedure highlights the 
advantages of the rapid heat-induced cleavage. 
 
MHHHHHHMVT FHTNHGDIVI KTFDDKAPET VKNFLDYCRE GFYNNTIFHR 
VINGFMIQGG GFEPGMKQKA TKEPIKNEAN NGLKNTRGTL AMARTQAPHS 
ATAQFFINVV DNDFLNFSGE SLQGWGYCVF AEVVDGMDVV DKIKGVATGR 
SGMHQDVPKE DVIIESVTVS ENGGGGGGGA KAKRPDFCLE PPYTGPCKAR 
IIRYFYNAKA GLCQTFVYGG CRAKRNNFKS AEDCMRTCGG A 
Figure 4.8. The sequence of His6PpiB_AKAK_BPTI fusion protein. BPTI segment is in bold, 
the trypsin cleavage site is underlined. 
 
The observed behaviour of the chlorinated amino acids is somewhat surprising, given 
their greater polarity and reactivity. β and γ-Chlorinated amino acid residues had been 
shown to react similarly with heteroatom nucleophiles,[136] but the rapid reaction of 
γ-chlorinated side-chains during exposure to 100°C in water without affecting the 
β-modified residues enables regiospecific functionalisation of the two classes of 
compounds. Additionally, in the past the chlorides were used in smaller peptides,[144] 
while the crystal structures of aprotinin demonstrated that the chlorinated amino acids 
could be introduced into larger proteins as well, without compromising the folding of 
the protein. The complete preservation of protein structure emphasises that chlorinated 
amino acids are not inherently detrimental to protein functionality and are potential 
substitutes for the aliphatic amino acids. This is in accordance with a recent 
demonstration that peptidyl-prolyl cis-trans isomerase B (PpiB) was soluble when 
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expressed globally substituted with the chlorinated isosteres, and, in the case of 
(2R,3R)-2-amino-3-chlorobutyric acid, the enzyme was even shown to be active.[102] 
Furthermore, as established with aprotinin in this study, structurally related amino acids 
can be easily exchanged without affecting protein structure or function, and the 
replacement can be used to limit the occurrence of codons used for the incorporation of 
modified amino acids, essentially putting the analogues under genetic control. 
 
 
 
 
 
 
 
Figure 4.9. The production of aprotinin (BPTI) through trypsin digestion of a fusion protein. 
Left: expression of His6PpiB_BPTI fusion protein; middle: trypsin digestion of His6PpiB_BPTI 
fusion protein in solution; right: pure aprotinin eluted from the trypsin column. 
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4.5. Conclusions 
The similar structures and similar roles of aliphatic amino acids allow them to be 
readily interchanged in proteins without affecting structure or function of the protein. 
The interchange can be used as a tool to reduce the incidence of sites of incorporation of 
unnatural amino acids supplied during protein expression, making the incorporation of 
the analogues site-specific. This enables the application of heat-labile γ-chlorinated 
amino acid-mediated fusion protein fragmentation to the production of more diverse 
(generally bigger) proteins. This is particularly pertinent when functionalised peptides 
are desired, as their production through other means can be problematic. The stability of 
β-chlorinated amino acids under the conditions of heat-controlled proteolysis makes this 
method particularly suitable for the production of halogenated peptides, in milligram 
quantities. The crystal structures demonstrate that β-chlorinated amino acids are able to 
fulfil the structural roles of aliphatic amino acids, making them highly suitable in 
protein design. 
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Chapter 5. Labile Analogues of Methionine 
 
 
 
ollowing the development of the method for peptide production through the 
expression of fusion proteins with readily cleavable linkers, an expansion of the set of 
latent substrates capable of bond cleavage was considered. While, the 
exchangeability[145] of the non-polar amino acids made the production of most targets 
possible with just the two analogues 25 and 26c, with seamless substitutions not 
affecting target structure or function, as demonstrated in the previous chapter, a wider 
range of latent analogues could provide more alternatives for amino acid substitutions, 
potentially requiring fewer modifications, and introduce more versatility to the method. 
A pursuit of a latent analogue of methionine 28 was deemed particularly worthy. As one 
of the least frequently occurring amino acid in proteins,[146] methionine was expected to 
be less frequently encountered in smaller peptide targets, thus requiring a lesser 
modification, and the infamous promiscuity of methionyl-tRNA synthetase (MRS) (see 
Introduction) made the endeavour more promising. The long library of known accepted 
(and rejected) unnatural analogues (Table 1.3) made it possible to make generalisations 
about the selection criteria of the synthetase and make predictions about the acceptance 
of new structures more reliably. 
F
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The primary commonality between all amino acids accepted by MRS appears to be a 
non-branching side-chain (Table 1.3). This is an added advantage as chemical synthesis 
of linear analogues is significantly simpler using more ‘routine’ bench chemistry. 
Additionally, multiple diastereomers are not possible without branching, making 
stereochemical considerations much simpler. 
The majority of the readily accepted analogues of methionine appear to have the same 
chain length as methionine 28, thus suggesting size exclusion by the active site is the 
dominant mechanism of substrate recognition, and the hydrogen bonding with the 
side-chain (Figure 1.7) is not essential. This is largely supported by the activation of the 
analogues with hydrocarbon side-chains 35-37 that are not capable of forming hydrogen 
bonds. 
The bonding with the side-chain does play a role, as exemplified by the recognition of 
ethionine 31 and trifluoromethionine 39, both sterically bigger than methionine 28, 
whereas their respective non-sulfur-containing isosteres homonorleucine 45 and 
trifluoronorleucine 46 are rejected. Additionally, homocysteine 50 is known to be 
turned over (proof-read) by MRS,[69,75] while hydrocarbon-chain bearing amino acids of 
similar size are not under normal circumstances.[107] The bond with the sulfur atom 
formed in the active site could potentially facilitate proper positioning of the residues. 
The observed trends in the recognition patterns of methionine analogues suggested that 
of the two selection mechanisms employed by MRS, size exclusion and hydrogen 
bonding, only one needs to be satisfied for an amino acid to be recognised as a 
substrate. Hence, amino acids with linear chains bearing terminal halogens could be 
potential substrates for MRS (Figure 5.1). 5-Chloro and 5-bromonorvalines 82a and 
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82b, with the same chain length as methionine, were anticipated to be recognised by the 
synthetase, much like the other isosteres of methionine 28. Although cyclisation of the 
residues would lead to 6-membered rings, peptide bond cleavage was still expected, and 
the analysis of both chlorinated and brominated amino acids would enable to compare 
the propensities of the two halogens for bond cleavage. 
Analogues 83a and 83b that matched the chain length of previously explored isosteres 
of isoleucine and leucine but were one carbon unit shorter than methionine 28, on the 
other hand, relied on the ability of the halogens to mimic the interactions of the sulfur. It 
was hoped that the amino acids could be activated like homocysteine 50, but the 
proof-reading mechanism employed by the enzyme (Scheme 1.20) would be ineffective 
due to the electrophilic nature of the halogens. 
Finally, 2-aminohex-5-enoic acid 35 was considered for proteolysis through 
iodolactonisation. Allylglycine 43 that was originally used to develop protein 
fragmentation through exposure to iodine (Scheme 1.6)[52,53] is rejected by MRS under 
normal circumstances,[107] but it was anticipated that the homologue 35, a known 
substrate,[107,108] could also lead to peptide bond cleavage when treated with iodine. 
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Figure 5.1. Intended halogenated analogues of methionine. 
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5.1. Preparation of the analogues of methionine 
Literature conditions[108,133] were followed in the preparation of the alkene containing 
amino acid (Scheme 5.1). Diethyl acetamidomalonate 74 was alkylated with 
4-bromobut-1-ene 84. After saponification and acid decarboxylation of the resultant 
malonate 85, 2-acetamidohex-5-enoate 86 was directly used for protein expression, 
taking advantage of the ability of S30 to deprotect amino acids in situ (vide supra). 
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Scheme 5.1. The synthesis of 2-acetamidohex-5-enoic acid 86. 
 
The analogues 83a and 83b were predicted to be too unstable for use in protein 
expression as free acids, based on work with γ-chlorovaline 26a (vide supra). Hence, 
the corresponding methyl esters 87a and 87b, able to generate the free acids 83a and 
83b in situ, were desired for use in protein expression. Homoserine 88 was chosen as 
the starting point for the synthesis (Scheme 5.2). As applied during the purification of 
the analogues of branched-chain amino acids (vide supra), the tBoc protecting group 
was chosen for the protection of the amino group. The halogen would be introduced at a 
final stage, making divergent synthesis was possible and leaving the possibility for the 
exploration of other potential leaving groups in the future. 
84 
74 
85 86 
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Scheme 5.2. Retrosynthetic analysis of the halogenated analogues. 
 
Initially installation of the methyl ester was attempted through esterification with 
methanol and thionyl chloride.[147] Unfortunately, the desired product was not observed. 
Instead, methoxinine methyl ester 90, a product of over-methylation, and homoserine 
lactone 91 were isolated (Scheme 5.3), indicating the conditions were too harsh. 
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Scheme 5.3. Attempted esterification of homoserine 88. 
 
It was then decided to introduce the tBoc group first and then selectively alkylate the 
carboxylate with iodomethane under mildly basic conditions, exploiting the different 
acidities of the hydroxy and the carboxy groups (Scheme 5.4).[148] The esterified 
homoserine 89 was isolated by flash silica chromatography, but the yields were low 
after initial trials. The poor yields were attributed to the propensity of the ester 89 to 
87a, X = Cl 
87b, X = Br 
89 88 
88 90 91 
Chlorinated Amino Acids in Peptide Production 
Chapter 5. Labile Analogues of Methionine 
210 
cyclise, likely catalysed by the acidic silica. Purification by chromatography was then 
abandoned, and the diprotected homoserine 89 was taken to the next step without 
purification or prolonged storage. 
An Appel reaction was used to introduce the halogens. Bromination in dichloromethane 
with 1 equivalent of carbon tetrabromide proceeded rapidly at room temperature and 
went to near completion with hours. The product 92b, however, was very prone to 
decomposition, as signified by gradual emergence of the colour of bromine in the 
sample. After purification by flash silica chromatography, the bromide 92b was kept at 
‒80°C to prevent break-down. 
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Scheme 5.4. Preparation of the halogenated esters. 
 
Chlorination, on the other hand, only proceeded at reflux in carbon tetrachloride (77°C) 
and required longer reaction times. Complete conversion was not achieved, despite the 
large excess of the chlorinating reagent, and competing lactonisation was observed 
during the reaction. After purification, however, the product 92a was a stable oil and 
could be stored on bench. 
The halogens 92a and 92b were treated with glacial TFA to give the methyl esters 87a 
and 87b, respectively. 
88 89 92a, X = Cl 
92b, X = Br 
87a, X = Cl 
87b, X = Br 
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The halogenated analogues of methionine 28 were then tested for incorporation into the 
test protein His6PpiB. 2-Acetamidohex-5-enoate 86 and several other commercially 
available amino acids were used as controls for the expression. Consistent with 
expectations, both analogues 87a and 87b led to protein production (Figure 5.2). 
Wild-type levels of protein were produced with norleucine 37 and 2-acetamidohex-5-
enoate 86, both known competitors of methionine 28,[107,108,111,114] and the chlorinated 
analogue 87a, whereas slightly lower amounts were obtained with the bromide 87b. 
This, however, is in stark contrast to the complete rejection of the other short-chained 
amino acids norvaline 42, allylglycine 43, homoserine 88 and homocysteine 50, where 
only background levels of protein expression were seen. The recognition of the halides 
87a and 87b by MRS as substrates strongly supports the idea that the halogens are 
forming a hydrogen bond in the active site of the enzyme to mimic the thioether of 
methionine. 
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Amino acids:  
Met 28:  + ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒  
Analogue:  ‒ ‒ 37 86 42 43 88 50 87a 87b  
 
 
  
Figure 5.2. SDS-PAGE analysis of the incorporation of analogues of methionine 28 into 
His6PpiB. 
 
Incorporation of the analogues was confirmed by ESI-MS analysis of the produced 
proteins (Figure 5.3). Complete replacement (7/7) of methionine was achieved with 
norleucine 37, 2-aminohex-5-enoic 35 acid and the chlorinated analogue 83a (generated 
in situ from the ester 87a), whereas only wild-type background protein was obtained 
with the shorter analogues. The brominated analogue 87b presented a curiosity in that 
fully brominated protein was not visible in the spectrum (expected mass 19480 Da); 
instead, the main peak was consistent with the replacement of 5/7 methionine residues 
with the bromide 83b and the remaining two sites occupied by homoserine 88. 
Hydrolysis of the bromide in solution is not surprising, particularly given the instability 
observed during the preparation of the intermediate 92b, and homoserine is a likely 
product of degradation. However, attempted protein expression in the presence 
homoserine 88 clearly established that the hydroxylated amino acid is not directly 
incorporated during protein expression (Figure 5.2), suggesting the hydroxylated 
residues detected in the proteins are a result of post-translational damage to brominated 
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residues. Furthermore, the presence of a clearly dominant signal suggested that the 
damage was occurring in a sequence-specific manner and the susceptibility of the 
brominated residues could be influenced by the location in the protein (e.g. buried vs. 
exposed on the surface). However, no conclusion could be drawn from the available 
data. 
More peculiarly, an additional weaker protein band at about ca. 16 kDa was observed 
by the SDS-PAGE analysis of the brominated protein sample (Figure 5.2), several 
kilodaltons smaller than His6PpiB (ca. 19 kDa). However, no material in that mass 
range was detectable by MS. Over several months at 4°C, the ‘16 kDa’ band became 
more intense, whereas the 19 kDa His6PpiB weakened. Concomitantly, the original 
19353 Da signal in the MS became weaker, and the satellite peak at 19272 Da became 
the dominant peak. The decrease of mass by 80 Da suggested elimination of bromide 
(isotopes of bromine could not be resolved) and the emergence of the satellite peak 
matched the intensification of the ’16 kDa’ protein band on SDS-PAGE, thus it was 
hypothesised that one of the remaining brominated side-chains in the protein was slowly 
reacting with an internal nucleophile, e.g. a cysteine thiol or a histidine imidazole, and 
the strain introduced to the chain by this reaction led to the aberrant migration of the 
protein on the gel. Bromoalkyl chains have been shown to readily react with proximal 
sulfur and nitrogen nucleophiles,[137] but no conclusive evidence to support this 
hypothesis is available, although the results of the fragmentation analysis are consistent 
with such reactions taking place (vide infra). 
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Figure 5.3. Deconvoluted ESI-MS of His6PpiB expressed with the analogues of (S)-methionine 
28. The spectra show complete replacement (7/7) of (S)-methionine 28 (blue) with 
(S)-norleucine 37 (19122 Da; red), (S)-2-amino-hex-5-enoic acid 35 (19109 Da; green) and 
(S)-2-amino-5-chlorobutyric acid 83a (19169 Da; orange), but not (S)-2-amino-5-bromobutyric 
acid 83b (purple; see text). A second (-28 Da) signal (particularly strong in the sample 
containing (S)-norleucine 37; red) corresponds to N-deformylated protein. 
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The halides 82a and 82b were also expected to be unstable with respect to lactonisation, 
similar to the γ-chlorinated amino acids, forming the lactone 93 (Scheme 5.5). In 
addition, participation of the free amine to form proline 13 would also be favourable 
due to the longer chain, as observed with chelate-directed functionalisation of 
(S)-norvaline.[125] Thus, to avoid decomposition, it was decided to attempt protein 
expression with di-protected amino acids 94a and 94b, relying on in situ deprotection. 
O-Methyl and N-acetyl protecting groups were chosen as (S)-N-acetylleucine methyl 
ester was shown to be deprotected by the S30 (Chapter 2). 
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X  
Scheme 5.5. The potential routes of decomposition of the halides 83a and 83b (left) and the 
protected stable analogues 94a and 94b (right). 
 
(S)-5-Hydroxynorvaline 95, the key intermediate in the synthesis of the halides 94a and 
94b, was prepared by reduction of (S)-glutamic acid 96 (Scheme 5.6).[149] 
Triethylborane was used to regioselectively protect the main-chain carboxy-group from 
reduction, producing the boroxazolidone 97 almost quantitatively. The side-chain was 
then selectively reduced with borane, and the boroxazolidone was hydrolysed with 
aqueous acid. 
 
93 82a, X = Cl 
82b, X = Br 
13 94a, X = Cl 
94b, X = Br 
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Scheme 5.6. Synthesis of (S)-5-hydroxynorvaline 95. 
 
Conversion of (S)-glutamic acid 96 to (S)-5-hydroxynorvaline 95 was not complete, 
with some starring material still present in the sample, but the hydroxynorvaline 95 was 
used in subsequent steps without purification due to the propensity for lactonisation 
(Scheme 5.7). Formation of the lactone 93 was not extensive during the preparation of 
5-hydroxynorvaline 95, but became a strongly competing reaction during the attempted 
acylation. Only small amounts of N-acetyl-5-hydroxynorvaline 98 were obtained, thus a 
different approach to prepare the desired compounds was attempted. 
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Scheme 5.7. Derivatisation of 5-hydroxynorvaline 95. 
 
Hydroboration of protected allylglycine 99 was considered (Scheme 5.8).[150] After 
methylation and acetylation of allylglycine 43, the alkene 99 was subjected to a variety 
of hydroborating agents, like 9-borabicyclo[3.3.1]nonane (9-BBN) and 
96 97 
95 
93 98 95 
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dicyclohexylborane 101, followed by hydrogen peroxide, but the desired product was 
not detected. Dicyclohexylborane 101 was produced in situ from borane and 
dicyclohexene and the formation was confirmed by EI-MS (low (Figure 5.4) and high 
resolution); the allylglycine-borone adduct, however, was never observed. The 
bulkiness of the borane reagents may have been a hinderance. Hydroxylated borane 102 
was also detected in the mixture (Figure 5.4), suggesting trace amounts of moisture may 
have interfered with the reaction. 
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Scheme 5.8. Hydroboration of allylglycine. 
 
By this stage of the synthesis, the homoserine derivatives 87a and 87b were produced 
and shown to substitute methionine 28 during cell-free protein expression. Therefore, as 
a set of halogenated analogues of methionine was available, it was decided to no longer 
pursue the compounds 94a and 94b. 
 
43 99 100 85% 
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Figure 5.4. EI-MS of dicyclohexylborane 101 intermediate. 
 
5.2. Fragmentation analysis of modified His6PpiB 
To validate the analogues of methionine could be used for peptide production, 
fragmentation of substituted protein was investigated. His6PpiB expressed with the 
halides 87a and 87b was subjected to 100°C in water for up to 1 h, and the samples 
were analysed by SDS-PAGE (Figure 5.5). As observed with analogues of BCAAs 
(Chapter 3), the reaction was complete within minutes, with little change visible after 
the first 5 min. Both the chlorinated and the brominated protein showed similar results, 
with no distinct protein bands clearly discernable in the heated samples. 
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t / min:       0           5        10       20       30      60                         0        5        10       20       30       60 
 
 
  
Figure 5.5. SDS-PAGE analysis of the fragmentation of His6PpiB expressed with the chloride 
87a (left) and the bromide 87b (right) instead of (S)-methionine 28 due to exposure to 100°C. 
 
The heat-treated samples were then analysed by MS. As His6PpiB contains seven 
methionine residues in the sequence, a total of eight peptides are expected upon 
complete fragmentation of the modified protein, listed in Table 5.1. In the sample of 
His6PpiB expressed with the chloride 87a, four of the predicted fragments, 2806 Da 
(Figure 5.6; [M+4H]
4+
, m/z = 703 Da), 2137 Da (Figure 5.6; [M+3H]
3+
, m/z = 713 Da), 
1584 Da (Figure 5.6; [M+2H]
2+
, m/z = 793 Da) and 943 Da (Figure 5.7; [M+H]
+
, m/z = 
944 Da), were clearly identified by MS, observed in both protonated and partly sodiated 
states. As with previously analysed samples (Chapter 3), some of the predicted 
fragments could not be detected, likely due to poor ionisability, and some of the 
detected signals could not be assigned to any compounds resulting for the collapse of 
His6PpiB, likely caused by impurities. 
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Table 5.1. Predicted peptide fragments generated by cleavage of His6PpiB at methionine 
positions. The N-terminal fragment may be N-formylated. 
Peptide fragment Mass, Da 
λ
∗
 101, 129 
HHHHHHλ
∗
 923 
VTFHTNHGDI VIKTFDDKAP ETVKNFLDYC REGFYNNTIF HRVINGFλ
∗
 5614 
IQGGGFEPGλ
∗
 943 
KQKATKEPIK NEANNGLKNT RGTLAλ
∗
 2806 
ARTQAPHSAT AQFFINVVDN DFLNFSGESL QGWGYCVFAE VVDGλ
∗
 4889 
DVVDKIKGVA TGRSGλ
∗
 1584 
HQDVPKEDVI IESVTVSEN 2137 
∗
λ denotes lactone produced by the fragmentation process 
 
A clearly discernable signal of a 3704 Da peptide (Figure 5.6; [M+5H]5+, 
m/z = 742 Da), however, was identified as matching the combined size of the two 
C-terminal-most predicted fragments of His6PpiB. The detected mass was consistent 
with elimination of the chloride from the halogenated residue at the interface between 
the two fragments, resulting in the 5-membered intermediate. However, the intermediate 
lactone-imine is unlikely to have survived the exposure to 100°C. It was therefore 
theorised that the chlorinated side-chain reacted with the imidazole ring of the 
neighbouring histidine (Figure 5.8). However, the exact structure of the fragment could 
not be deduced from the mass spectrum, as the chlorinated residue could have reacted 
with any other side-chain. 
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Figure 5.6. Representative ESI-MS signals of the 2806 Da, 2137 Da and 1584 Da peptide 
fragments identified in the sample of heat-treated His6PpiB expressed with the chloride 87a 
instead of (S)-methionine 28. Broad window (top) and enlarged images shown. 
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Figure 5.7. Representative ESI-MS signals of the 943 Da (IQGGGFEPGλ
∗
) peptide fragment 
identified in the sample of heat-treated His6PpiB expressed with the chloride 87a instead of 
(S)-methionine 28. 
 
While the exact nature of the peptide could not be identified, it was clear that the 
fragment was a result of incomplete fragmentation of His6PpiB. The two C-terminal 
fragments of His6PpiB comprising the larger peptide were detected individually 
(1584 Da and 2137 Da; Figure 5.6), thus confirming that peptide bond cleavage at the 
intended cleavage site was not completely precluded, but the modification of the 
halogenated residue leading to the formation of the larger 3704 Da fragment appeared to 
be in competition with bond scission. No other fragments resulting from incomplete 
bond cleavage were identified, however, suggesting the side reaction is sequence 
dependent, and the extent to which each of the pathways is followed could not be 
determined from the mass spectra as the peptides detected in Figure 5.6 are all in 
different charged states and structurally different, thus the intensities of the signals are 
not a true reflection of the relative amounts of the fragments. 
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Figure 5.8. Representative ESI-MS signal of the 3704 Da peptide fragment identified in the 
sample of heat-treated His6PpiB expressed with the chloride 87a instead of (S)-methionine 28. 
 
In the sample of the heat treated His6PpiB expressed with the bromide 87b the strongest 
signals in the mass spectrum belonged to the 3704 Da fragment (Figure 5.9). None of 
the predicted eight fragments (Table 5.1) were clearly discernable. This could be 
explained by the damage to the brominated side-chains observed by mass spectrometry 
in full-length His6PpiB (vide supra). The detection of the single fragment indicated the 
brominated amino acid 83b is capable of facilitating bond fragmentation, but the 
susceptibility to side reactions posed a serious hindrance to the use as a cleavable linker. 
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Figure 5.9. ESI-MS of His6PpiB expressed with the bromide 87b instead of (S)-methionine 28 
after exposure to 100°C for 5 min. 
 
To test whether the unsaturated but-3-enyl side-chain can be exploited for proteolysis 
like the olefins described in Chapter 3, His6PpiB containing 2-aminohex-5-enoic acid 
35 was incubated with excess amounts of molecular iodine in tetrahydrofuran from 
5 min to 1 h on ice. Protein expressed with norleucine 37 was used as control, allowing 
the comparison between the reactivities of the alkene and the corresponding alkane, 
rather than a thioether of methionine 28. The samples retained the colour of iodine 
throughout the incubation, thus indicating that iodine was not prematurely consumed. 
After the desired time the reaction was quenched with tris(2-carboxyethyl)phosphine 
(TCEP) and the samples were analysed by SDS-PAGE. 
No intact protein was detectable in samples with unsaturated side-chains after 5 min, 
whereas the saturated control was not degraded after 1 h (Figure 5.10), suggesting the 
alkene-bearing chain was fully capable of mediating peptide bond cleavage. However, a 
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number of additional protein bands, attributable to damaged His6PpiB whose migration 
was affected by modifications, appeared in the control sample, highlighting the 
susceptibility of the protein to side reactions with iodine. Furthermore, no change was 
seen between the 5 min and 1 h samples, indicating the rate of non-specific reactions 
occurring on the protein rivals the rate of bond cleavage, thus explaining why yields of 
iodine-mediated peptide production are lower than the yields of heat cleavage (see 
Chapter 3). 
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Figure 5.10. SDS-PAGE analysis of the reaction of His6PpiB expressed with norleucine 37 
(left) and 2-acetamidohex-5-enoic acid 86 (right) in place of (S)-methionine 28 with iodine at 
0°C. After the indicated time the reactions were quenched with TCEP. 
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ESI-MS was then used to probe the side-reactions occurring on the protein during 
iodination. Wild-type His6PpiB was treated with small amounts of iodine for 5 min. The 
sample was then stored at -78°C to stop the reaction, and only thawed immediately prior 
to the analysis. No single species was clearly identifiable in the spectrum, but instead an 
array of peaks, roughly clustered into five groups, ranging from 20.0 kDa to 20.6 kDa 
(Figure 5.11; cf. 19.2 kDa for unmodified His6PpiB). The masses of the five peak 
clusters roughly correspond to His6PpiB with 7-11 added iodine atoms. The aromatic 
residues are most susceptible to the addition of iodine. As His6PpiB contains one 
tryptophan, three tyrosine and twelve phenylalanine residues, the MS pattern suggests 
fairly rapid double iodination of tyrosine and the tryptophan, with potentially slower 
modification of phenylalanine. This reactivity of the aromatic systems toward iodine 
can account for the lower yields of recovered peptide hormones after iodine-mediated 
protein fragmentation, as compared to the yields of heat-responsive fragmentation. 
 
 
 
 
 
 
 
Figure 5.11. Deconvoluted ESI-MS spectrum of His6PpiB after exposure to iodine. 
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5.3. Production of oxytocin 
Following the success of the preliminary fragmentation analysis, the utility of latent 
analogues of methionine was tested in the preparation of a model peptide, using the 
previously described model (Chapter 3). Oxytocin was chosen as it naturally lacks 
methionine in the sequence (CYIQNCPLG),* making it an ideal candidate. 
The gene for oxytocin was obtained as a DNA primer and attached to the C-terminus of 
His6PpiB via a methionine residue (Figure 5.12) by PCR amplification, as described 
earlier. The fusion protein was expressed in the cell-free system with the analogues of 
methionine 87a, 87b and 86 (Figure 5.13). 
 
MHHHHHHMVT FHTNHGDIVI KTFDDKAPET VKNFLDYCRE GFYNNTIFHR 
VINGFMIQGG GFEPGMKQKA TKEPIKNEAN NGLKNTRGTL AMARTQAPHS 
ATAQFFINVV DNDFLNFSGE SLQGWGYCVF AEVVDGMDVV DKIKGVATGR 
SGMHQDVPKE DVIIESVTVS ENGGGGGGGA MCYIQNCPLG 
 
Figure 5.12. The sequence of His6PpiB_OXT fusion protein. The hormone segment is in bold, 
the cleavage point is underlined. 
 
Essentially complete substitution was achieved with the chloride 87a, as confirmed by 
ESI-MS (Figure 5.14). The chlorinated protein was heated to 100°C for 5 min and then 
analysed by reverse phase HPLC (Figure 5.15). To ensure any non-specific disulfide 
bonds established between the produced oxytocin and other fragments during the heat 
treatment could not sequester the target protein, the sample was reduced with TCEP 
* ‒ the dash denotes a disulfide bridge 
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prior to the analysis. Much to the anticipation, the oxytocin peptide was detected and 
isolated from the sample (Figure 5.16), eluting at 14.5 min. 
 
Amino acids:  
Met 28:                    +          ‒          ‒          ‒ 
Analogue:                    ‒         87a      87b      86 
 
 
  
Figure 5.13. SDS-PAGE analysis of cell-free protein expression of His6PpiB_OXT fusion 
protein with the analogues 87a, 87b and 86 in place of (S)-methionine 28. 
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Figure 5.14. Deconvoluted ESI-MS spectra of His6PpiB_OXT fusion proteins expressed with 
all natural amino acids (below; blue) and with methyl 2-amino-4-chlorobutanoate 87a instead of 
(S)-methionine 28 (above; red). The mass reduction of 92 Da corresponds to complete 
replacement (8/8) of methionine (8×11.5 Da; the apparent change of 91 Da is the result of 
unresolved peaks due to isotopic distribution). 
 
Aside from the target oxytocin, other fragments from the carrier protein His6PpiB, 
detected in the heated sample (vide supra), were also isolated and clearly identified by 
ESI-MS (Figure 5.15). Even more satisfactorily, the largest of the fragments from the 
carrier protein (5614 Da) that could not be detected in the mixture, likely due to poorer 
ionisability, eluted as a single species (27.8 min) and was clearly identified (Figure 
5.17). Interestingly, no fragments resulting from incomplete fragmentation were 
detected, although they could have been masked by co-eluting impurities, as not all of 
the peaks in the chromatogram were identified. 
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Figure 5.15. HPLC chromatogram of His6PpiB_OXT fusion protein expressed with the chloride 
87a instead of methionine 28 after exposure to 100°C for 5 min, analysed on a Symmetry300
TM
 
C18 column (4.6×150 mm, 5µ), eluting with acetonitrile gradient from 10% to 60% in 
0.1% TFA over 40 min, 1 mL/min. 
 
 
 
 
 
 
Figure 5.16. The MS signal of the isolated oxytocin fragment, produced after heat-treatment 
(100°C for 5 min) of His6PpiB_OXT fusion protein expressed with the chloride 87a instead of 
(S)-methionine 28. 
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Figure 5.17. ESI-MS of the 5614 Da peptide fragment eluted at 27.8 min. 
 
To estimate the yield of peptide bond fragmentation, the concentration of the purified 
chlorinated fusion protein was measured by absorbance at 280 nm. The extinction 
coefficient was calculated based on the amino acid sequence using online ProtParam 
tool; the chlorinated side-chains were judged not to influence the absorbance at 280 nm. 
To account for the impurities that were non-specifically retained during nickel affinity 
chromatography, the intensities of protein bands on the SDS-PAGE gel were integrated 
using ImageJ image processing software; based on the gel in Figure 5.13 ca. 20% of the 
protein in the sample were contaminants. 
HPLC traces were recorded at 210 nm. A calibration curve was used to measure the 
amount of isolated oxytocin. 
The efficiency of the bond cleavage to produce oxytocin was found to be about 40%. 
More accurate estimates were not possible due to the difficulty of measuring exact 
concentrations of the fusion protein. However, the 40% yield is significantly smaller 
than the >70% observed in the preparation of GRPG and CCKG (Chapter 3). The 
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cysteine at the N-terminus of oxytocin is likely responsible for the drop in the yield of 
bond cleavage. The nucleophile in the proximity of the scissile bond can interfere with 
the chemical cleavage, either by mediating the collapse of the cyclic intermediate in a 
way that does not lead to bond cleavage (Scheme 1.3, right) or directly displacing the 
chloride leaving group as observed with the 3704 Da fragment (Figure 5.8), and the 
high temperatures are likely to exacerbate the side-reactions. This was particularly 
prominent during the attempted preparation of prolactin releasing peptide prohormone 
PRPG that starts with serine (Chapter 3). While problems associated with the serine at 
the cleavage point can be partly circumvented during cyanogen bromide-mediated 
cleavage, no PRPG was produced using heat responsive bond cleavage. Although 
cysteine in not reported as interfering with the cyanogen bromide-mediated cleavage 
reaction, the increased reactivity of the thiol group at higher temperatures is not 
surprising. 
Neighbouring residue participation can also potentially explain the intensity of the 
5614 Da fragment in the chromatogram (Figure 5.15). Besides being the biggest peptide 
fragment and hence having the largest extinction co-efficient, the cleavage points at 
both termini of the peptide are next to amino acids with non-nucleophilic side-chains 
(valine at the N-terminus, isoleucine at the C-terminus), thus bond cleavage would have 
less interference and the peptide is expected to be produced with the highest possible 
yields. 
Although production of oxytocin was not achieved with as high a yield as the 
previously reported peptides (Chapter 3, Chapter 4), the reduction in yield is a 
consequence of the sequence of the target peptide, specifically, the N-terminal residue. 
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As was demonstrated by the fragmentation analysis (vide supra), the bond cleavage is 
efficient when the chlorinated side-chain does not precede a serine, threonine or 
cysteine. Hence, the chloride 87a presents an efficient method for cleavage of peptide 
bonds at methionine residues. 
Expression level of the brominated His6PpiB_OXT fusion protein was lower (Figure 
5.13), likely due to more rapid decomposition of the brominated amino acid 83b 
generated in situ from the ester 87b. As was the case with brominated His6PpiB (vide 
supra), some of the brominated side-chains hydrolysed after incorporation into protein, 
based on ESI-MS (Figure 5.18). The major peaks at 20846.5 Da and 20913.7 Da seen in 
the spectrum approximately matched the masses of proteins with four and three out of 
eight damaged brominated side-chains, respectively. 
 
 
 
 
 
 
 
Figure 5.18. Deconvoluted ESI-MS spectrum of His6PpiB_OXT fusion protein expressed with 
methyl 2-amino-4-bromobutanoate 87b instead of methionine 28. 
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Oxytocin was detected in the sample of the brominated protein exposed to 100°C for 
5 min by HPLC (Figure 5.19), but only about 5% of the expected amount was 
recovered. This is not surprising given the propensity of the brominated side-chain for 
undergoing side reactions. Additionally, the brominated residue bridging the carrier 
protein and oxytocin is most likely exposed to the solvent, making the halide 
particularly susceptible to external reagents. As such, the brominated amino acid 87b 
may not be particularly well suited for the preparation of small peptides via the 
described approach, although production of peptides with less reactive N-termini may 
have substantially higher yields. Regardless, the brominated side-chains have been 
utilised in the post-translational functionalisation of proteins,
[137]
 and the capacity to 
introduce the functionality into proteins through protein expression can significantly 
simplify the preparation procedures. 
 
 
Figure 5.19. HPLC chromatogram of His6PpiB_OXT fusion protein expressed with the 
bromide 87b instead of (S)-methionine 28 after exposure to 100°C for 5 min, analysed on a 
Symmetry300
TM
 C18 column (4.6×150 mm, 5µ), eluting with acetonitrile gradient from 10% to 
60% in 0.1% TFA over 30 min, 1 mL/min. 
OXT 
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Finally, the unsaturated protein was investigated. Based on MS analysis, near complete 
substitution of methionine 28 with the alkene 35 was achieved (Figure 5.20). The 
protein was treated with molecular iodine at 0°C from 2 to 10 min, following a 
previously described method (Chapter 3). However, oxytocin was not detected. 
One possible explanation for the lack of oxytocin production could be a different 
mechanism of protein fragmentation. While protein substituted with the alkene 35 
clearly underwent fragmentation upon exposure to iodine (Figure 5.10), the longer chain 
of the labile amino acid could lead to cleavage of an alternate peptide bond. 
Alternatively, the side-reactions associated with iodination could be consuming the 
target peptide too rapidly. Finally, the cysteine could be interfering with the 
fragmentation. Iodination was successfully used to produce prolactin releasing peptide 
prohormone (PRPG), containing N-terminal serine; however, while the lower 
temperature prevented the reaction between the hydroxyl group and the cyclic 
intermediate in the case of PRPG, the thiol on oxytocin could still capture the iodinated 
alkene, thus preventing the bond cleavage. Regardless, production of oxytocin via this 
approach was not successful. 
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Figure 5.20. Deconvoluted ESI-MS spectrum of His6PpiB_OXT fusion protein expressed with 
2-acetamidohex-5-enoic acid 86 instead of (S)-methionine 28. The 20680.4 Da peak 
corresponds to 8/8 replacements of methionine, 20700.5 Da – 7/8 replacements, 20720.9 Da – 
6/8 replacements. 
 
5.4. Conclusions 
Two halogenated analogues of methionine were successfully synthesised and 
incorporated into proteins during cell-free protein expression. The ability of the 
halogens to form a hydrogen bond the active site of MRS, mimicking the thioether 
group of methionine, has enabled the recognition of the unnatural amino acids despite 
their shorter side-chains, as compared to methionine. 
The chlorinated analogue leads to reliable fragmentation of proximal peptide bonds in 
response to heat exposure; the utility of the analogue was demonstrated through the 
production of peptide hormone oxytocin. The yield of the oxytocin was lower than the 
yields observed with other peptide hormones, most likely a consequence of a cysteine 
residue in the vicinity of the scissile bond. 
1.90e4 1.95e4 2.00e4 2.05e4 2.10e4 2.15e4 2.20e4 
Mass, Da
20680.4117 
20700.5193
20720.9204 
20741.9663
20653.4263
20763.6869 20845.6873
20814.0030
20888.200519692.2690 20638.228820274.3318 20932.7130 21355.989021443.415519597.5840 21695.711219322.4857
Chlorinated Amino Acids in Peptide Production 
Chapter 5. Labile Analogues of Methionine 
237 
The brominated analogue could not be effectively utilised for the production of small 
peptides through fragmentation of peptide bonds due to undergoing prominent side 
reactions. However, the facile incorporation of this amino acid into proteins could be 
exploited as a method of incorporating reactive functional groups into proteins. 
The unsaturated analogue of methionine 2-aminohex-5-enoic acid was shown to lead to 
protein fragmentation when exposed to iodine, but the production of oxytocin was 
unsuccessful. 
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Chapter 6. Conclusions and Future Directions 
 
 
 
he inability of the native protein synthetic machinery to discriminate against 
unnatural amino acids, due to lack of evolutionary pressure to evolve such ability, is 
extremely valuable in the production of functionalised proteins. Understanding the 
selection criteria of the synthetases enables more reliable development of potential 
substrates. With the demonstration that γ-chlorovaline 26a is a substrate of IRS, which 
had previously been masked by instability of the analogue, it was concluded AARSs of 
the BCAA family are not able to distinguish between a chlorine atom and a methyl 
group, enabling facile replacement of largely unreactive aliphatic amino acids with 
electrophilic chlorinated analogues. The survey of the known substrates of MRS 
enabled the development of two new analogues of methionine 28, the chloride 83a and 
the bromide 83b, showing that the halogens are able to mimic the bonding interactions 
of (thio)ethers in the active site of MRS. 
The γ-chlorinated amino acids 25, 26a and 83a, owing to the favourable formation of 
5-membered rings, had a latent capacity, promoted by elevated temperatures, to 
facilitate the cleavage of proximal peptide bonds. This capacity was utilised in the 
preparation of peptides, expressed by a cell-free system as fusion proteins. Three 
peptide prohormones, each lacking leucine, isoleucine or methionine, were produced by 
utilising the available γ-chlorinated analogues 25, 26a and 83a, respectively. The nature 
T 
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of cell-free expression systems enabled simultaneous incorporation of two unnatural 
amino acids into the proteins, allowing preparation of modified peptides. 
Proteins expressed with the β-chlorinated amino acid of the series 15a, 15b and 27 were 
not fragmented by temperature. The radical differences in reactivity between the β- and 
γ-chloroamino acids were exemplified by the preparation of chlorinated aprotinin; 
protein chains containing the chlorides 15a and 15b were separated from the carrier 
protein using the analogue of leucine 25. Crystal structures of the chlorinated aprotinin 
revealed no rearrangement of the peptidic chain had occurred as a consequence of the 
substitution, thus indicating that the halogenated residues are not inherently detrimental 
to proteins and can be incorporated into functional proteins for subsequent modification. 
Despite the dramatic differences in response to temperature, both β- and γ-chloroamino 
acids would be expected to react with nucleophiles. As genetically-encoded halogenated 
amino acids have been employed for protein cross-linking through cross-reaction with 
nucleophilic side-chains,[137] the chlorinated isosteres of proteogenic amino acids 
described in this Thesis have the potential to be applied for the same purpose, avoiding 
the need for engineered systems. 
This might be particularly true with brominated amino acids. Exploration of the 
reactivity of the γ-brominated residue 83b showed that while the residue is able to 
promote peptide bond cleavage like the corresponding chlorinated residues, it appeared 
predisposed to react with external nucleophiles under more tame conditions, making the 
analogue more suitable for use for labelling of proteins rather than fragmentation. 
Similarly, brominated isosteres of the aliphatic amino acids would be expected to be 
more reactive than the chlorinated counterparts. However, as incorporation of the said 
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brominated amino acids has not yet been demonstrated, the full potential of these 
residues remains to be explored. 
The potential applications of the halogenated analogues of the proteogenic amino acids 
are particularly pertinent in light of the interchangeability of leucine and isoleucine with 
no consequences to protein structure and function, as demonstrated through the 
production of aprotinin. While heat sensitive analogues of isoleucine, leucine and 
methionine are available, this exchangeability of hydrophobic amino acids extended the 
applicability of the method to preparation of targets naturally containing all three 
residues, and provided a means to control the site of incorporation of the residue 
through modification of the gene sequences. 
The production of aprotinin also showcases the scalability of the system. The ability to 
produce large quantities of material is critical for practical applications, like protein 
crystallography. The potential to express modified proteins on a large scale can further 
facilitate the application of functionalised amino acids. 
The developments in the use of halogenated amino acids can also simplify the use other 
functionalised amino acids, like 2-amino-3-methylpent-4-ynoic acid 77a. As an 
analogue of isoleucine 7, the amino acids substitutes a biologically inert saturated 
hydrocarbon chain with an alkynyl side-chain that is equally unreactive towards 
biological systems, with only some loss in flexibility of the chain. While alkyne 
analogues of methionine also exist (Table 1.3), the isoleucine analogue 77a is less likely 
to perturb protein function, as the thioether group of methionine is sometimes involved 
in biological interactions.[151] The alkyne side chain provides a more specific tag for 
protein modification, compared to the halogenated side-chains, and can be used for 
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protein labelling using bioorthogonal chemistry under mild biological conditions. 
Similar chemistry is already employed in protein studies, relying on engineered systems 
to genetically encode functionalised amino acids,[93,94] and the analogue of isoleucine 
could simplify the experimental design using the strategy for strategic positioning of the 
residue in the protein. 
Despite the capacity to control the substitution patterns by amino acid replacement, at 
times proteins containing all twenty amino acids may be desired. Thus, for a successful 
use of heat-induced proteolysis for site-specific bond cleavage a route for incorporation 
of a lactonisation-prone amino acid as the 21st amino acid might be a worthy pursuit in 
the future. The inherent instability of γ-chlorinated amino acids is likely to present 
additional challenges to those encountered in the expansion of genetic code, but the 
development of such a system enable the use of heat-controlled proteolysis without any 
sequence restrictions in the target peptide. 
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Chapter 7. Experimental 
 
7.1. General experimental 
NMR spectra were recorded on a Varian MR400 (400 MHz for 1H, 376 MHz for 19F 
and 100 MHz for 13C), Varian Mercury 300 (300 MHz for 1H and 75 MHz for 13C), 
Varian Inova 500 (500 MHz for 1H and 125 MHz for 13C), Bruker AscendTM 400 
(400 MHz for 1H and 100 MHz for 13C), Bruker Avance 600 (600 MHz for 1H and 
150 MHz for 13C) and Bruker Avance 800 (800 MHz for 1H and 200 MHz for 13C) 
spectrometers. The residual solvent peak was used as reference. Chloroform-D 
(99.8% D), DMSO-D6 (99.9% D) and acetone-D6 (99.9% D) were purchased from 
Cambridge Isotope Laboratories Inc. and methanol-D4 (99.8% D) and D2O (99.8% D) 
were from Sigma-Aldrich Co. 
Low resolution (LR) electron spray ionisation (ESI) mass spectrometry was carried out 
using a Micromass LC-ZMD single quadrupole liquid chromatograph mass 
spectrometer, electron impact (EI) mass spectrometry was conducted on Waters 
AutoSpec Premier spectrometer. High resolution mass spectrometry was carried out on 
a Waters LCT PremierTM XE orthogonal acceleration time-of-flight (oa-TOF) mass 
spectrometer. Mass spectrometry of short peptides was conducted on an Agilent 1100 
series LC/MSD TOF instrument (direct injection) or Waters Acquity spectrometer with 
TQ detector. Mass spectra of large proteins were collected on an Agilent 1100 series 
LC/MSD TOF instrument (direct injection). 
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Preparative HPLC was performed on a Waters 600 controller with Waters 717plus 
autosampler and a Waters 2996 photodiode array detector, running Empower 2 
software. Analytical HPLC was performed on a Waters Alliance Separation module 
2695 with a Waters 2996 photodiode array detector, running Empower 2 software, and 
an Agilent Hewlett-Packard series 1100 separation system with Chemstation. 
Silica chromatography was performed with Silica gel 60 (0.040-0.063 mm) from 
Merck. Thin layer chromatography was performed on TLC plates Silica gel 60 F254 
from Merck, visualising with irradiation under UV lamp and potassium permanganate, 
vanillin or ninhydrin dip. 
Melting point analyses were carried out using OptiMelt Automated Melting Point 
System from Stanford Research Systems, operated with Meltview software. All melting 
points are uncorrected. 
Optical rotation was measured on a PerkinElmer Model 343 Polarimeter at 589 nm 
using a 1 dm pathlength cuvette. 
All samples were freeze-dried using FreeZone 4.5 freeze-drier from Labconco. 
Chemicals for synthesis were purchased from Sigma-Aldrich Co., TCI, Alfa-Aesar and 
Merck. Inorganic chemicals were from AJAX or Scharlau. Solvents for synthesis were 
obtained from Merck, VWR International and Sigma-Aldrich Co. Solvents for HPLC 
were obtained from Sigma-Aldrich Co. or Scharlau. Water was purified with a MilliQ-
Reagent water system. 
DNA primers for construction of the fusion were ordered from IDT®. Phusion® DNA 
polymerase, restriction enzymes and T7 quick DNA LigationTM kit were obtained from 
Chlorinated Amino Acids in Peptide Production 
Chapter 7. Experimental 
245 
New England BioLabs® Inc. Alkaline phosphatase was from Roche Diagnostics GmbH. 
Qiagen® Gel extraction kit was used to recover DNA after agarose gel electrophoresis. 
For protein expression DNA plasmid was amplified in E.coli AN1459 cells and isolated 
using Qiagen® Maxi or Mega kits. 
 
7.2. Cell-free protein expression 
Cell-free protein expression was carried out as described before.[16,102,123] Spectra/Por 
dialysis membrane (#2, MWCO: 12-14 kDa) was purchased from Spectrum 
Laboratories Inc. T7 RNA polymerase was obtained from New England BioLabs® Inc. 
The reactions were carried out for 14 h at 30°C. 
The proteogenic amino acids were supplied in 1 mM concentration. Non-proteogenic 
amino acids were used in 2 mM concentration and the corresponding natural amino acid 
was withheld. All initial incorporation experiments were carried out on His6PpiB. 
Sequence: 
MHHHHHHMVT FHTNHGDIVI KTFDDKAPET VKNFLDYCRE GFYNNTIFHR 
VINGFMIQGG GFEPGMKQKA TKEPIKNEAN NGLKNTRGTL AMARTQAPHS 
ATAQFFINVV DNDFLNFSGE SLQGWGYCVF AEVVDGMDVV DKIKGVATGR 
SGMHQDVPKE DVIIESVTVS EN 
 
The contents of the inner reaction were then purified using HisTrapTM HP columns from 
GE Healthcare using conditions recommended by the manufacturer. Amicon Ultra-4 
(YM-3,000) centrifugal filter devices from Millipore were used for sample 
concentration and buffer removal. Protein concentrations were measured on NanoDrop 
ND-1000 spectrophotometer from ThermoScientific. Gels (20% acrylamide) for SDS-
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PAGE analysis were cast using acrylamide and bis-acrylamide solutions from Bio-RAD 
and run on Mini-PROTEIN Tetra system. Bio-Safe Coomassie Blue was used for gel 
staining. Protein markers were purchased from New England Biolabs® Inc. Mass 
spectra of the proteins were collected on an Agilent 1100 series LC/MSD TOF 
instrument (direct injection). 
 
7.3. Synthesis of compounds from Chapter 2. 
Chlorination of (S)-valine and derivatives 8a-c 
(S)-valine 8a, N-acetyl-(S)-valine 8b or (S)-valine methyl ester 8c were dissolved in 
TFA in a quartz flask in batches of 500 mg, and chlorine gas was bubbled through the 
solution under irradiation by a 300 W sunlamp.[119] The solvent was then evaporated in 
vacuo to dryness, and the residue was used for analysis or subsequent experiments as 
described below or in the main text. 
 
Methyl 2-[(tert-butoxycarbonyl)amino]-4-chloro-3-methylbutanoates 56a,b 
N
t
Boc
O
O
Cl
H
N
t
Boc
O
O
Cl
H
 
The dried residue of (S)-valine methyl ester 8c (4 g, 24 mmol) chlorination mixture was 
dissolved in dry dichloromethane and treated with triethylamine until pH ≥ 7. 
Di-tert-butyl dicarbonate (4.6 g, 21 mmol) was then added and the mixture was stirred 
56a 56b 
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at room temperature for 16 h. All volatiles were then removed in vacuo and a portion of 
the material was subjected to purification by HPLC (Alltima C18 5µ 250×22 mm 
column, 10 mL min-1, 60% methanol). After lyophilisation of the collected fractions 
2-[(tert-butoxycarbonyl)amino]-4-chloro-3-methylbutanoate 56a,b (155 mg) was 
isolated as a mixture of (2S,3S) and (2S,3R) diastereomers as a colourless oil. The ratio 
of the diastereomers in the mixture varied slightly from batch to batch, but was on 
average 1:1. NMR peaks were assigned to the individual diastereomers with the help of 
COSY, 13C-HSQC and 13C-HMBC. 
tR = 29.0 min; diastereomer 1: 
1H NMR (400 MHz, CDCl3): δ = 5.21 (d, J = 7 Hz, 1 H; 
NH), 4.40 (dd, J = 8, 5 Hz, 1 H; CHN), 3.74/3.75 (s, 3 H; OCH3), 3.59-3.53 (m, 1 H; 
CHHCl), 3.42 (dd, J = 11, 7 Hz, 1H; CHHCl), 2.45-2.29 (m, 1 H; CHCH3), 1.43 (s, 9 H; 
C(CH3)3), 1.03 ppm (d, J = 7 Hz, 3 H; CHCH3); 
13C NMR (100 MHz, CDCl3): 
δ = 172.1/171.8, 155.6/155.3, 80.1, 55.9, 52.5/52.3, 46.6, 39.1, 28.2, 14.6 ppm; 
diastereomer 2: 1H NMR (400 MHz, CDCl3): δ = 5.09 (d, J = 7 Hz, 1 H; NH), 4.58 
(dd, J = 9, 3 Hz, 1 H; CHN), 3.74/3.75 (s, 3 H; OCH3), 3.59-3.53 (m, 1 H; CHHCl), 
3.33 (dd, J = 11, 7 Hz, 1 H; CHHCl), 2.45-2.29 (m, 1 H; CHCH3), 1.43 (s, 9 H; 
C(CH3)3), 0.94 ppm (d, J = 7 Hz, 3H; CHCH3); 
13C NMR (100 MHz, CDCl3): 
δ = 172.1/171.8, 155.6/155.3, 80.1, 55.0, 52.5/52.3, 47.0, 39.1, 28.2, 12.8 ppm; LRMS 
(ESI, +ve): m/z: 288.5, 290.5 [M++Na]; HRMS (ESI, +ve): m/z: calcd for 
[C11H20NO4Cl+Na]
+ 288.0979 and 290.0949, found 288.0979 and 290.0941. 
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Methyl 2-amino-4-chloro-3-methylbutanoates 26c and 52c 
NH
2
O
O
Cl
NH
2
O
O
Cl  
The mixture of the chlorides 56a,b was treated with trifluoroacetic acid (5 mL) and the 
solution was stored for 1 h at room temperature. All volatiles were then removed in 
vacuo to give methyl 2-amino-4-chloro-3-methylbutanoate as a mixture of (2S,3R)-26c 
and (2S,3S)-52c diastereomers as an amorphous colourless solid. 
m.p. 75.5-77.5°C; (2S,3R)-26c: 1H NMR (400 MHz, D3COD): δ = 4.29 (d, J = 4 Hz, 
1 H; CHN), 3.86 (s, 3 H; OCH3), 3.73 (dd, J = 11, 8 Hz, 1 H; CHHCl), 3.66 (obscured 
dd, J = 11, 6 Hz, 1 H; CHHCl), 2.43 (dddq, J = 8, 7, 6, 4 Hz, 1 H; CHCH3), 1.10 ppm 
(d, J = 7 Hz, 3 H; CCH3); 
13C NMR (100 MHz, D3COD): δ=169.6, 55.7, 54.0/53.8, 
47.0, 39.3, 13.4 ppm; (2S,3S)-52c: 1H NMR (400 MHz, D3COD): δ = 4.26 (d, J = 4 Hz, 
1 H; CHN), 3.87 (s, 3 H; OCH3), 3.69-3.66 (obscured, 2 H; CH2Cl), 2.59 (dp, J = 7, 
4 Hz, 1 H; CHCH3), 1.13 ppm (d, J = 7 Hz, 3 H; CCH3); 
13C NMR (100 MHz, D3COD): 
δ=170.2, 55.8, 54.0/53.8, 46.5, 38.5, 13.6 ppm; LRMS (ESI, +ve): m/z: 166.1, 168.1 
[M++H]; HRMS (ESI, +ve): m/z: calcd for [C11H20NO4Cl+H]
+ 166.0635 and 168.0605, 
found 166.0637 and 168.0610. 
 
 
 
26c 52c 
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tert-Butyl (4-methyl-2-oxotetrahydrofuran-3-yl)-carbamates 57a and 57b 
N
t
Boc
O
O
H
     
N
t
Boc
O
O
H
 
The dried residue of (S)-valine 8a (5 g, 42.7 mmol) chlorination mixture was dissolved 
in water and Na2CO3(sat.) was added and until pH ≥ 7. The solution was stirred at room 
temperature for 4 h. Di-tert-butyl dicarbonate (9.3 g, 42.7 mmol) and β-cyclodextrin 
(2.4 g, 2.1 mmol) were then added to the mixture, and the solution was stirred for 16 h a 
room temperature. The solution was then extracted with ethyl acetate, the organic phase 
was dried (MgSO4) and evaporated in vacuo. A portion of the residue was purified by 
HPLC (Alltima C18 5µ 250×22 mm column, 12 mL min-1, 40% methanol) to give the 
title compounds 57a (120 mg) and 57b (170 mg) as white crystalline solids. 
Spectroscopic data are consistent with literature reports.[125] 
(2S,3R)-57a: tR = 30.4 min; m.p. 123-215°C; [α]D
20 = ‒54.2 (c = 0.02 in methanol); 
1H NMR (300 MHz, CDCl3): δ = 5.12 (d, br, J = 8 Hz, 1 H; NH), 4.38 (t, J = 9 Hz, 1 H; 
OCHH), 4.10-3.97 (m, 1 H; NCH), 3.79 (t, J = 10 Hz, 1 H, OCHH), 2.58-2.40 (m, 1 H; 
NCCH), 1.43 (s, 9 H; C(CH3)3), 1.19 ppm (d, J = 6 Hz, 3 H; CCCH3). 
(2S,3S)-57b: tR = 28.0 min; m.p. 110.5-112°C; [α]D
20 = +41.6 (c = 0.02 in methanol); 
1H NMR (300 MHz, CDCl3): δ = 5.12 (s, br, 1 H; NH), 4.48 (t, J = 6 Hz, 1 H; NCH), 
4.37 (dd, J = 9, 5 Hz, 1 H; OCHH), 4.06 (t, J = 9 Hz, 1 H, OCHH), 2.98-2.84 (m, 1 H; 
NCCH), 1.42 (s, 9 H; C(CH3)3), 0.97 ppm (d, J = 6 Hz, 3 H; CCCH3). 
 
57a 57b 
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Methyl (Z)-2-formamido-3-(trifluoromethyl)pent-2-enoate 61 
NH
CF3
O
O
O
 
Sodium tert-butoxide (1.15 g, 12 mmol) was dissolved in dry tetrahydrofuran and the 
solution was cooled to ‒40°C. Technical grade methyl isocyanoacetate 58 (1 mL, 
11 mmol) was then added dropwise and the solution was stirred for 30 min under 
nitrogen atmosphere. 1,1,1-Trifluorobutanone 59 (1.9 mL, 14 mmol) in dry 
tetrahydrofuran was then added, maintaining the temperature of the reaction at -40°C, 
and the mixture was stirred for 1 h. The mixture was then allowed to warm to room 
temperature and 1 M HCl(aq.) was added until pH = 4, and the mixture was stirred for an 
additional 1 h. The volatiles were then removed in vacuo, the residue was dissolved in 
water and extracted with ethyl acetate. The organic layer was dried (MgSO4) and 
evaporated. The residue was purified by flash silica chromatography, eluting with 
petroleum ether / ethyl acetate = 3:1, to give the target compound as a yellowish oil that 
solidified upon standing (610 mg, 2.7 mmol, 25%). Spectroscopic data are consistent 
with literature reports.[126] 
Rf = 0.4; 
1H NMR (300 MHz, (CD3)2CO): δ = 9.28 (s, br, 1 H; NH), 8.21 (s, 1 H; 
NCH), 3.79 (s, 3 H; OCH3), 2.30 (q, J = 8 Hz, 2 H; CH2), 1.11 ppm (t, J = 8 Hz, 3 H; 
CCH3). 
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Methyl 2-formamido-3-(trifluoromethyl)pentanoate 
NH
CF3
O
O
O
±  
Methyl (Z)-2-formamido-3-(trifluoromethyl)pent-2-enoate 61 (462 mg, 2.05 mmol) was 
dissolved in methanol and 10% Pd/C was added to the solution. The mixture was stirred 
for 16 h at room temperature under hydrogen atmosphere. The catalyst was then filtered 
off with celite, the solvent was evaporated in vacuo and the residue was subjected to 
flash silica chromatography, eluting with petroleum ether / ethyl acetate = 1:1. The 
target compound was isolated as a white amorphous solid (365 mg, 1.61 mmol, 78%). 
Spectroscopic data are consistent with literature reports.[126] 
Rf = 0.5; 
1H NMR (300 MHz, CDCl3): δ = 8.24 (s, 1 H; NCH), 6.36 (s, br, 1 H; NH), 
5.11 (dd, J = 6, 3 Hz, 1 H; O2CCH), 3.81 (s, 3 H; OCH3), 2.75-2.58 (m, 1 H; F3CCH), 
1.89-1.61 (m, 2 H; CH2), 1.11 ppm (t, J = 8 Hz, 3 H; CCH3). 
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2-Amino-3-(trifluoromethyl)pentanoic acid 24a 
NH2
CF3
O
OH
±  
Methyl 2-formamido-3-(trifluoromethyl)pentanoate (353 mg, 1.56 mmol) was dissolved 
in acetone (2 mL) and 6 M HCl(aq.) (20 mL) was added. The solution was stirred with 
reflux for 16 h. The mixture was then cooled and all volatiles were removed in vacuo to 
give the amino acid as a while solid (280 mg, 1.51 mmol, 97%). Spectroscopic data are 
consistent with literature reports.[126] 
m.p. 175-178°C; 1H NMR (300 MHz, D3COD): δ = 4.27 (br, 1 H; NCH), 3.12-2.93 (m, 
1 H; F3CCH), 1.94-1.60 (m, 2 H; CH2), 1.11 ppm (t, J = 8 Hz, 3 H; CCH3); 
19F NMR 
(376 MHz, D3COD): δ = 71.07 ppm (d, JHF = 10 Hz, 3 F). 
 
5,5,5-Trifluoro-3-methylpentanoic acid 67 
OH
CF3
O
 
Method 1: Cyanoacetic acid 63 (50 g, 0.59 mol), acetone 64 (35 g, 0.6 mol) and 
ammonium acetate (4 g, 52 mmol) were dissolved in benzene (100 mL) and the solution 
was stirred with reflux in a Dean-Stark apparatus until water condensation ceased (ca. 
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72 h). The Dean-Stark apparatus was then replaced with distillation equipment and the 
solution was distilled at atmospheric pressure. After benzene was removed, the fraction 
containing 3-methylbut-3-enenitrile 65 (80 - 115°C) and the isomerised by-product 
3-methylbut-2-enenitrile was collected as a clear liquid (29.7 g) and used without 
further purification. 
Impure 3-methylbut-3-enenitrile 65 (29.7 g, 0.35 mol), TFA (47.3 mL, 0.62 mol) and 
sodium acetate (1.37 g, 16.7 mmol) were dissolved in methanol (200 mL) and water 
(30 mL) was added. The solution was electrolysed with platinum wires with stirring 
until 62 kC were passed through the solution (ca. 44 h). The mixture was then diluted 
with water (700 mL) and extracted with dichloromethane. Dichloromethane was 
distilled off at atmospheric pressure and the remaining solution was vacuum-distilled. 
10% Pd/C was added to the collected volatiles and the mixture was stirred for 16 h at 
room temperature under hydrogen atmosphere. The catalyst was then filtered off with 
celite and the flow-through was distilled through a Vigreux column. The fraction 
collected between 165°C and 170°C containing 5,5,5-trifluoro-3-methylpentannitrile 66 
was mixed with 6 M HCl(aq.) (70 mL) and the biphasic mixture was stirred with reflux 
overnight. The phases were then separated and the organic layer was mixed with 10% 
(w/w) NaOH(aq.). The two layers were then separated and the aqueous layer was 
acidified with 6 M HCl(aq.). A new layer of organic material separated from the aqueous 
solution that was collected and redistilled to give the title compound as a colourless 
liquid (2.08 g, 12.2 mmol, 2%). Spectroscopic data are consistent with literature 
reports.[129] 
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Method 2: Benzyl(triphenylphosphoranylidene)acetate 69 (40 g, 97 mmol) and 
4,4,4-trifluorobutanone (4.4 g, 35 mmol) were dissolved in dichloromethane (200 mL) 
and the solution was stirred with reflux for 16 h. The mixture was then cooled and all 
volatiles were evaporated in vacuo. The residue was purified by flash silica 
chromatography, eluting with petroleum ether / ethyl acetate = 19:1, to give the 
products of the Wittig reaction as a mixture of cis and trans alkenes. The alkenes were 
then dissolved in ethanol, 10% Pd/C was added and the mixture was incubated under 
hydrogen atmosphere (50 psi) with shaking for 3 h. The catalyst was then filtered off 
through celite and the flow-through was distilled to give the title compound as a 
colourless liquid (1.1 g, 6.6 mmol, 19%). 
1H NMR (300 MHz, CDCl3): δ = 10.94 (s, br, 1 H; COOH), 2.54-1.96 (m, 5 H), 
1.13 ppm (d, J = 6 Hz, 3 H; CH3); 
19F NMR (376 MHz, CDCl3): δ = 63.56 ppm (t, JHF = 
11 Hz, 3 F). 
 
Methyl 5-methyl-5-(2,2,2-trifluoroethyl)-1,3-oxazolidine-4-carboxylate 72 
N
O
O
O
F
3
C  
Methyl isocyanoacetate 58 (0.2 mL, 2.2 mmol) and 4,4,4-trifluorobutanone 68 (0.3 mL, 
2.64 mmol) were dissolved in dry ether (5 mL) and Cu(I) oxide (16 mg, 0.1 mmol) was 
added. The mixture was stirred under nitrogen atmosphere for 16 h. The mixture was 
then subjected to flash silica chromatography, eluting with petroleum ether / ethyl 
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acetate = 1:1, to give the title compound, a mixture of two diastereomers with a ratio of 
ca. 3:7, as a colourless oil (397 mg, 1.8 mmol, 80%). The compound was highly 
moisture sensitive; analytical purity was not attainable. 
Rf = 0.45; major diastereomer: 
1H NMR (400 MHz, CDCl3): δ = 6.91 (obs, 1 H; 
N=CH), 4.56 (d, J = 2 Hz, 1 H; O2CCH), 3.74 (s, 3 H; OCH3), 2.67-2.53 (m, 2 H; CH2), 
1.36 ppm (s, 3 H; CCH3); 
13C NMR (100 MHz, CDCl3): δ = 169.0, 155.8, 124.6 (q, JCF 
= 278 Hz; CF3), 82.8, 75.1, 52.3, 43.5 (q, JCF = 28 Hz; CCF3), 20.5 ppm (q, JCF = 2 Hz); 
19F NMR (376 MHz, CDCl3): δ = 61.00 ppm (t, JHF = 10 Hz, 3 F); minor diastereomer: 
1H NMR (400 MHz, CDCl3): δ = 6.90 (obs, 1 H; N=CH), 4.42 (d, J = 2 Hz, 1 H; 
O2CCH), 3.74 (s, 3 H; OCH3), 2.51-2.41 (m, 2 H; CH2), 1.59 ppm (s, 3 H; CCH3); 
13C NMR (100 MHz, CDCl3): δ = 169.2, 155.9, 125.0 (q, JCF = 278 Hz; CF3), 82.7, 
77.2, 52.4, 37.5 (q, JCF = 29 Hz; CCF3), 25.6 ppm (q, JCF = 2 Hz); 
19F NMR (376 MHz, 
CDCl3): δ = 60.54 ppm (t, JHF = 11 Hz, 3 F); LRMS (ESI, +ve): m/z: 226.2 [M
++H]; 
HRMS (ESI, +ve): m/z: calcd for [C8H10NO3F3+H]
+ 226.0691, found 226.0691. 
 
tert-Butyl (diethoxyphosphoryl)[(tert-butoxycarbonyl)amino]acetate 73 
O
O
t
Bu
t
BocN
PO OEt
OEt
H
 
tert-Butyl (tert-butoxycarbonyl)glycinate (2 g, 8.7 mmol) was dissolved in dry carbon 
tetrachloride, N-bromosuccinimide (1.54 g, 8.7 mmol) was added and the mixture was 
stirred for 4 h with irradiation under a 300W sunlamp, until the starting material was 
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consumed. The solution was then filtered and the filtrate was evaporated in vacuo. The 
resultant yellow oil was redissolved in dichloromethane and triethyl phosphite (1.7 mL, 
9.6 mmol) was added. The solution was stirred under nitrogen atmosphere for 16 h. The 
solvent was then evaporated in vacuo and the residue was purified by flash silica 
chromatography, eluting with petroleum ether / ethyl acetate = 1:1, to give the title 
compound as a colourless oil (2.86 g, 7.8 mmol, 90%). Spectroscopic data are 
consistent with literature reports.[152] 
Rf = 0.38; 
1H NMR (300 MHz, CDCl3): δ = 5.32 (d, br, J = 8 Hz, 1 H; NH), 4.70 (dd, 
JHP = 22 Hz, JHH = 9 Hz, 1 H; NCH), 4.26-4.05 (m, 4 H; CH2), 1.48 (s, 9 H; C(CH3)3), 
1.43 (s, 9 H; C(CH3)3), 1.32 ppm (t, J = 7 Hz, 6 H; POCCH3). 
 
3-Bromobut-1-yne 79 
Br  
Triphenyl phosphite (23 mL, 87 mmol) was dissolved in dry ether (50 mL) in a glove 
box and bromine (4.4 mL, 86 mmol) was added dropwise. The precipitate was 
repeatedly washed with ether and decanted in the glove box, until the washings were 
colourless. After the final wash the powder was dried at 50°C under vacuum for 3 h. 
Premixed but-3-yn-2-ol 78 (3 mL, 38 mmol) and pyridine (3.8 mL, 48 mmol) were 
added dropwise to the solid with stirring at 0°C and the slurry was stirred at room 
temperature under nitrogen atmosphere for 2 h. The mixture was then vacuum-distilled, 
collecting the volatiles at -196°C. The yellow liquid was redistilled at atmospheric 
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pressure to give the title compound as an opaque colourless liquid (3.3 g, 25 mmol, 
66%). Spectroscopic data are consistent with literature reports.[153] 
1H NMR (300 MHz, CDCl3): δ = 4.58 (dq, J = 7, 2 Hz, 1 H; BrCH), 2.65 (d, J = 2 Hz, 
1 H; C≡CH), 1.92 ppm (d, J = 7 Hz, 3 H; CH3). 
 
2-Acetamido-3-methylpent-4-ynoic acids 81a and 81b 
NH
O
OH
O
±
NH
O
OH
O
±  
3-Bromobut-1-yne 79 (1 g, 7.5 mmol), diethyl acetamidomalonate 74 (1.78 g, 
8.2 mmol) and caesium carbonate Cs2CO3 (2.7 g, 8.25 mmol) were added to dry 
acetonitrile (4 mL) and the mixture was subjected to microwave irradiation (100°C, 
300 W) for 1 h with stirring. The reaction mixture was then filtered to remove inorganic 
salts and the filtrate was evaporated to dryness. 
The residual oil was suspended in 10% (w/w) Na2CO3(aq.) solution and the suspension 
was stirred with reflux for 16 h. The reaction mixture was then cooled down and 
extracted with chloroform. The aqueous layer was then acidified with HCl(aq.) until pH = 
3. All volatiles were then evaporated in vacuo and the crystalline residue was extracted 
with hot (55°C) acetone. The solvent was then evaporated in vacuo and the residue was 
purified by reverse phase HPLC, eluting with 15% methanol in 0.1% TFA, 10 mL/min. 
The minor (2S,3R)-(±) diastereomer 81b eluted at 27 min (108 mg, 0.64 mmol, 8.5%), 
81a 81b 
Chlorinated Amino Acids in Peptide Production 
Chapter 7. Experimental 
258 
the major (2S,3S)-(±) diastereomer 81a was collected at 31 min (305 mg, 1.8 mmol, 
24%). Spectroscopic data are consistent with literature reports.[133] 
(2S,3S)-(±)-81a: 1H NMR (300 MHz, D3COD): δ = 4.55 (d, J = 5 Hz, 1 H; NCH), 3.22-
3.10 (m, 1 H; C≡CCH), 2.49 (d, J = 2 Hz, 1 H; C≡CH), 2.05 (s, 3 H; NCCH3), 1.22 ppm 
(d, J = 7 Hz, 3 H; CCCH3). 
(2S,3R)-(±)-81b: 1H NMR (300 MHz, D3COD): δ = 4.57 (d, J = 6 Hz, 1 H; NCH), 
3.08-2.96 (m, 1 H; C≡CCH), 2.46 (d, J = 2 Hz, 1 H; C≡CH), 2.02 (s, 3 H; NCCH3), 1.24 
ppm (d, J = 7 Hz, 3 H; CCCH3). 
 
(2S,3S)- And (2S,3R)-2-amino-3-methylpent-4-ynoic acids 77a and 77b 
NH
2
O
OH
NH
2
O
OH
 
(2S,3S)-(±)-2-Acetamido-3-methylpent-4-ynoic acid 81a (305 mg, 1.8 mmol) was 
dissolved in water and 0.1 M NaOH(aq.) was added until pH ≈ 7.5. Several milligrams of 
acylase were added to the solution and the mixture was incubated at 30°C for 48 h. The 
solution was then filtered through a YM-10 filter and the flow-through was subjected to 
ion-exchange chromatography, eluting with 10% (w/w) NH3(aq.). The solvent was 
removed in vacuo to give (2S,3S)-2-amino-3-methylpent-4-ynoic acid 77a (35.6 mg, 
0.28 mmol, 31%) as a colourless solid. (2S,3R)-(±)-2-Acetamido-3-methylpent-4-ynoic 
acid 81b (108 mg, 0.64 mmol) was treated the same way to give (2S,3R)-2-amino-3-
77b 77a 
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methylpent-4-ynoic acid 77b (10.0 mg, 0.08 mmol, 25%). Spectroscopic data are 
consistent with literature reports.[133] 
(2S,3S)-77a: m.p. 198°C (dec.); [α]D
20 = ‒31.2 (c = 0.02); 1H NMR (300 MHz, 
D3COD): δ = 3.42 (d, J = 5 Hz, 1 H; NCH), 3.27-3.16 (m, obs, 1 H; C≡CCH), 2.64 (d, J 
= 2 Hz, 1 H; C≡CH), 1.35 ppm (d, J = 7 Hz, 3 H; CH3). 
(2S,3R)-77b: m.p. 205°C (dec.); [α]D
20 = ‒35.5 (c = 0.02); 1H NMR (300 MHz, 
D3COD): δ = 3.68 (d, J = 4 Hz, 1 H; NCH), 3.29-3.22 (m, obs, 1 H; C≡CCH), 2.66 (d, J 
= 2 Hz, 1 H; C≡CH), 1.23 ppm (d, J = 7 Hz, 3 H; CH3). 
 
7.4. Additional experimental data for Chapter 3. 
(2R,3R)- And (2R,3S)-2-amino-3-chlorobutyric acids 15a and 15b 
NH
2
Cl
O
OH
     
NH
2
Cl
O
OH
 
(2S,3R)-Threonine (1 g, 8.4 mmol) was suspended in HCl-saturated dioxane (5 mL) and 
thionyl chloride (0.8 mL, 11 mmol, 1.3 eq.) was added.[154] The mixture was heated to 
50°C in a sealed tube with stirring for 12 h. All volatiles were then evaporated in vacuo 
and the residue was redissolved in minimal amount of dry ethanol. Propylene oxide was 
added dropwise to the solution until precipitation stopped. The white precipitate 
containing the target compound with small amounts of unreacted starting material (80% 
conversion) was collected by centrifugation. A portion of the precipitate was subjected 
15a 15b 
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to purification by HPLC (Alltima C18 5µ 250×22 mm column, 10 mL min-1, 60% 
methanol in 0.05% HCl(aq.)). The collected fractions were evaporated, redissolved in dry 
ethanol and reprecipitated with propylene oxide to give (2R,3S)-2-amino-3-
chlorobutyric acids 15b a white powder (220 mg). The (2R,3R)-diastereomer 15a was 
prepared from (2S,3S)-allo-threonine using the same procedure. The 1H NMR spectra 
are consistent with published data.[155] 
(2R,3R)-15a: m.p. 122-126°C; [α]D
20 = ‒26.2 (c = 0.02); 1H NMR (300 MHz, D3COD): 
δ = 4.68 (dq, J = 7, 4 Hz, 1 H; CHCl), 3.74 (d, J = 5 Hz, 1 H; NCH), 1.66 ppm (d, 
J = 7 Hz, 3 H; CH3). 
(2R,3S)-15b: m.p. 115°C (dec.); [α]D
20 = 13.6 (c = 0.01); 1H NMR (300 MHz, 
D3COD): δ = 4.71 (dq, J = 7, 4 Hz, 1 H; CHCl), 3.88 (d, J = 3 Hz, 1 H; NCH), 1.56 
ppm (d, J = 7 Hz, 3 H; CH3). 
 
(2R,3S)-(±)-2-Amino-3-Chloropentanoic acid 27 
NH
2
Cl
O
OH
±  
Methyl isocyanoacetate 58 (1 mL, 11 mmol) and propanal (1 mL, 13.2 mmol) were 
dissolved in dry ether and copper(I) oxide (80 mg, 0.55 mmol, 0.05 eq.) was added.[130] 
The suspension was stirred for 16 h at room temperature under nitrogen atmosphere. All 
volatiles were then evaporated in vacuo and the residue was subjected to flash silica 
27 
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chromatography eluting with light petroleum and ethyl acetate (1:1). Methyl 5-ethyl-
4,5-dihydro-1,3-oxazole-4-carboxylate was collected as a colourless oil (860 mg, 
5.5 mmol, 50%), exclusively in anti-configuration. The material was unstable upon 
storage (analytical purity was not attainable). 
Rf = 0.4; 
1H NMR (300 MHz, CDCl3): δ = 6.94 (s, 1 H, N=CH), 4.64 (q, J = 7 Hz, 1 H; 
NCHCH), 4.32 (dd, J = 7, 1 Hz, 1 H; NCHC=O), 3.80 (s, 3 H; OCH3), 1.74 (p, J = 
7 Hz, 2 H; CH2), 1.01 ppm (t, J = 7 Hz, 3 H; CCH3); 
13C NMR (75 MHz, CDCl3): 
δ = 171.4, 156.8, 82.7, 71.7, 52.7, 28.0, 8.9 ppm; LRMS (ESI, +ve): m/z: 158.2 
[M++H]; HRMS (ESI, +ve): m/z: calcd for [C7H11NO3+H]
+ 158.0817, found 158.0814. 
Methyl 5-ethyl-4,5-dihydro-1,3-oxazole-4-carboxylate (860 mg, 5.48 mmol) was mixed 
with 4 M HCl(aq) and the solution was stirred with reflux for 16 h.
[156] The mixture was 
then cooled and evaporated to dryness in vacuo. The residue was dissolved in a minimal 
amount of dry ethanol and propylene oxide was added dropwise until precipitation 
occurred. The precipitate was collected by centrifugation and washed with ethanol to 
give (2S,3R)-(±)-3-hydroxynorvaline 14 as a white porous powder (690 mg, 5.19 mmol, 
95%). The 1H NMR spectrum is consistent with published data. 
14: m.p. 175-185°C (dec.; lit.[156] 214-215°C); 1H NMR (300 MHz, D3COD): δ = 3.95-
3.86 (m, 1 H; HOCH), 3.41 (d, J = 4 Hz, 1 H; NCH), 1.74-1.45 (m, 2 H; CH2), 
1.01 ppm (t, J = 7 Hz, 3 H; CH3). 
(2S,3R)-(±)-3-Hydroxynorvaline 14 (400 mg, 3.5 mmol) was converted to (2R,3S)-(±)-
3-chloronorvaline 27 following the procedure as described for the chlorides 15a and 
15b, except HPLC purification was not required. After precipitation with propylene 
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oxide, the collected precipitate was washed with water to remove any unreacted starting 
material (the chloride 27 was strikingly insoluble in water, methanol or DMSO) to give 
(2R,3S)-(±)-3-chloronorvaline 19 as an off-white powder (420 mg, 2.8 mmol, 78%). 
27: m.p. 130.5-135°C; 1H NMR (300 MHz, D3COD+TFA): δ = 4.40 (d, J = 3 Hz, 1 H; 
NCH), 4.29 (dt, J = 7, 3 Hz, 1 H; CHCl), 1.98 (p, J = 7 Hz, 2 H; CH2), 1.11 ppm (t, 
J = 7 Hz, 3 H; CH3); 
13C NMR (75 MHz, D3COD+TFA): δ=168.4, 63.0, 59.0, 29.2, 
12.0 ppm; LRMS (ESI, +ve): m/z: 152.0, 154.1 [M++H]; HRMS (ESI, +ve): m/z: calcd 
for [C5H10NO2Cl+H]
+ 152.0478 and 154.0449, found 152.0475 and 154.0437. 
 
Establishment of the stereochemistry at position C-4 of methyl (2S,4S) and 
(2S,4R)-2-amino-4-chloropentanoates 
NH2
O
O
Cl
NH2
O
OH
Cl
NH2
O
O
NH2
O
OH
OH
NaOD
D
2
O
 
Methyl (2S,4S) and (2S,4R)-2-amino-4-chloropentanoates were individually dissolved 
in D2O with NaOD and the solutions were incubated at room temperature for 16 h. 
After the hydrolysis of the methyl esters, the resulting diastereomers of 2-amino-4-
chloropentanoic acid 25 lactonised in situ and subsequently hydrolysed to give 2-amino-
4-hydroxyacids. The relative stereochemistry at position C-4 of the hydrolysis products 
was established by 1H NMR by comparison with literature values.[157] As the 
stereocentre at position C-4 inverted once during the transformation and the stereocentre 
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at position C-2 was not affected, the stereochemistry of the starting chlorides could be 
determined based on the stereochemistry of the hydrolysis products. 
(2S,4S)-2-amino-4-hydroxypentanoic acid: 
1
H NMR (500 MHz, D2O): δ = 4.03-3.96 
(m, 1 H; NCH), 3.73 (dd, J = 9, 4 Hz, 1 H; OCH), 2.03 (dt, J = 15, 4 Hz, 1 H; CHH), 
1.72 (dt, J = 15, 9 Hz, 1 H, CHH), 1.17 ppm (d, J = 6 Hz, 3 H; CH3). 
(2S,4R)-2-amino-4-hydroxypentanoic acid: 
1
H NMR (500 MHz, D2O): δ = 3.96-3.89 
(m, 1 H; NCH), 3.89-3.85 (m, 1 H; OCH), 1.98-1.87 (m, 2 H; CH2), 1.16 ppm (d, J = 
6 Hz, 3 H; CH3). 
 
Lactonisation of the diastereomers of 4-chloronorvaline 25 
As observed with the chlorinated isosteres of isoleucine (Chapter 2), both diastereomers 
of the analogue of leucine 25 were prone to decomposition, with the products of 
hydrolysis positively identified by 
1
H NMR as the corresponding 5-membered lactones, 
by comparison with published data.
[125]
 To accurately measure the rates of lactonisation, 
the mixture containing the two diastereomers and their stable precursor (S)-norvaline 42 
was dissolved in D2O and pD was adjusted to ca. 7 with 1 M NaOD in D2O. 
1
H NMR 
spectra of the mixture were recorded every 30 min for 6 h at 37°C, and the amounts of 
the chlorides relative to (S)-norvaline were measured. 
Logarithmic plots of the amounts of the chlorides confirmed the lactonisation follows 
1
st
 order kinetics; the half-lives of decomposition for the two compound were found to 
be 255 min (4.25 h) for the (2S,4R)-diastereomer ( ) and 398 min (6.6 h) for the 
(2S,4S)-diastereomer ( ), consistent with previous reports.
[102]
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Cholecystokinin-7-glycine propeptide 
NH2
O
NH
OH
O
NH
S
O
NH
O
NH
NH
O
NH
S
O
NH
O
OH O
NH
O
OH
 
The octapeptide was synthesised on a CEM Liberty Microwave Peptide Synthesizer by 
Fmoc chemistry, on Fmoc-Gly-WANG resin (352 mg, sub. 0.71 mmol g-1, 0.25 mmol) 
from Auspep. Fmoc protected amino acids (tBu side-chain protection for Tyr and Asp, 
tBoc for Trp) and other chemicals for coupling were obtained from GL Biochem 
(Shanghai) Ltd. The coupling was carried out at 75°C for 5 min, using 4 eq. of each 
protected amino acid with HBTU (4 eq.) and DIPEA (3.6 eq.); deprotection (2×) was at 
75°C for 3 min (initial deprotection 30 s) with 20% piperidine in DMF with HOBt 
(4 eq.). After the synthesis the resin was treated with TFA (1 mL; 2.5% H2O, 
2.5% TIPS) for 24 h and the acid solution was dropwise added to ether (100 mL) at 0°C. 
The precipitate was collected by centrifugation, air dried and purified by preparative 
HPLC (Alltima C18 5µ 250×22 mm column, 10 mL min-1, 35% acetonitrile, 0.1% 
TFA). The fractions were lyophilised to give the target peptide as a white powder 
(3.5 mg, 3.5 µmol, 1.5%). Rf = 16.3 min. 
m.p. 155-165°C; 1H NMR (800 MHz, DMSO): δ = 10.77 (s, 1 H; Trp-NHε), 9.31 (s, br, 
1 H; Tyr-OH), 8.71 (s, br, 1 H; Met2-HN), 8.23-8.20 (m, 2H; Met
5-HN + Gly
8-HN), 8.18 
(t, J = 5 Hz, 1 H; Gly3-HN), 8.11 (d, J = 8 Hz, 1 H; Asp-HN), 8.05 (d, J = 7 Hz, 1 H; 
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Trp-HN), 7.95 (d, J = 8 Hz, 1 H; Phe-HN), 7.59 (d, J = 8 Hz, 1 H; Trp-HAr), 7.30 (d, 
J = 8 Hz, 1 H; Trp-HAr), 7.26-7.21 (m, 4 H; Phe-HAr), 7.16 (tt, J = 7, 2 Hz, 1 H; Phe-
HAr), 7.14 (d, J = 2 Hz, 1 H; Trp-HAr), 7.04 (t, J = 8 Hz, 1 H; Trp-HAr), 7.02 (d, J = 
9 Hz, 2 H; Tyr-HAr), 6.96 (t, J = 8 Hz, 1 H; Trp-HAr), 6.68 (d, J = 8 Hz, 2 H; Tyr-HAr), 
4.56 (dt, J = 8, 5 Hz, 1 H; Trp-Hα), 4.51 (q, J = 7 Hz, 1 H; Asp-Hα), 4.47 (dt, J = 9, 
5 Hz, 1 H; Phe-Hα), 4.37 (br, 1 H; Met
2-Hα), 4.29 (dt, br, J = 8, 6 Hz, 1 H; Met
5-Hα), 
3.86 (br, 1 H; Tyr-Hα), 3.74 (d, J = 6 Hz, 2 H; Gly
8-Hα), 3.71 (dd, J = 17, 6 Hz, 1 H; 
Gly3-Hα), 3.66 (dd, J = 17, 6 Hz, 1 H; Gly
3-Hα), 3.13 (dd, J = 15, 5 Hz, 1 H; Trp-Hβ), 
3.05 (dd, J = 14, 5 Hz, 1 H; Phe-Hβ), 2.99-2.93 (m, 2 H; Tyr-Hβ + Trp-Hβ), 2.82 (dd, 
J = 14, 9 Hz, 1 H; Phe-Hβ), 2.73 (dd, J = 14, 9 Hz, 1 H; Tyr-Hβ), 2.63 (dd, J = 16, 5 Hz, 
1 H; Asp-Hβ), 2.49-2.43 (m, 2 H; Met
2-Hγ + Asp-Hβ), 2.41-2.36 (m, 2 H; Met
2-Hγ + 
Met5-Hγ), 2.35-2.30 (m, 1 H; Met
5-Hγ), 2.01 (s, 3 H; Met-Hε), 1.99 (s, 3 H; Met-Hε), 
1.96-1.91 (m, 1 H; Met2-Hβ), 1.90-1.84 (m, 1 H; Met
5-Hβ), 1.81-1.73 ppm (m, 2 H; 
Met2-Hβ + Met
5-Hβ); 
13C NMR (200 MHz, DMSO): δ = 172.1, 171.6, 171.0, 170.9, 
170.8, 170.7, 170.3, 168.5, 157.7, 157.5, 156.4, 137.6, 136.0, 130.4, 129.1, 128.0, 
127.3, 126.2, 125.4, 123.7, 120.8, 118.5, 118.2, 115.3, 111.2, 109.8, 65.8, 54.8, 54.2, 
53.9, 53.4, 51.9, 51.9, 49.7, 45.7, 41.8, 40.9, 37.4, 36.7, 36.2, 31.9, 31.7, 29.4, 29.3, 
27.6, 14.6, 14.5 ppm; LRMS (ESI, +ve): m/z: 1006.7 [M++H]; HRMS (ESI, +ve): m/z: 
calcd for [C47H59N9O12S2+H]
+ 1006.3803, found 1006.3804. 
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7.5. Experimental procedures of Chapter 4. 
Gene construction 
All genes for expression were ligated into a pET vector with T7 promoter. The initial 
fusion protein was prepared by ligation of the aprotinin gene to PpiB gene by using the 
two-step PCR mutagenesis. The gene for aprotinin was obtained from GeneArt AG. The 
gene for PpiB was available as described in previous chapters. All modified fusion 
proteins were obtained by mutagenesis of the original fusion protein via the same 
approach. 
 
Protein production and purification 
Cell-free protein expression was carried out at 30°C for 16 h as described in previous 
chapters. The volume of the inner chamber was 10 mL. After the expression the inner 
reaction mixture with all insoluble material was incubated at 100°C for 5 min, then 
guanidinium chloride was added to the final concentration of 6 M. The samples were 
then purified using HisTrapTM Ni(II)-affinity columns under denaturing conditions, 
following manufacturer’s recommendations. The eluted protein was diluted 1:10 in 
refolding buffer containing 0.1 M Tris·HCl, 0.2 M KCl, 1 mM EDTA, 5 mM DTT, pH 
8.7 and incubated for 16 h at room temperature. Trypsin (20 mg) was then added to the 
refolded protein and incubated for 1 h; grade I trypsin was obtained from Sigma-Aldrich 
Co. The complex was then again purified using HisTrapTM Ni(II)-affinity columns 
under native conditions, following manufacturer recommendations. The eluate was 
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concentrated and washed through Amicon® Ultra (YM-3000) centrifugal filter devices 
from Millipore. 
 
Crystallisation 
The aprotinin-trypsin complex was transferred to 20 mM HEPES buffer, pH 7.5, 
through repeated wash through Amicon® Ultra-4 (YM-3,000) centrifugal filter devices 
from Millipore and concentrated to ca. 10 mg mL-1 protein concentration; protein 
concentrations were measured by absorbance at 280 nm on a NanoDrop ND-1000 
spectrophotometer from ThermoScientific, the extinction coefficients were estimated 
using online ProtParam tool. Crystallisation was carried out using hanging-drop vapour-
diffusion method. 24-well plates and 18 mm siliconised glass circular cover slides were 
purchased from Hampton Research. 1 mL reservoir solution contained 200 mM HEPES, 
pH 7.5, 1.45 M (NH4)2SO4 and 10 mM CaCl2,
[140] 1 µL of which was added to 10 µL of 
protein solution. Crystals suitable for crystallography were obtained within a week. 
 
Data collection 
Crystals were cryoprotected in reservoir solution containing 20% glycerol (v/v). 
Diffraction data were collected using Cu radiation (wavelength 1.5418 Å) at a 
temperature of 100 K, recorded as a contiguous sequence of 1° rotations using a 
MAR345 image plate detector mounted on a mardtb desktop beamline with a GeniX 
micro-focus X-ray source with cooling supplied by an Oxford Cryostream 700 series. 
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Between 129 and 180 frames were collected for each crystal with exposure time of 2400 
or 3600 s per frame. 
 
Structure refinement 
Structure refinements were carried out on refmac 5.8.0073 as implemented in CCP4.[158] 
Model was built with Coot,[159] using a published structure 3otj as an initial model. 
Coordinates of the chlorinated residues SCB ((2R,3S)-2-amino-3-chlorobutyryl) and 
RCB ((2R,3R)-2-amino-3-chlorobutyryl) for refinement were constructed using 
PRODRG server.[160] 
 
7.6. Synthesis of compounds from Chapter 5. 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-4-chlorobutanoate 92a 
N
t
Boc
O
O
Cl
H
 
(S)-Homoserine 88 (600 mg, 5 mmol) and triethylamine (1 mL, 7.5 mmol) were 
dissolved in water and di-tbutyl-dicarbonate (1.2 g, 5.5 mmol) in acetone was added. 
The solution was stirred with reflux for 3 h, then cooled down and evaporated to 
dryness in vacuo. The residue was redissolved in dimethylformamide and iodomethane 
(0.4 mL, 6 mmol) was added. Hünig’s base was added until pH >> 7 and the reaction 
was stirred for 16 h at room temperature. All volatiles were then removed in vacuo to 
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give crude methyl (2S)-2-[(tert-butoxycarbonyl)amino]-4-hydroxybutanoate 89 as a 
colourless oil that was used in the subsequent step without further purification. 
The protected homoserine 89 was dissolved in carbon tetrachloride (50 mL) and 
triphenylphosphine (1.6 g, 6 mmol) was added with stirring. The reaction was stirred 
with reflux for 24 h. The solution was then allowed to cool and the solvent was 
evaporated in vacuo. The oily residue was purified by silica chromatography, eluting 
with light petroleum / ether = 1:1. The target compound was obtained as a colourless oil 
(460 mg, 1.8 mmol, 37% over three steps). 
Rf = 0.5; [α]D
20 = ‒47.6 (c = 0.05 in methanol); 1H NMR (400 MHz, CDCl3): δ = 5.13 
(br, 1 H; NH), 4.46 (q, br, J = 5 Hz, 1 H; NCH), 3.77 (s, 3 H; OCH3), 3.60 (t, J = 7 Hz, 
2 H; CH2Cl), 2.40-2.26 (m, 1 H; NCCHH), 2.20-2.06 (m, 1 H; NCCHH), 1.45 (s, 9 H; 
C(CH3)3); 
13C NMR (100 MHz, CDCl3): δ = 172.4, 155.3, 80.3, 52.6, 51.4, 40.5, 35.6, 
28.3; LRMS (ESI, +ve): m/z: 274.1, 276.2 [M++Na]; HRMS (ESI, +ve): m/z: calcd for 
[C10H18NO4Cl+Na]
+ 274.0822 and 276.0793, found 274.0823 and 276.0794. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-4-bromobutanoate 92b 
N
t
Boc
O
O
Br
H
 
Crude methyl (2S)-2-[(tert-butoxycarbonyl)amino]-4-hydroxybutanoate 89 (approx. 
200 mg, 0.86 mmol) was dissolved in dry dichloromethane and triphenylphosphine 
(270 mg, 1 mmol) and carbon tetrabromide (332 mg, 1 mmol) were added with stirring. 
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The reaction was stirred at room temperature under nitrogen atmosphere for 4 h. The 
solvent was than evaporated in vacuo and the residue was purified by silica 
chromatography, eluting with light petroleum / ether = 1:1, to give the target compound 
as a colourless oil (205 mg, 0.7 mmol, 80%). The compound was extremely prone to 
decomposition and was thus stored at -80°C. Spectroscopic data are consistent with 
literature reports.[148] 
Rf = 0.5; [α]D
20 = ‒42.8 (c = 0.01 in methanol); 1H NMR (400 MHz, CDCl3): δ = 5.10 
(br, 1 H; NH), 4.44 (q, br, J = 4 Hz, 1 H; NCH), 3.78 (s, 3 H; OCH3), 3.44 (t, J = 7 Hz, 
2 H; CH2Br), 2.49-2.35 (m, 1 H; NCCHH), 2.28-2.15 (m, 1 H; NCCHH), 1.46 (s, 9 H; 
C(CH3)3). 
 
Methyl (2S)-2-amino-4-chlorobutanoate 87a 
Cl
O
NH2
O
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-4-chlorobutanoate 92a was dissolved in 
glacial TFA and stored at room temperature for 1 h. All volatiles were then evaporated 
in vacuo to give the target compound as a viscous colourless oil with essentially 
quantitative conversion. The compound was used without further processing. 
[α]D
20 = +14.7 (c = 0.02); 1H NMR (400 MHz, D3COD): δ = 4.23 (t, J = 7 Hz, 1 H; 
NCH), 3.86 (s, 3 H; OCH3), 3.76 (t, J = 7 Hz, 2 H; CH2Cl), 2.44 (dq, J = 15, 7 Hz, 1 H; 
NCCHH), 2.30 (dq, J = 15, 7 Hz, 1 H; NCCHH); 13C NMR (100 MHz, D3COD): δ = 
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170.5, 54.0, 51.6, 40.9, 34.6; LRMS (ESI, +ve): m/z: 152.0, 154.1 [M++H]; HRMS 
(ESI, +ve): m/z: calcd for [C5H10NO2Cl+H]
+ 152.0478 and 154.0449, found 152.0478 
and 154.0451. 
 
Methyl (2S)-2-amino-4-bromobutanoate 87b 
Br
O
NH2
O
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-4-bromobutanoate 92b was deprotected 
with glacial TFA in the same way as methyl (2S)-2-[(tert-butoxycarbonyl)amino]-4-
chlorobutanoate 92a. 
[α]D
20 = +10.2 (c = 0.01); 1H NMR (400 MHz, D3COD): δ = 4.23 (br, 1 H; NCH), 3.87 
(s, 3 H; OCH3), 3.60 (t, J = 7 Hz, 2 H; CH2Br), 2.60-2.46 (m, br, 1 H; NCCHH), 2.40-
2.30 (m, 1 H; NCCHH); 13C NMR (100 MHz, D3COD): δ = 170.5, 54.1, 52.7, 34.9, 
28.2; LRMS (ESI, +ve): m/z: 196.0, 198.0 [M++H]; HRMS (ESI, +ve): m/z: calcd for 
[C5H10NO2Br+H]
+ 195.9973 and 197.9953, found 195.9977 and 197.9957. 
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Diethyl (acetylamino)(but-3-en-1-yl)malonate 85 
NHAc
O
EtO OEt
O
 
Diethyl acetamidomalonate 74 (136 mg, 0.63 mmol), caesium carbonate Cs2CO3 
(220 mg, 0.68 mmol) and 4-bromobut-1-ene 84 (100 µg, 0.74 mmol) were added to dry 
acetonitrile (0.75 mL) in a microwave tube and the mixture was subjected to microwave 
irradiation (100°C, 200 W) for 1 h with stirring. The reaction mixture was then filtered 
to remove inorganic salts and the filtrate was evaporated to dryness. The residue was 
purified by flash silica chromatography, eluting with cyclohexane / ethyl acetate = 1:1, 
to give the target compound as a colourless oil (110 mg, 0.41 mmol, 64%). 
Spectroscopic data are consistent with literature reports.[108] 
Rf = 0.47; 
1H NMR (400 MHz, CDCl3): δ = 6.77 (s, br, 1 H; NH), 5.80-5.67 (m, 1 H; 
CH=CH2), 5.04-4.92 (m, 2 H; CH=CH2), 4.23 (q, J = 7 Hz, 4 H; OCH2), 2.47-2.39 (m, 
2 H; CH2CH=CH2), 2.03 (s, 3 H; NCCH3), 1.95-1.85 (m, 2 H; CH2CH2CH=CH2), 1.25 
(t, J = 7 Hz, 6 H; OCCH3). 
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2-Aminohex-5-enoic acid 86 
N
O
OH
H
O
 
Diethyl (acetylamino)(but-3-en-1-yl)propanedioate 85 (45 mg, 0.17 mmol) was 
suspended in aqueous sodium carbonate Na2CO3 solution (10% w/w) and the mixture 
was stirred with reflux for 16 h. The clear solution was then cooled down and HCl(aq.) 
was added until pH ≈ 3. The solution was then swirled and all volatiles were removed in 
vacuo. The solid residue was extracted with hot acetone (55°C). The solvent was 
removed in vacuo to give the target compound as a colourless oil (25 mg, 0.15 mmol, 
86%). Spectroscopic data are consistent with literature reports.[108] 
1H NMR (400 MHz, D3COD): δ = 5.89-5.75 (m, 1 H; CH=CH2), 5.09-4.97 (m, 2 H; 
CH=CH2), 4.38 (dd, J = 9, 5 Hz, 1 H; NCH), 2.23-2.06 (m, 2 H; CH2CH=CH2), 1.99 (s, 
3 H; CH3), 1.97-1.84 (m, 1 H; CHHCH2CH=CH2), 1.83-1.70 (m, 1 H; 
CHHCH2CH=CH2). 
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B,B-Diethylboroxazolidone 97 
OH
O
NH2
O O
B
 
(S)-Glutamic acid 96 (2 g, 13.6 mmol) was suspended in sodium-dried dimethoxyethane 
(20 mL) and triethylborane (1 M in THF, 16 mL, 16 mmol) was added under nitrogen 
atmosphere with stirring. The solution was stirred with reflux under nitrogen 
atmosphere for 20 h, after which time most of the solid solubilised. The mixture was 
then cooled and filtered. The flow-through was evaporated in vacuo to give the title 
compound as a white gum (quant.) that was used in the next step without further 
purification. Spectroscopic data are consistent with literature reports.[149] 
1H NMR (300 MHz, (CD3)2SO): δ = 6.51 (dd, J = 11, 8 Hz, 1 H; NHH), 5.62 (dd, J = 
12, 8 Hz, 1 H; NHH), 3.65-3.45 (m, 1 H; NCH), 2.44 (t, J = 8 Hz, 2 H; O2CCH2), 2.12-
1.98 (m, 1 H; NCCHH), 1.80-1.64 (m, 1 H; NCCHH), 0.74-0.64 (m, 6 H; CH3), 0.29-
0.10 ppm (m, 4 H; BCH2). 
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A2. X-Ray data and structure validation reports 
 
The disk attached to the back cover of this Thesis contains the pdb and mtz files of the 
crystal structures C1, C2 and C3 described in Chapter 4. 
 
The following pages have the validation reports for the crystal structures C1, C2 and 
C3. 
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Structure C1 
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Structure C2 
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Structure C3 
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